Asthma inhaler running out? Hard to tell

NEW YORK — Because asthma inhalers do not include dose counters, asthma sufferers may unknowingly run out of their rescue medication, experts warn in a new report. They call for manufacturers of pressurized metered-dose inhalers, or pMDIs, to include dose counters as a standard feature.

These devices are the cornerstone of asthma treatment. They contain a specified number of doses of medication. But after an asthma sufferer has used up the potentially lifesaving medication, pMDI canisters may continue to deliver 20 to 80 percent more puffs containing little more than inactive propellant.

How do patients know when their pMDI is empty or when it’s time to refill their inhaler prescription? Nancy Sander, founder and president of the Allergy and Asthma Network Mothers of Asthmatics in Fairfax, Virginia and colleagues surveyed 500 US families with asthma to find out.

They report that 87 of 342 respondents (25 percent) who said they used a bronchodilator for relief of an asthma attack reported having found their pMDI empty during one of these attacks. Seven of these patients had to call 911 as a result.

Seventy-one of these 87 asthma patients (82 percent) wrongly thought that they could tell when their asthma inhaler was empty when absolutely nothing came out of it.

The survey team also found that only 36 percent of pMDI users reported ever having been told by their doctor to keep track of doses they used. This is an “alarming finding,” study co-author Dr. Bradley E. Chipps, of Capital Allergy and Respiratory Disease Center in Sacramento, California, said in a statement.

Even if more had been told, “without an integrated dose counter, there is no reliable way for patients to track medication usage,” Chipps said.

The methods people with asthma currently use to determine whether medication remains in the pMDI are all “faulty,” said Sander.

These include maintaining a diary, which is “wholly impractical” as pMDIs are used on an intermittent basis. Only 8 percent of those surveyed used this method.

Spray testing — the most common method of testing pMDIs — is totally ineffective because propellant remains in the device after the medication is used up, as mentioned.

There is no solid evidence to support the reliability of the float test — floating the canister in water and noting its position to determine if medication is left inside. Although advocated in the past, many pMDI manufacturers now advise against immersing or floating the canister.

The survey results appear in the July issue of Annals of Allergy, Asthma & Immunology. In a commentary, Dr. John Oppenheimer supports the authors’ conclusion that manufacturers of inhaled medicines should include dose counters as a standard feature on multidose inhalers. [

Without dose counters, patients are left to wonder whether their inhaler is “running on empty,” writes Oppenheimer from the University of Medicine and Dentistry of New Jersey.

Recently, the US Food and Drug Administration advised pMDI manufacturers to include dose counters in the future. The first pMDI with a dose counter was introduced this month and others are not far behind, Sander said. “We hope these advances will help reduce emergency department visits, hospitalizations, missed school and work days and death due to empty inhalers,” she added.

SOURCE: Annals of Allergy, Asthma & Immunology, July 2006.

City Urges Ontario Government to Crack Down on Noisy, Illegal Pocket Bikes

By ALLISON JONES

TORONTO (CP) – They’re noisy, pint-sized and potentially dangerous – and police across Ontario could soon be handing down stiffer penalties to those who ride so-called “pocket bikes” on city streets and sidewalks, if the province’s largest municipality gets its way.

The loud, lightweight motorcycles, also known as mini-motos, are about one-third of a standard-size bike and an increasingly common sight on the streets of the big city, where municipal leaders are growing concerned about the potential dangers they pose.

In the coming weeks, Ontario’s Ministry of Transportation will receive a motion passed unanimously last week by Toronto city council asking it to amend the Highway Traffic Act in order to crack down on pocket-bike riders.

Under the act it’s already illegal to ride on public roads, because the size of the bike makes it difficult for other motorists to see. Currently, police can levy a $105 fine against a person who rides a pocket bike on the street for not having a permit or plates.

Toronto city council wants the province to give police across the province the power to not only confiscate the bike, but also impound it.

“This is a law that in a sense protects people from their own stupidity,” said Toronto city Coun. Glenn De Baeremaeker, a vocal backer of the motion.

“It will be a huge deterrent. It would be cheaper for them to buy a new bike than to get it out of the 1/8impound lot 3/8.”

The type of pocket bikes zipping down the street weigh between 14 and 25 kilograms, stand less than 50 centimetres tall and cost just a few hundred dollars. Some can reach a top speed upwards of 50 kilometres an hour.

Lee Kuhn, who operates LKR Pocket Bikes in Smithville, Ont., said pocket bikes have actually been around for 20 years.

The recent pocket bike proliferation is because over the past few years Chinese manufacturers have been making less expensive versions of European models, which traditionally retailed for several thousand dollars, Kuhn said.

“About three-a-half years ago I was one of the original Chinese bike importers in Canada,” he said.

In the first three years, his shop has sold 10,000 bikes, mostly to distributors.

“We haven’t sold any for about six months because we saw what was happening. We just didn’t want to be a part of it, of them being out on the street.”

LKR now sells about 100 of the more expensive European pocket bikes – designed exclusively for the race track – each year, as well as other motorized bikes.

Kuhn is also chairman of the Mini Moto Racing Association of Canada (MMRAC), which he established two years ago.

He said he supports the city’s motion because the bikes were never designed to be ridden on the street or the sidewalk.

“On the street, people can’t see you; (the bikes) are just too short,” he said.

“People look out their car window, they might see the top of your head, because that’s how low to the ground you are. They were never designed for that, they’re just way too small for it.”

There have been several accidents and resulting injuries involving pocket bikes across North America in recent years. Michel-Andre Thibert, 16, of Ottawa, died last year when the pocket bike he was riding collided with a car near his home.

The danger of pocket bikes on streets and sidewalks is just one of the reasons the motion has the support of De Baeremaeker, who said he’s bothered by the noisy drone he constantly hears in his own neighbourhood.

“I’ve seen them two and three at a time in every part of my subdivision, and it’s outrageously annoying to people who are just trying to relax on a Sunday morning,” he said.

The reason they’re so noisy? Pocket bikes are powered by engines similar to that of a chainsaw.

It will take a couple of weeks for the motion to go through the administrative process at Toronto City Hall before it can be sent to the Ministry of Transportation.

“We will review any motion that comes from the City, including this one,” said ministry spokesman Bob Nichols. “(The ministry) will also consult with police first before any decisions are made regarding pocket bikes.”

Should the ministry follow through on the motion, Ontario would be following the example of California, where peace officers can seize a pocket bike and hold it for a maximum of 48 hours.

De Baeremaeker said the intent of the motion is not to punish those who abide by the law and race their pocket bikes legally on closed courses.

However, “there are some very irresponsible people doing very irresponsible and dangerous things with these bikes,” he said.

“We have to protect the public and the people making those stupid decisions to ride them.”

Lebanese ladies pick up brooms as dustmen flee war

By Laila Bassam

BEIRUT (Reuters) – Picking up brooms and donning green
overalls, dozens of women have taken to cleaning the streets of
Beirut after Israeli air strikes scared off refuse collectors
and left the capital strewn with festering rubbish.

Around 2,000 refuse collectors and street-sweepers, most of
Syrian or Asian origin, have fled Lebanon since the start of
the war 18 days ago, paralyzing Sukleen, the firm charged with
keeping Beirut and Mount Lebanon clean.

With no one to empty skips and bins, bags of rubbish began
piling up on street corners and litter was left to fester,
prompting some women to volunteer to clean up their city.

“If we don’t do anything, those who do not get killed by
Israeli missiles will get killed … by germs and diseases,”
said Najwa Baroudi, a designer and artist who was helping clean
a street in Beirut.

Dressed in the bright green overalls of Sukleen refuse
collectors, Baroudi was gathering up rubbish from the road and
placing it in the skips which another woman was helping lift
and dump into the churning gut of the garbage truck.

Mona al-Hajj, a housewife who was helping sweep bustling
Hamra Street, said Sukleen was trying to find new employees but
that something had to be done before the flies and cockroaches
infested Lebanese homes.

“Piles of rubbish are mounting up outside our homes so what
are we waiting for?” she asked. “Beirut municipality, students,
charities, housewives, doctors, engineers and employees are all
taking part.”

NO SHAME

Lebanese are not known for their ecological awareness and
tend to look down on refuse collection as a job for poor
migrant workers, not themselves. Sukleen is finding it hard to
recruit new rubbish collectors to replace those who fled.

Sukleen director Antoine Qurban said about 50 of the
company’s office staff had taken to the streets last week to
pick up rubbish in a symbolic gesture.

“Of course they were unable to fill the place of 2,000
workers but they were making a point to the Lebanese that this
is a respectable thing to do,” Qurban said.

“This job is not shameful because these are our streets and
our neighborhoods, we made them dirty and it is our
responsibility to keep them clean.”

Bassem al-Turk, head of the volunteer section at Sukleen,
said people were keen to help out and many were bringing their
children along to join in.

The American University of Beirut sent an email to students
calling for volunteers to help keep the neighborhood clean.

Wadad al-Hoss, volunteering with her father, former
Lebanese Prime Minister Salim al-Hoss, said the campaign began
when the rubbish began to pile up and it was clear there was no
one to collect it.

“When we started out, we were only five women and two men
but now there are teams in every neighborhood,” she said.

“This is a service to the nation and to citizens. It is not
shameful; we are cleaning our streets as we clean our homes.”

Irradiated thighs burn more fat during workouts: study

By Megan Rauscher

NEW YORK (Reuters Health) – Exercising on a stationary
bicycle burns significantly more fat when the waist, hip, and
thighs are warmed with water-filtered infrared-A (wIRA) during
the workout, according to a study conducted in Germany.

Fatty tissue contains a large amount of energy and normally
has a slow metabolism with low tissue temperature. Previous
studies have shown that wIRA increases tissue temperature and
local metabolism.

It seemed “physiologically plausible” that warming and
metabolic increase of fatty tissue by wIRA simultaneously
combined with moderate physical exercise would favor regional
fat burning more than exercise alone, Dr. Gerd Hoffmann from
Johann Wolfgang Goethe University Frankfurt/Main.

They showed this to be the case in a controlled study in
which 40 obese women exercised on a stationary bicycle for 45
minutes three times per week for 4 weeks. The women were
randomly assigned to exercise with or without wIRA.

An irradiation unit called the Hydrosun 6000 (Hydrosun
Medizintechnik, Mllheim, Germany) was used to irradiate the
waist, hip, and thighs.

“wIRA mainly consists of radiation with good penetration
into tissue, similar to sun heat radiation in moderate climatic
zones, which is filtered by water vapor in the atmosphere,”
Hoffmann explained. The radiators are cylindrical in shape,
approximately 40 cm long and need only an electrical power
supply.

According to their report, published in the online journal
GMS German Medical Science, the sum of circumferences of the
waist, hips and both thighs decreased during the 4 weeks
significantly more in the wIRA group than in the control group

.

Moreover, body weight and fat mass decreased markedly more
in the wIRA group than in the control group. The wIRA group
lost approximately 4 pounds, while the control group lost no
weight.

There were no “undesired effects” seen with wIRA in the
study. On the contrary, some of the women found the wIRA
irradiation “pleasant and relaxing” for the muscles, Hoffmann
said.

“The results of the study indicate that wIRA irradiation
during moderate ergometer endurance exercise can be used — in
combination with an appropriate nutrition — to improve body
composition, especially local fat distribution, and reduction
of fat and body weight in obese persons,” Hoffmann said.

“Longer periods than the investigated 4 weeks can be
assumed to be even more effective,” he added.

SOURCE: GMS German Medical Sciences 2006.

China’s Growing Pollution Reaches U.S. Mainland

MOUNT TAMALPAIS STATE PARK, Calif. — On a mountaintop overlooking the Pacific Ocean, Steven Cliff collects evidence of an industrial revolution taking place thousands of miles away.

The tiny, airborne particles Cliff gathers at an air monitoring station just north of San Francisco drifted over the ocean from coal-fired power plants, smelters, dust storms and diesel trucks in China and other Asian countries.

Researchers say the environmental impact of China’s breakneck economic growth is being felt well beyond its borders. They worry that as China consumes more fossil fuels to feed its energy-hungry economy, the U.S. could see a sharp increase in trans-Pacific pollution that could affect human health, worsen air quality and alter climate patterns.

“We’re going to see increased particulate pollution from the expansion of China for the foreseeable future,” said Cliff, a research engineer at the University of California, Davis.

He has monitoring stations on Mount Tamalpais, Donner Summit near Lake Tahoe, and Mount Lassen in far Northern California. Those sites see little pollution from local sources, and the composition of the dust particles matches that of the Gobi Desert and other Asian sites, Cliff said.

About a third of the Asian pollution is dust, which is increasing due to drought and deforestation, Cliff said. The rest is composed of sulfur, soot and trace metals from the burning of coal, diesel and other fossil fuels.

Cliff is studying whether transported particulate matter could affect climate by trapping heat, reflecting light or changing rainfall patterns.

Most air pollution in U.S. cities is generated locally, but that could change if citizens in China, India and other developing nations adopt American-style consumption patterns, researchers say.

“If they started driving cars and using electricity at the rate in the developed world, the amount of pollution they generate will increase many, many times,” said Tony Van Curen, a UC Davis researcher who works with Cliff.

The U.S. Environmental Protection Agency estimates that on certain days nearly 25 percent of the particulate matter in the skies above Los Angeles can be traced to China. Some experts predict China could one day account for a third of all California’s air pollution.

Dan Jaffe, an atmospheric scientist at the University of Washington, said he has detected ozone, carbon monoxide, mercury and particulate matter from Asia at monitoring sites on Mount Bachelor in Oregon and Cheeka Peak in Washington state.

“There is some amount of the pollution in the air we breathe coming from halfway around the world,” Jaffe said. “There ultimately is no ‘away.’ There is no place where you can put away your pollution anymore.”

China’s environmental problems are severe and getting worse. Nearly 30 years of relentless industrial expansion has fouled the country’s rivers, lakes, forests, farmland and skies.

The World Bank estimates that 16 of the world’s 20 most polluted cities are in China, and air pollution is blamed for about 400,000 premature deaths there each year.

Coal-fired power plants supply two-thirds of China’s energy and are its biggest source of air pollution. Already the world’s largest producer and consumer of coal, China on average builds a new coal-fired power plant every week.

Meanwhile, car ownership is soaring as the country’s economy grows about 10 percent a year, contributing carbon dioxide and other greenhouse gases linked to global warming.

If current trends continue, China will surpass the U.S. as the world’s largest emitter of greenhouse gases in the next decade, said Barbara Finamore, who heads the Natural Resources Defense Council’s China Clean Energy program, which is helping the country boost its energy efficiency.

“China’s staggering economic growth is an environmental time bomb that, unless defused, threatens to convulse the entire planet regardless of progress in all other nations,” Finamore said.

Even Chinese environmental officials warn that pollution levels could quadruple over the next 15 years if the country doesn’t curb energy use and emissions. Beijing plans to spend $162 billion on environmental cleanup over the next five years, but the scale of the country’s pollution problems is immense.

“When you look at China’s population growth and industrial growth, it’s hard to imagine how air quality could improve in the near future,” said Ruby Leung, a researcher at the Energy Department’s Pacific Northwest National Laboratory in Richland, Wash., which collaborates with Chinese government scientists on atmospheric research.

Earlier this year, Leung and her colleagues published a study that found particulate pollution has darkened China’s skies over the past 50 years by absorbing and deflecting the sun’s rays.

China’s pollution also regularly dirties the air in neighboring South Korea and Japan, but until recently researchers didn’t think it had much effect on North America.

U.S. scientists have recently found that Asian pollution is consistently transported across the Pacific on air currents. It can take anywhere from five days to two weeks for particles to cross the ocean.

Some scientists predict that global warming could change those circulation patterns, either speeding or slowing the transport of pollutants from Asia.

China’s environmental challenges are daunting, but the country is taking action to reduce its energy use and air pollution, said NRDC’s Finamore. Beijing has set ambitious goals for increasing energy efficiency, fuel economy standards and use of renewable power sources such as wind and solar, she said.

“There are tremendous opportunities for China to slow the amount of pollution it pumps in the air,” Finamore said.

HCA Names Kevin Hicks Research Medical Center CEO

KANSAS CITY, Mo., July 27 /PRNewswire/ — HCA today announced that Kevin Hicks has been named president and CEO of Research Medical Center effective Aug. 1.

(Photo: http://www.newscom.com/cgi-bin/prnh/20060727/CGTH052 )

“Hicks bring more than 18 years of CEO-level experience to his new position,” said Bryan R. Rogers, president of HCA Midwest Health System. “His wealth of experience within a variety of hospital settings will contribute to his successful leadership of Research Medical Center.”

In his new role, Hicks will oversee all hospital operations, including service expansions, new product line development, outpatient operations, medical office property and physician practices. In addition, he will direct the hospital’s strategic initiatives and provide oversight to the hospital’s $92 million in capital improvements, many of which have been completed and others that have a spring 2007 targeted completion.

The construction and renovation at Research Medical Center includes the emergency department doubling in size from 11,400 square feet to 24,000 square feet and increasing patient rooms from 15 to 23 as well as adding a six-bed chest pain center, a new Cancer Center expansion, cosmetic upgrades to the Women’s Services department and high-end patient room upgrades, all private patient rooms and the availability of VIP patient rooms.

Some projects have already been completed such as the first phase of the new emergency department, the admitting and registration departments that were relocated adjacent to the newly renovated main lobby and increased surface parking totaling nearly 800 spaces.

Having led many growth initiatives, Hicks is well positioned to oversee the $92 million in capital improvements at Research Medical Center. Hicks most recently served as president and CEO of Overland Park Regional Medical Center. He has also held CEO and senior management positions within both the HCA and former Health Midwest systems.

“Research Medical Center is a great hospital steeped in tradition. I look forward to leading the medical center as its new CEO,” said Hicks. “With its cutting-edge technology and outstanding staff and physician base, the hospital is a hallmark for high quality patient care in Kansas City.”

Hicks has a Bachelor of Science in Business Administration from the University of Kansas, a Master’s of Business Administration with an emphasis in Personnel Management and a Master’s of Hospital Administration from the University of Missouri-Columbia. He is married with four children.

About Research Medical Center

Research Medical Center, a dual campus HCA Midwest healthcare facility, serves patients from a 150-mile region surrounding Kansas City by providing an abundance of services and access to advanced technology. The hospital, located at 2316 East Meyer Boulevard in Kansas City, Mo., is one of the region’s leading acute care hospitals. The 511-bed facility features a broad range of highly specialized, state-of-the-art services. In addition, the 37-acre Research Brookside Campus, located at 6601 Rockhill Road, Kansas City, Mo., includes outpatient facilities, medical office buildings and a comprehensive health and fitness center. For more information, go to http://www.researchmedicalcenter.com/ .

About HCA Midwest

HCA Midwest Health System is the area’s largest healthcare network, consisting of hospitals, outpatient centers, clinics, physician practices, surgery centers and an array of other services to meet the healthcare needs of the greater Kansas City area. HCA Midwest Health System has invested more than $500 million to enhance and expand patient services since entering the community in April 2003. HCA Midwest Health System facilities in the Kansas City metropolitan area include Allen County Hospital, Menorah Medical Center, and Overland Park Regional Medical Center in Kansas; and Cass Medical Center, Independence Regional Health Center, Lafayette Regional Health Center, Lee’s Summit Hospital, Medical Center of Independence, Research Belton Hospital, Research Medical Center, Research Medical Center-Brookside Campus, and Research Psychiatric Center in Missouri. To learn more about HCA Midwest Health System and the array of services available at its facilities, please visit HCAMidwest.com, or call 816-751-3000.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20060727/CGTH052AP Archive: http://photoarchive.ap.org/AP PhotoExpress Network: PRN9PRN Photo Desk, [email protected]

HCA Midwest Health System

CONTACT: Rob Dyer, V.P., Marketing & PR, HCA Midwest Health System,+1-816-508-4169, or [email protected] ; or Linda Shaffer, APR, V.P.,PR & Marketing Research Medical Center, +1-816-823-0502, [email protected]

US issues high-strength hydrogen peroxide warning

WASHINGTON (Reuters) – Drinking or injecting high-strength
hydrogen peroxide products sold online to treat serious
diseases such as AIDS can be extremely harmful, U.S. health
officials said on Thursday.

The “35 percent food grade hydrogen peroxide” products are
highly corrosive and ingesting them could cause stomach
irritation and ulcers, the Food and Drug Administration said.

Injecting the products intravenously could lead to blood
vessel inflammation, bubbles in blood vessels and potentially
life-threatening allergic reactions, the agency added.

The FDA said it had not approved 35 percent hydrogen
peroxide for any use. The agency sent warnings to two
Texas-based firms, DFWX and Frad 35 Inc., that it said were
illegally selling 35 percent hydrogen peroxide products to
treat AIDS, cancer, emphysema and other serious diseases.

“No one has presented any evidence that hydrogen peroxide
taken internally has any medical value. In fact, consuming
hydrogen peroxide in the manner touted by these Web sites could
lead to tragic results,” Dr. Steven Galson, director of the
FDA’s Center for Drug Evaluation and Research, said in a
statement.

Donald Worden, owner of Frad 35 Inc., said he would
continue selling his 35 percent hydrogen peroxide product. He
said his Web site provided links to information about potential
medical uses but that he was not promoting it for that purpose.

“There are references to what doctors and other
publications have done. I make reference to that only to give
… people information that they want,” Worden said in an
interview.

He said the military, universities and independent
laboratories were among his clients. He added that his product
was “technical grade,” which his Web site said could be used
for treating waste water.

The strength of hydrogen peroxide solutions sold
over-the-counter for disinfecting wounds is 3 percent.

Officials at DFWX were not immediately available for
comment.

Babies Finding Early Voice Through Sign Language

By Jill Serjeant

LOS ANGELES — Nine-month-old Alexandra lets her mother know when she is hungry. Andrew, 11 months, makes it clear he wants some milk.

They may be too young to speak, but Alexandra and Andrew have joined the growing numbers of hearing babies who are learning sign language to tell their parents what they are thinking.

Once confined to communicating with the deaf, sign language is undergoing a rebirth as a way for new parents to understand the needs of their offspring long before they can talk.

“It is about empowering children to communicate. They can communicate with you at an early age and not be frustrated,” said Etel Leit who runs baby sign language classes in Los Angeles.

Dismissed by some critics as a fad or part of the over-achieving parent syndrome, baby signing is spreading in many parts of the United States but seems biggest in California where it began about seven years ago.

Devotees include actress Debra Messing of “Will & Grace” and a toddler signed with Robert de Niro in the 2004 Hollywood comedy “Meet the Fockers.”

“The biggest interest is in California. People in California love new and interesting things,” said Professor Deena Bernstein, head of speech language hearing sciences at Lehman College in New York.

Books, flashcards, videos and classes hail the benefits of teaching babies as young as 6 months old to sign with their parents, promising improved IQ, accelerated speech development and less frustration for everyone during the “terrible twos.”

Leit spent 16 years as a language teacher before setting up her own signing business and says she is getting workshop requests from daycare centers and playschools.

DEALING WITH DIAPERS

On a Monday morning in west Los Angeles, Leit lead a handful of mothers, babies and some of their nannies in an hour-long class featuring action songs, games and the week’s special topic — “dealing with diapers.”

The infants — around a year old — looked mostly bemused or laughed as their mothers wiggled their hands and fingers to make gestures for “diaper,” “wet,” “dirty” and “clean.”

Some mothers are meeting opposition from older relatives who feel the classes will delay language development. Leit, however, stresses combining signing with talking to one’s baby rather than replacing speech with signs.

And she has some encouraging success stories, like the one about the mother who went into her crying 13-month-old at night and the child signed that she was scared. A car alarm was blaring outside and when the window was closed the child went back to sleep.

“The mom would never have realized that without signing because at 13 months a child can’t say, ‘I’m afraid’.” said Leit.

‘NEW FAD’

Psychology professor and mom Susan Murphy said she joined the class because of research that suggested signing reduces frustration. “Andrew (11 months) is also very active and I think he has a lot to say,” she added.

Liza Roser Atwood has spent years working with deaf children and wanted her own hearing daughter Alexandra, 9 months, to reap the benefits.

“She makes the sign for ‘eat’ so I know when she is hungry and when I make the sign for ‘daddy’ she turns round and looks back,” she said.

Professor Bernstein is skeptical of some of the loftier claims. She said more scientifically controlled evidence was needed to persuade her that signing alone accelerates intellect or language development any more than long periods of one-on-one attention, reading and stimulating play.

“I find that people in Los Angeles try to hook on to any new fad that comes along. They also have the money for it. You are not going to find this in areas where there is poverty,” Bernstein said.

Politics and Machismo Stunt Philippine Birth Control

By Carmel Crimmins

MANILA — Nick couldn’t believe so many of his friends had become accidental fathers when he returned to the Philippines after five years overseas.

“There are still a lot of people who just don’t buy condoms,” said the 29-year-old business student.

“It’s partly a religious thing — the act of buying them means that you intend to have sex. But there are a lot of guys who really don’t care if they get you pregnant.”

A macho culture and myths about side-effects from condoms, used by only an estimated 1.9 percent of married couples, and vasectomies mean that contraception in the developing Southeast Asian country is seen as the woman’s problem.

And a problem it is.

Now home to around 85 million people, the Philippines has one of the fastest-growing populations in Asia with around 2 million babies born every year, many of them in overstretched public hospitals where new mothers have to share beds.

The number of Filipinos is expected to swell to 142 million by 2040, by the government’s own estimates, and the rapid arrival of new mouths to feed is straining the country’s creaking infrastructure and choking efforts to cut poverty.

While family size has fallen to 3.5 children per woman from six in the 1970s, Filipino mothers, on average, still have one more child than they want to, according to research by the Alan Guttmacher Institute.

To deal with the financial and emotional strain, around half a million women are estimated to have abortions every year despite the procedure being illegal and strictly taboo in the overwhelmingly Roman Catholic country.

Nearly 80,000 are hospitalized with complications.

PLAYING SAFE

The Catholic faith, which opposes artificial birth control, is often blamed for the population boom. But a government survey showed that among the 51 percent of married women who do not use family planning, only 2.4 percent said it was due to religion.

The main reason for women avoiding birth control, aside from wanting a child, was fear of side-effects, sometimes reflecting the negative attitude of their husbands to condoms, intra-uterine devices and pills.

But a lack of education about contraceptives and poor access are also major issues and some experts say the government, under pressure from the dominant Catholic church, is to blame.

“I know so many Catholics practicing modern contraceptive methods and it doesn’t bother their conscience,” said Eden Divinagracia, executive director of the Philippine NGO council on population, health and wealth.

“But the administration right now is not supportive of family planning. The president is playing safe.”

Successive governments have shied away from widely supplying contraceptives or teaching birth control in schools for fear of triggering the wrath of the country’s bishops, who can make or break an administration.

President Gloria Macapagal Arroyo, who survived an impeachment attempt last year, is particularly reliant on the support of the church and shows no sign of reversing her emphasis on natural family planning over artificial methods.

In the meantime, job creation cannot keep up with the growth in the labor force and education standards are dropping due to overcrowded schools.

Elizabeth Pangalanan, executive director of the Center for Integrative and Development Studies, said the state was conceding to one religion in matters of reproductive health.

“The state should enforce these rights,” she said at a recent forum. “The Catholic church has often exaggerated certain issues and takes them out of context. What it needs is honesty and truth-telling, which they often preach, regarding sex education.”

PRIVATE INITIATIVES

With the central administration turning the other cheek and only a handful of local governments devoting funding to condoms and pills, poor Filipinos — who make up the bulk of the population — must rely on foreign donors for contraceptives.

The U.S. government agency USAID has been the biggest provider of birth control devices in the Philippines for the past 30 years but has stopped supplying condoms and plans to end the rest of its contraceptive donation program by 2008.

USAID, which declined a Reuters request to comment, has said its phase-out was in line with Manila’s goal of self-reliance in family planning and pointed to the private sector as an alternative supplier of contraceptives.

But Dr. Zahidul Huque of the United Nations Population Fund said private businesses were not ready to take up where USAID was leaving off for fear of a negative reaction from the church.

“USAID are pulling out without preparing the country,” Huque said.

In the absence of a government push to tackle population growth, charities and local medical professionals are trying to fill the gap.

Dr. Jonathan Flavier, one of the few Filipino men to have had a vasectomy, is encouraging others to have the procedure. For him, the problem is not machismo but fear about an operation that lasts, at most, 30 minutes.

“We are more scaredy cats than macho,” Flavier said.

Cancer Prevention Institute Publishes Atlas of Cancer in Ohio

DAYTON, Ohio, July 26 /PRNewswire/ — The Cancer Prevention Institute (CPI) just released the first and only cancer reference guide showing incidence and mortality rates for 16 of the most common cancers, mapped by county in Ohio. CPI, based in Dayton, Ohio, is committed to cancer screening and education for the underserved and a member of Premier Health Partners.

The book, Atlas of Cancer Incidence & Mortality in Ohio 1996 – 2001, by Jerzy E. Tyczynski, PhD; Kari Pasanen, MSc; Hans J. Berkel, MD, PhD; and Eero Pukkala, PhD, was published in June 2006 to help CPI identify patterns of cancers in Ohio. Researchers will use the data to better understand the magnitude and scope of cancer so community health programs can be designed to successfully lower cancer death rates.

“The outcome of this project indicates elevated risk for cancer in various hot spots of Ohio, and highlights unfavorable differences in mortality among blacks, but surprisingly does not provide for a large variation in geographic difference for cancer in the state,” said Jerzy E. Tyczynski, PhD, an author of the book while working at CPI and now an epidemiologist with a pharmaceutical company. “My conception for this project had as much to do with creating a measurement device for future programming as it did with determining the occurrence and frequency of cancer so we could better direct our work in preventing it.”

The authors used a research mapping technique developed by the Finnish Cancer Registry in Helsinki, Finland that focused on a “smoothing” method in which weighted averages of cancer per county were calculated versus geographic location of a patient with cancer at the time of diagnosis. The result is pages of color-coded smooth maps of Ohio without county borders.

For up to nine copies of the wire-bound book or CD-rom, price is $45 including s/h through http://www.cancerpreventioninstitute.org/. Discounts are given for book orders more than 10. For information, contact 877-274-4543.

Cancer Prevention Institute

CONTACT: Jayme Soulati of Marketing, Media & More for CPI,+1-937-312-1363

Web site: http://www.cancerpreventioninstitute.org/

Canada to compensate victims of hepatitis scandal

By David Ljunggren

OTTAWA (Reuters) – Canada, still struggling with the
after-effects of a long-running scandal over tainted blood,
said on Tuesday it planned to pay a total of C$1.1 billion
($965 million) to around 5,500 people who had contracted
hepatitis C from transfusions.

The victims had been excluded from an earlier compensation
plan that paid out money to people who were infected between
1986 and 1990, the year when Canada adopted tests that better
screened blood for impurities and diseases.

Prime Minister Stephen Harper, whose Conservatives promised
in opposition they would compensate all victims, said the plan
still had to be approved by courts where people seeking
compensation have launched class action lawsuits.

“Because these victims have waited long enough for what is
due to them, our government is going to do everything in its
power to ensure that matters are moved ahead as quickly as
possible,” he told a news conference, saying he hoped the money
would be paid out early next year.

Tens of thousands of blood transfusion recipients in Canada
contracted the AIDS and hepatitis C viruses from contaminated
blood and blood products in the 1980s.

Around 3,000 have died so far and some of the money Harper
announced will go to the estates of the deceased.

Renee Daurio, who caught hepatitis C from a blood
transfusion in 1979, welcomed the promise of compensation but
said it could not erase years of suffering.

“No amount of money can bring back your health. No amount
of money will bring those lost years back,” Daurio told CBC
television, saying she took up to 50 pills a day.

Three doctors, the former head of the Canadian Red Cross
Society’s blood transfusion service and the U.S. pharmaceutical
company that provided the blood are currently on trial.

Prosecutors say the accused knew the blood could be
contaminated but continued to use it.

The charges include criminal negligence causing bodily harm
and endangering the public, which carry a maximum 10-year
prison sentence. The trial is expected to end early next year.

The earlier compensation package, brought in by the then
Liberal government in 1998, covered around 10,000 people but
would not pay those who became infected before 1986 on the
grounds that no suitable tests existed at that time.

“All should be compensated equally, because all of the
victims have endured pain and suffering,” said Harper, who was
speaking in the southern Ontario town of Cambridge. His
Conservative Party took office in February this year after more
than 12 years of Liberal rule.

($1=$1.14 Canadian)

Vital Diagnostics Division of Clinical Data Announces Launch of Lumy Microplate Luminometer and Turbi-Quick POC Immunoanalyzer to International Market

Clinical Data, Inc. (NASDAQ: CLDA), a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as clinical diagnostics to improve patient care, announced today that its Vital Diagnostics(TM) division launched the Lumy(R) Microplate Luminometer and Turbi-Quick POC immunoanalyzer to the international market via OEM and distribution.

The Lumy is highly flexible and powerful instrument for all bioluminescense and chemiluminescense applications. It is controlled by an easy to use and innovative Windows-based software package. Lumy offers the highest sensitivity in the market and already has a wide range of tests available. It provides an economical solution for glow-only luminescence testing and the small footprint makes it the ideal solution for small laboratories.

The Turbi-Quick(TM) is the company’s new benchtop analyzer for the rapid quantification of immuno proteins in doctor’s offices and small laboratories. It is fast, easy to use and provides low cost per test with no calibration necessary. The calibration curve is stored on a smart card provided with the kit. A wide range of tests are available including specific proteins, HbA1c, ferritin, and a coagulation panel.

Sakari Boman, Director of International Sales for Vital Scientific, the International business unit of Vital Diagnostics, said, “These new devices broaden the reach of our distributors into even more labs with additional assays. We continue to bring products to market that drive testing closer to the patient. This is good for the patient and their healthcare providers. These new products are now available through our Vital Scientific Sales Team. Please contact us at [email protected].”

Vital Diagnostics again notes it will be participating at booth #2063 at the AACC 2006 Annual Meeting and Clinical Lab Exposition to be held from July 23-27 in Chicago and available to discuss its product offerings.

About Clinical Data, Inc.

Clinical Data, Inc. is a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as genetic tests to improve patient care. The Company, founded in 1972, is organized under three worldwide divisions segmented by service offerings and varying client constituents: PGxHealth(TM); Cogenics(TM); and Vital Diagnostics(TM). Clinical Data’s Therapeutic Diagnostics(TM) division, PGxHealth, builds upon existing assets and know-how acquired from Genaissance Pharmaceuticals in the areas of genomics-based, genetic tests and therapeutic efficacy and safety biomarker development for drug utilization. PGxHealth plans to develop and introduce novel Therapeutic Diagnostics in some instances in combination with new and existing therapeutics. Clinical Data’s Pharmacogenomics and Molecular Services(TM) division, Cogenics, consolidates the operations of Genaissance Pharmaceuticals, Inc., Lark Technologies, Inc. and Icoria, Inc., each acquired during 2005, and Genome Express SA, acquired in 2006. Cogenics provides a comprehensive range of molecular and pharmacogenomics services to pharmaceutical, biotech, academia, agricultural, and government clients. These services are offered in both research and regulated environments and have applications across the lifecycle of pharmaceutical product development including pharmacovigilance requirements post-launch. Clinical Data’s Vital Diagnostics division consolidates the operations of Clinical Data Sales & Service, Inc., Vital Scientific NV, Vital Diagnostics Pty. Ltd., and Electa Lab s.r.l. This division serves the clinical laboratory in the traditional in-vitro diagnostics market worldwide with a focus on the physician’s office, hospital and small-to-medium sized laboratory segments. With customers in approximately 100 countries, Vital Diagnostics has achieved a leading market share for instruments and reagents sold into moderately complex physicians’ office laboratories within the United States. Clinical Data currently employs a staff of over 430. The Company is headquartered in Newton, Massachusetts with operations in Texas, Connecticut, RTP – North Carolina, Rhode Island, and California as well as internationally in the UK, France, the Netherlands, Italy and Australia. Furthermore, Clinical Data has numerous distribution, licensing, development and other collaborations with key partners.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as “expect(s)”, “feel(s)”, “believe(s)”, “will”, “may”, “anticipate(s)” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our recent acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; competition from pharmaceutical, biotechnology and diagnostics companies; the strength of our intellectual property rights; the effect on the Company’s operations and results of significant acquisitions or divestitures made by major competitors; the Company’s ability to achieve expected synergies and operating efficiencies in all of its acquisitions, and to successfully integrate its operations; and those risks discussed and identified by Clinical Data in its public filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data’s SEC reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2006, and fiscal 2005 and 2006 quarterly reports on Forms 10-QSB and 10-Q.

Internet Website: www.clda.com

Nasal Rinsing Technique Eases Sinusitis

NEW YORK (Reuters Health) – Nasal irrigation, a traditional therapy that has been shown to help people with chronic sinus problems, can be easily learned with a 30-minute group training session, a new study shows.

Patients in the study also reported a sense of “empowerment” because they could use and adjust the technique effectively on their own rather than requiring multiple doctor visits and prescriptions, Dr. David Rabago of the University of Wisconsin at Madison and colleagues report.

Used for thousands of years in the Ayurvedic and Yogic traditions, nasal irrigation involves rinsing the nasal cavity with a saline solution to get rid of mucus that may contain allergens or infectious agents.

Rabago and colleagues had previously reported that a six-month trial of nasal irrigation in patients with chronic stuffy nose (rhinitis) and sinusitis reduced symptoms and medication use and improved quality of life. In the current study, Rabago and his team surveyed 28 patients who participated in the study about their experience.

The patients found that barriers to learning the technique included fear of having liquid in the nasal cavity, initial discomfort and mild side effects, the need to learn how to perform nasal irrigation effectively, and the need to set aside time for nasal irrigation, Rabago and his team report in the Annals of Family Medicine.

However, participants said that the 30-minute group sessions in which they learned to perform the technique — especially “coached practice” — helped them to overcome these misgivings.

They also reported incorporating nasal irrigation into their existing daily hygiene routine, using warm water, and making adjustments to the salt content and schedule to ease discomfort.

“This ability to manage their own treatment likely contributed to the reported sense of empowerment and personal control of their chronic symptoms, further enabling continued use,” Rabago and his colleagues write.

They also comment that they were surprised by the “passion and drama” of many of the patients’ reports of how using the technique eased their symptoms and improved their quality of life.

SOURCE: Annals of Family Medicine, July/August 2006.

Intraepithelial Lymphocytosis in Architecturally Preserved Proximal Small Intestinal Mucosa: An Increasing Diagnostic Problem With a Wide Differential Diagnosis

By Brown, Ian; Mino-Kenudson, Mari; Deshpande, Vikram; Lauwers, Gregory Y

Context.-An increased intraepithelial lymphocyte density in an architecturally normal proximal small intestinal mucosal biopsy is a common finding facing surgical pathologists dealing with gastrointestinal biopsy specimens. Approximately 1% to 2% of all proximal small intestinal biopsies will show this change. It is increasingly recognized by surgical pathologists that gluten- sensitive enteropathy is an important cause of this pattern; however, gluten-sensitive enteropathy accounts for the minority of all cases. A wide variety of immunologic stimuli can raise intraepithelial lymphocyte numbers. Among the other common associations are enteric infection, autoimmune disease, drugs, and gastric Helicobacter infection.

Objective.-To outline the causes of intraepithelial lymphocytosis, to highlight the importance and the difficulties faced in establishing gluten-sensitive enteropathy as the cause, and to aid the surgical pathologist in the routine sign out of these cases.

Data Sources.-A review of the literature detailing the causes or associations of proximal small intestinal intraepithelial lymphocytosis is presented.

Conclusions.-Increased lymphocyte numbers in the epithelium of architecturally preserved proximal small intestinal biopsies is a morphologic feature associated with a broad differential diagnosis.

(Arch Pathol Lab Med. 2006;130:1020-1025)

Intraepithelial lymphocytes (IELs) are a normal constituent of the small intestinal mucosa where they play a significant role in immune surveillance and activation.1 The vast majority of IELs are of T-cell type and express an α/β T-cell receptor on their surface.2 Only approximately 5% have surface γ/δ T-cell receptors (a population that is expanded in the setting of gluten sensitivity).2-4

The upper normal limit of IELs in the proximal small intestine has long been considered to be 40 IELs per 100 epithelial cells,1,5 a ratio used as a criterion of the Marsh classification for gluten sensitivity.6 This figure was derived by counts performed on thickly sectioned (7-m) hematoxylin-eosin sections.5 However, recent studies using hematoxylin-eosin sections cut at 3 m7 and 4 m8 and CD3 immunohistochemistry7 have shown the upper limit of normal in the proximal small intestine (especially in the duodenum) to be 25 IEL per 100 epithelial cells. Theoretically up to 2.5% (

NORMAL VILLI

Given that the villi in proximal small intestinal biopsies are seldom perfectly orientated and may appear bent or are tangentially cut,11 it has been suggested that 4 normal fingerlike villi in a row with a villus-to-crypt ratio between 3:1 and 5:1 be seen to consider the biopsy architecturally normal.11,12 In the normal villi, IELs decrease in number from the base toward the tip13 and counting IELs at the tips of the villi is recommended as the most useful method of confirming an increase.13-15

In practice, it is wise to avoid counting IELs in villi that are not well oriented because tangential sections of the villus base can produce an artificial impression of an increased number.

CD3 immunohistochemistry (Figure 1) can aid the detection of IELs particularly because some lymphocytes can have irregular nuclear outline mimicking granulocytes and others could be mistaken for epithelial cell nuclei.14,16 However, not all pathologists have found this additional stain helpful, cautioning that it decreases the sensitivity derived from appreciating a loss of the normal IEL decrescendo pattern.17

CAUSES OF INCREASED IELs IN ARCHITECTURALLY NORMAL SMALL INTESTINAL BIOPSIES

Because IELs are a functioning component of the intestinal immune system, it is not unexpected that immunologic stimulation whether by an ingested antigen, endogenous antigen, or autoimmune causation can lead to increased IELs. In many cases there will be associated epithelial cell injury and death (by apoptosis) leading in time to villus atrophy. Conditions associated with normal villus architecture would seem to represent a mild or early manifestation of this process.

Figure 1. CD3 immunohistochemical study of normal small bowel (original magnification 100).

Figure 2. Marsh type 1 lesion in a young female patient with serology proven gluten-sensitive enteropathy (hematoxylin-eosin, original magnification 200).

Figure 3. CD3 immunohistochemical study of gluten-sensitive enteropathy (original magnification 100). Note the increased exocytosis in this example of gluten-sensitive enteropathy with the characteristic top-heavy pattern.

Figure 4. Example of tropical sprue in middle-aged Guatemalan woman. The biopsy demonstrates a preserved villous architecture with exquisite lymphocytic exocytosis in the surface epithelium. The symptomatology and histologic alteration disappeared after antibiotic therapy thematoxylin-eosin, original magnification 100).

Gluten-Sensitive Enteropathy With Normal Villus Architecture

That gluten sensitivity can be morphologically manifest by intraepithelial lymphocytosis without villus atrophy is increasingly being appreciated by pathologists (Figure 2). The reported prevalence of gluten-sensitive enteropathy (GSE) as the cause of increased IELs in architecturally normal small intestinal biopsies has ranged from 9% to 40%,9,10,18 although for reasons mentioned subsequently the exact prevalence is difficult to determine.

It is, nonetheless, important to try to recognize the gluten- sensitive patients with mild morphologic changes because these people can develop significant nutritional deficiencies leading to anemia (usually iron deficiency type) and osteoporosis.19,20 Furthermore, there is a small risk for the subsequent development of malignancy (particularly intestinal T-cell lymphoma, but also upper gastrointestinal tract carcinomas) in these patients as well as in their first-degree relatives.19,20 Terms such as gluten sensitivity with mild enteropathy, latent celiac disease, and potential coeliac disease have been applied to this condition.17,21 Despite mild changes on small bowel biopsy, these patients can have significant clinical symptoms and signs because these correlate better with the length of involvement of the small intestine than with the severity of villus architectural change.22 Also because the architectural change in GSE can be patchy, biopsies showing normal architecture may not reflect villus change elsewhere in the small intestine.

A major problem confronting clinicians is to establish which cases of intraepithelial lymphocytosis represent the Marsh type 1 pattern of gluten sensitivity from the other possible causes of this morphologic pattern. The magnitude of this problem is highlighted when one considers the severe dietary alterations and lifelong clinical follow-up required in patients diagnosed with gluten sensitivity, while failure to establish the diagnosis puts patients at risk of the complications listed previously. Although small intestinal biopsy remains the gold standard for the diagnosis of GSE, it is usually supplemented by serologic tests. The latter includes immunoglobulin (Ig) A antiendomysial antibodies, IgA antitissue transglutaminase (which has largely replaced the IgA antiendomysial antibody test), and IgA and IgG antigliadin antibodies. The first 2 have optimal sensitivity and specificity as well as high positive predictive value.23,24 A positive IgA antiendomysial antibody test or a significantly raised anti-tissue transglutaminase titer helps confirm the diagnosis of GSE even when villus architecture is normal.25 Unfortunately, the likelihood of a positive test correlates with the degree of mucosal injury and GSE cases with intraepithelial lymphocytosis alone can often have antibody titers in the normal range.25-28 Thus, negative serology does not exclude a diagnosis of GSE with a Marsh type 1 pattern.

Where available, testing for human leukocyte antigen DQ haplotype is being increasingly used. However, this is only helpful in excluding gluten sensitivity (or making it less likely)29 because celiac disease associated DQ haplotypes (DQ2 and DQ8) are seen in many of the normal population.30 This leaves many clinicians to resort to a trial of gluten-free diet or sometimes a gluten challenge followed by rebiopsy.

Importantly, the surgical pathologist may be able to assist in this situation. It is recognized that biopsies displaying an even distribution of IELs along the villi or a villus tip accentuation with a consequent loss of the normal decrescendo pattern (decrease in IEL numbers from base to tip of villi) are more likely to be associated with GSE than cases without this alteration (Figure 3).9,13,14,15 This is, however, not specific to GSE and not all cases of gluten sensitivity show this feature.9,13 However if present, it should be highlighted in the surgical pathology report.

Hypersensitivity to Other Alimentary Proteins

Hypersensitivity to nongluten components of foods including cereals, cow’s milk, soy produc\ts, fish, rice, and chicken are also associated with increased IELs in affected patients, although villus atrophy is usually present.31-37

We and others have observed intraepithelial lymphocytosis in children with autism, whether or not it is associated with lactase deficiency frequently recorded in these patients.38

Infections

Parasitic infections such as Giardin lamblia and Cryptosporidium can lead to increased lymphocytic exocytosis. Elevated IEL counts can also be seen as a result of viral enteritis and in the setting of tropical sprue,39,40 although some degree of villus atrophy is usually recognized (Figure 4). Goldstein17 has also noted increased IELs in the duodenal bulb in patients with Helicobacter pylori gastritis. We and others41 have observed this association with gastric H pylori infection not infrequently (Figure 5). The intraepithelial lymphocytosis can also be seen beyond the duodenal bulb and is usually not associated with gastric intraepithelial lymphocytosis.

Bacterial overgrowth whether related to gastric hypochlorhydria or intestinal dysmotility has been associated with an increase of IELs (in the absence of villus atrophy) when compared with control biopsies.42 However, only some cases in that study had an IEL density greater than what is currently considered the normal range. In the study by Kakar et al,9 2 cases of intraepithelial lymphocytosis were related to bacterial overgrowth.

Drugs

Various drugs have been associated with colonic intraepithelial lymphocytosis (ie, lymphocytic colitis),43,44 so it is intuitively expected that drugs could be responsible for similar change in proximal intestine. However, at present there is a paucity of literature supporting this presumption. Kakar et al9 noted nonsteroidal anti-inflammatory drug use in 14% of patients in their series. Similarly, in our experience 15% of patients with increased IELs were on nonsteroidal anti-inflammatory drugs at the time of biopsy. We also found 20% of patients were taking a proton pump inhibitor (I. Brown, unpublished data, 2004).

Autoimmune Conditions

Disorders of immune regulation are frequently associated with elevated IELs and various degrees of villus atrophy. Fourteen percent of patients in the series by Kakar et al9 had an associated immune dysregulation condition. Reported conditions include Hashimoto thyroiditis, Graves disease, rheumatoid arthritis, psoriasis, multiple sclerosis, and systemic lupus erythematosus (Figure 6).1,9,45 We have also noted an association in 2 patients with ankylosing spondylitis and in 1 patient with progressive systemic sclerosis. Intestinal intraepithelial lymphocytosis in the setting of glomerulonephritis particularly when presenting with nephrotic syndrome is also reported.46

Autoimmune enteropathy, an ostensibly uncommon condition usually seen in a pediatric setting, can mimic GSE clinically and histologically.47,48 Villus atrophy is normally observed but morphologically milder cases could enter the differential diagnosis under discussion. In addition, this condition is reported in adults48 and may be underrecognized.

Figure 5. Mild lymphocytic exocytosis in a duodenal biopsy from a patient with Helicobacter pylori gastritis. The changes disappeared after anti-Helicobacter therapy (hematoxylin-eosin, original magnification 200).

Figure 6. Increased lymphocytic exocytosis in a middle-aged woman with a history of lupus. Serologic markers for gluten-sensitive enteropathy were negative and she failed to respond to a gluten- free diet (hematoxylin-eosin, original magnification 100).

Figure 7. Prominent lymphocytic exocytosis in a duodenal biopsy from a young male with active Crohn ileitis (hematoxylin-eosin, original magnification 200).

Figure 8. Jejunal biopsy from an elderly man with refractory gluten-sensitive enteropathy. Polymerase chain reaction and flow cytometry demonstrated a monoclonal T-cell population (hematoxylin- eosin, original magnification 200).

Patients with hypogammaglobulinemia whether due to IgA deficiency or common variable immunodeficiency often have increased IELs in the proximal small intestine. Despite the defective humoral immune system in these patients, this finding has a cellular immunologic basis pathogenically analogous to GSE. Villus atrophy is usually seen but can be mild. Of diagnostic value are associated features including reduced numbers of plasma cells, frequent parasitic infection (eg, Giardia) and lymphoid follicle formation.49-51

Recently, it has been reported that chronic inflammatory conditions of the colon such as ulcerative colitis,52 Crohn disease (Figure 7),9,17,52 and collagenous and lymphocytic colitis9 can be concurrently associated with proximal small intestinal intraepithelial lymphocytosis. In both lymphocytic and collagenous colitis, the association appears to be exclusive of gluten sensitivity in many cases despite the recognized association of both conditions with celiac disease.44,53,54

Interestingly, the finding of small intestinal intraepithelial lymphocytosis in Crohn disease can be seen at the time of active disease but may also precede active Crohn enteritis,17 possibly in a fashion analogous to focal colonic intraepithelial lymphocytosis preceding Crohn colitis.55

An enigmatic condition termed diffuse lymphocytic $nstroenteropathy56 characterized by intraepithelial lymphocytosis throughout the upper gastrointestinal tract has been reported. Whether this is a distinct morphologic entity, a variant of gluten sensitivity, or an unusual immune reaction pattern to various (and unrecognizable) stimuli is unclear.

Finally with respect to immune causation, proximal small intestinal biopsies in patients with graft versus host disease can, although uncommonly, display prominent numbers of IELs.11 The finding of epithelial cell apoptosis and some degree of architectural disturbance57 together with the clinical setting allows for the correct diagnosis.

Neoplastic Disorders

The preinfiltrative (or cryptic) form of intestinal T-cell lymphoma (enteropathy-associated T-cell lymphoma) in which the neoplastic cells (often surprisingly nonatypical) can present within a minimally or nonatrophic small intestine mucosa (Figure 8).58 Failure to respond to a gluten-free diet and a significant malabsorption problem are frequent accompaniments. In addition to immunohistochemical evaluation, flow cytometric studies or polymerase chain reaction for T-cell receptor gene rearrangement are usually necessary to establish a firm diagnosis.

Intraepithelial Lymphocytosis Without Definitive Diagnosis

Finally there are a significant number of patients displaying intraepithelial lymphocytosis in their proximal small intestine who manifest ongoing often nonspecific gastrointestinal symptoms but for whom a specific diagnosis cannot be made. Some of these patients meet clinical criteria for irritable bowel syndrome and may respond symptomatically to a gluten-free diet. Whether these patients have a subtle form of gluten sensitivity remains uncertain although there is some experimental support for this suggestion.59

CONCLUSION

Up to 2.5% of proximal small intestinal mucosal biopsies display increased IELs (>25 IELs per 100 epithelial cells) in the absence of villus architectural change. In most cases this is due to immunologic activation of the lymphocytes that are normally resident in the epithelium. The causes for this increase in numbers of IELs are multiple and include reactions to intraluminal antigens and small intestinal manifestations of autoimmune or other allied diseases (see Table). Gluten sensitivity is a common cause, accounting for 9% to 40% of cases.9,10,18 Other common associations include gastric H. pylori infection, a drug reaction, and autoimmune lymphocyte stimulation. In a significant number of cases, a cause is never established. It is the practice of one of us (I.B.) to add a comment to the surgical pathology report in cases in which intraepithelial lymphocytosis is the diagnosis. This comment states “the finding of intraepithelial lymphocytosis with preserved villus architecture is a non specific immunological phenomenon that has a large number of possible causes. A mild histological manifestation of gluten sensitivity is one of these causes. Unfortunately, celiac serology may be negative even in patients that subsequently prove to be gluten sensitive. Other common causes of this appearance include infective enteritis, H. pylori infection, a drug effect eg NSAIDs, and autoimmune disease. In many cases a specific cause is not identified.”

Causes of Proximal Small Intestinal Intraepithelial Lymphocytosis With Normal Villus Architecture*

The establishment of a diagnosis of gluten sensitivity can be clinically difficult and relies on a weighted assessment of clinical, serologic, and histopathologic data. Surgical pathologists can help by highlighting cases that have a uniform distribution of IELs over the villus length rather than those showing increased numbers but in a persisting decrescendo pattern because the latter is an unusual feature for GSE.

Awareness of the various conditions associated with increased IELs in architecturally preserved proximal small intestinal mucosa is important to guide the clinician toward a correct diagnosis.

References

1. Ferguson A. Intraepithelial lymphocytes of the small intestine. Gut. 1977;18:921-937.

2. Arato A, Hecsek G, Savilahti E. Immunohistochemical findings in the jejunal mucosa of patients with coeliac disease. Scand J Castroenterol Suppl. 1998;228:3-10.

3. Spencer J, MacDonald TT, Diss TC, Walker-Smith JA, Lichtiea PJ, Issacson PG. Changes in intraepithelial lymphocyte subpopulations in coeliac disease and enteropathy associated T cell lymphoma (malignant histiocytosis of the intestine). Gut. 1989;30:339-346.

4. Maki M, Holm K, Collin P, Savilahti E. Increase in gamma/ delta T cell receptor hearing lymphocytes in normal small bowel mucosa in latent co\eliac disease. Gut. 1991;32:1412-1414.

5. Ferguson A, Murray D. Quantitation of intraepithelial lymphocytes in human jejunum. Gut. 1971;12:988-994.

6. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol. 1999;11:1185-1194.

7. Verress B, Franzen L, Bodin L, Borch K. Duodenal intraepithelial lymphocyte-count revisited. Scand J Gastroenterol. 2004;138-144.

8. Hayat M, Cairns A, Dixon MF, O’Mahuny S. Quantitation of intraepithelial lymphocytes in human duodenum: what is normal? J Clin Pathol. 2002;55:393-395.

9. Kakar S, Nehra V, Murray JA, Dayharsh GA, Burgart LJ. Significance of intraepithelial lymphocytosis in small bowel biopsy samples with normal mucosal architecture. Am J Gastroenterol. 2003;98:2027-2033.

10. Mahadeva S, Wyatt JI, Howdle PD. Is a raised intraepithelial lymphocyte count with normal duodenal villus architecture clinically relevant? J Clin Pathol. 2002;55:424-428.

11. Goldman H, Antonioli DA. Mucosal biopsy of the esophagus, stomach and proximal duodenum. Hum Pathal. 1982;13:423-448.

12. Segal GH, Petras RE. Small intestine. In: Sternberg SS, ed. Histology for Pathologists. New York, NY: Raven Press; 1992:571- 574.

13. Goldstein NS, Underbill J. Morphologic features suggestive of gluten sensitivity in architecturally normal duodenal biopsy specimens. Am J Clin Pathol. 2001;116:63-71.

14. Biagi F, Luinetti O, Campanella J, et al. Intraepithelial lymphocytes in the villus tip: do they indicate potential coeliac disease? I Clin Pathol. 2004;57:835-839.

15. Jarvinen TT, Collin P, Rasmussen M, et al. Villus tip intraepithelial lymphocytes as markers of early-stage coeliac disease. Stand J Gastroenterol. 2004;39:428-433.

16. Mino M, Lauwers GY. Role of lymphocytic immunophenotyping in the diagnosis of gluten-sensitive enteropathy with preserved villus architecture. Am J Surg Pathol. 2003;27:1237-1242.

17. Goldstein NS. Proximal small bowel mucosal villus intraepithelial lymphocytes. Histopathology. 2004;44:199-205.

18. Wahab PJ, Crusius JB, Meijer JW, Mulder CJ. Gluten challenge in borderline gluten sensitive enteropathy. Am J Gastroenteml. 2001;96:1464-1469.

19. Marsh MN. Screening tor latent gluten sensitivity: questions many, but answers few. Eur J Gastroenterol Hepatol. 1996;8:3-6.

20. Ciclitira PJ. AGA technical review on celiac sprue. Gastroenterology. 2001;120:1526-1540.

21. Holmes GKT. Potential and latent coeliac disease. Eur J Gastmenterol Hepatol. 2001;11:1057-1060.

22. Marsh MN. Clinical and pathological spectrum of coeliac disease. Gut. 1993;34:1740.

23. Pittschreler K, Ladinser B. Coeliac disease: screened by a new strategy. Acta Pediatr Suppl. 1996;412:42-45.

24. Dietrich WF, Laag E, Schopper H, et al. Autoantibodies to tissue transglutaminase as predictors of celiac disease. Gastruenterulogy. 1998;115:1317-1321.

25. Ferguson A, Gillette H, Humphrey K, Kingstone K. Heterogeneity of celiac disease: clinical pathological, immunological and genetic. Ann N Y Acad Sci. 1998;859:112-121.

26. Rostami K, Kerikhaert I. Sensitivity of antiendomysial and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice. Am J Gastroentivol. 1999;94:888-894.

27. Tursi A, Brandimarte G, Giorgetti G, Gigliobianco A, Lombardi D, Gasbarrini G. Low prevalence of antigliadin and antiendomysial antibodies in subclinical/silent celiac disease. Am J Gastroenterol. 2001;96:1507-1510.

28. Murray JA, Herlein J, Mitros F, Goeken JA. Serologic testing for celiac disease in the United States: results of a multilanoratory comparison study. Clin Diagn Lab Immunol. 2000;7:584- 587.

29. Collin P. New diagnostic finding in coeliac disease. Ann Med. 1999;31:399-405.

30. Murdock AM, Johnston SD. Diagnostic criteria for coeliac disease: time for change? Eur J Gastroenterol Hepatol. 2005;17:41- 43.

31. Kaukinen K, Turjanmaa K, Maki M, et al. Intolerance to cereals is not specific for coeliac disease. Stand J Gastroenterol. 2000;35:942-946.

32. Taylor CJ. Predictive value of intraepithelial lymphocyte count in childhood coeliac disease. J Pediatr Gastroenterol Nutr. 1988;7:532-536.

33. Kokkonen K, Holm K, Karttunen TJ, Maki M. Children with untreated food allergy express a relative increment in the density of duodenal γδ T cells. Scand J Gastroenterol. 2000;11:1137-1142.

34. Ament ME, Rubin CE. Soy protein: another cause of the flat intestinal lesion. Gastroenterology. 1972;62:227-234.

35. Kuitunen PM, Rapola J, Savilahti E, Visakorpi JK. Response of the jejunal mucosa to cow’s milk in the malabsorption syndrome with cow’s milk intolerance. Piediatr Scand. 1973;62:585-595.

36. Victoria C, Camarero C, Sojo A, Ruiz A, Rodrigius-Soriano J. Enteropathy related to fish, rice and chicken. Arch Dis Child. 1982;57:44-48.

37. Savilahti E. Food induced malabsorption syndrome. J Pediatr Gastroenterol Nutr. 2000;30(suppl):561-566.

38. Ashwood P, Anthony A, Torrente F, Wakefield AJ. Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10. J Clin Immunol. 2004;24:664-673.

39. Montgomery RD, Shearer ACI. The cell population of the upper jejunal mucosa in tropical sprue and post infective malabsorption. Gut. 1974;15:387-391.

40. Ferguson A, McClure JP, Townley RR. Intraepithelial lymphocyte counts in small intestinal biopsies from children with diarrhoea. Acta Paediatr Scand. 1976;65:541-546.

41. Memeo L, Jhang I, Hibshoosh H, Green PH, Rotterdam H, Bhagat G. Duodenal intraepithelial lymphocytosis with normal villous architecture: common occurrence in H. pylori gastritis. Mod Pathol. 2005;18:1134-1144.

42. Riordan SM, McIver CJ, Wakefield D, Duncombe VM, Thomas MC, Bolin TD. Small intestinal mucosal immunity and morphometry in luminal overgrowth of indigenous gut flora. Am J Gastroenterol. 2001;96:494-500.

43. Treanor D, Sheahan K. Microscopic colitis: lymphocytic and collagenous colitis. Curr Diagn Pathol. 2002;8:33-41.

44. Wang N, Dumot JA, Achkar E, Easley KA, Petras RE, Goldblum JR. Colonic epithelial lymphocytosis without a thickened subepithelial collagen table: a clinicopathological study of 40 cases supporting a heterogeneous entity. Am J Surg Pathol. 1999;21:1068-1074.

45. Michaelsson G, Kraaz W, Gerden B, et al. Increased lymphocytic infiltration in duodenal mucosa from patients with psoriasis and serum IgA antibodies in gliadin. Br J Dermatol. 1995;133:896-904.

46. Rostoker G, Delchier JC, Chaumette MJ. Increased intestinal intraepithelial T lymphocytes in primary glomerulonephritis: a role of oral tolerance breakdown in the pathophysiology of human primary glomerulonephritides. Nephrol Dial Transplant. 2001;16:511-517.

47. Russo PA, Brochu P, Seidman EG, Claude RC. Autoimmune enteropathy. Pediatr Dev Pathol. 1999;2:65-71.

48. Corazza GR, Biagi F, Volta U, Andreani ML, DeFranceshi L, Gasbarrina G. Autoimmune enteropathy and villous atrophy in adults. Lancet. 1997;350:106-109.

49. Klemola T. Immunohistochemical findings in the intestine of IgA deficient persons: number of intraepithelial T lymphocytes is increased. J Paediatr Gastroenterol Nutr. 1998;7:537-543.

50. Washington K, Stenzel TT, Buckley RH, Gottfried MR. Gastrointestinal pathology in patients with common variable immunodeficiency and X linked agammaglobulinaemia. Am J Surg Pathol. 1996;20:1240-1252.

51. Lai Ping So A, Mayer L. Gastrointestinal manifestations of primary immunodeficiency disorders. Semin Gastrointest Dis. 1997;8:22-32.

52. Tobin JM, Sinha B, Romani P, Saleh AR, Murphy MS. Upper gastrointestinal mucosal disease in pediatric Crohn disease and ulcerative colitis: a blinded, controlled study. J Pediatr Gastroenterol Nutr. 2001;32:443-448.

53. Freeman HJ. Collagenous colitis as the presenting feature of biopsy: defined coeliac disease. J Clin Gastroenterol. 2004;38:664- 668.

54. Koskela RM, Niemela SE, Karttunen TJ, Lehtola JK. Clinical characteristics of collagenous and lymphocytic colitis. Scand J Gastroenterol. 2004;39:837-845.

55. Goldstein NS, Gyorfi T. Fotal lymphocytic colitis and collagenous colitis: patterns of Crohn’s colitis? Am J Surg Pathol. 1999;23:1075-1081.

56. Lynch DA, Sobala GM, Dixon MF, et al. Lymphocytic gastritis and associated small bowel disease: a diffuse lymphocytic gastroenteropathyi J Clin Pathol. 1995;48:939-945.

57. MacDonald GB, Shulman HM, Sullivan KM, Spencer GD. Intestinal and hepatic complications of human bone marrow transplantation Part 1. J Gastroenterol. 1986;90:460-177.

58. Daum S, Weiss D, Hummel M, et al. Frequency of clonal intraepithelial T lymphocyte proliferations in enteropathy-type intestinal T cell lymphoma, coeliac disease and refractory sprue. Cul. 2001;49:804-812.

59. Wahnschaffe U, Ullrich R, Riecken EO, Schulzke JD. Coeliac disease-like abnormalities in a subgroup of patients with irritable bowel syndrome. Gastroenterology. 2001;121:1329-1338.

Ian Brown, MBBS, FRCPA; Mari Mino-Kenudson, MD; Vikram Deshpande, MD; Gregory Y. Lauwers, MD

Accepted for publication February 14, 2006.

From Sullivan Nicolaides Pathology, Taringa, Queensland, Australia (Dr Brown); and the Gastrointestinal Pathology Service, Department of Pathology, Massachusetts General Hospital, Boston (Drs Mino-Kenudson, Deshpande, and Lauwers).

The authors have no relevant financial interest in the products or companies described in this article.

Reprints: Ian Brown, MBBS, FRCPA, Sullivan Nicolaides Pathology, Taringa, Queensland, Australia (e-mail: [email protected]).

Copyright College of American Pathologists Jul 2006

(c) 2006 Archives of Pathology & Laboratory Medicine. Provided by ProQuest Information and Learning. All rights Reserved.

Annan pushes AIDS drug makers to lower prices

By Irwin Arieff

UNITED NATIONS (Reuters) – U.N. Secretary-General Kofi
Annan encouraged executives from nine drug companies on Monday
to lower prices of AIDS medicines and step up efforts to
develop AIDS drugs and diagnostics for children.

Annan for the first time included generic drug makers in
his latest in a series of meetings with top drug makers at U.N.
headquarters over the past five years.

The meetings aim to encourage the pharmaceutical firms to
broaden access to AIDS drugs, care and support services in low-
and middle-income countries.

While the executives had helped, the AIDS epidemic was
“still outpacing our efforts, and we need to work together in a
broad partnership to step up the response,” he said.

At his request, the officials agreed to review the prices
of existing and new HIV medications and diagnostics to make
them more affordable, accessible and appropriate for use in
low- and middle-income countries, Annan said.

They also pledged to give greater priority to developing
pediatric formulations of HIV medications and diagnostic tools
for children.

Attending the meeting were Stephen Saad, group chief
executive of South Africa’s Aspen Pharmacare Holdings Ltd.;
Chairman P. V. Ramprasad Reddy of Indian drug maker Aurobindo
Pharma Ltd.; Gary Cohen, executive vice-president of U.S. firm
Becton Dickinson & Co.’s BD Medical unit, and Peter Dolan,
chief executive officer of U.S.-based Bristol-Myers Squibb Co..

Also attending along with Annan and U.N. officials involved
in the fight against AIDS were Jean-Pierre Garnier, chief
executive officer of British drug maker GlaxoSmithKline Plc;
B.P.S. Reddy, founder of Indian pharmaceutical firm Hetero
Drugs Ltd.; Christine Poon, vice chairman of U.S.-based Johnson
& Johnson; U.S.-based Merck & Co. Inc. Chief Executive Officer
Richard Clark, and Malvinder Mohan Singh, chief executive
officer of India’s Ranbaxy Laboratories Ltd..

Endo Announces Commercial Availability of Opana(R) ER (Oxymorphone HCl) Extended-Release and Opana(R) (Oxymorphone HCl) Immediate-Release Tablets CII

CHADDS FORD, Pa., July 24 /PRNewswire-FirstCall/ — Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc. , has announced the commercial availability of Opana(R) ER and Opana(R) tablets. Endo has begun shipments to its customers and is instituting a wholesale and retail stocking program to ensure these products are distributed to retail pharmacies across the U.S. over the next several weeks. Opana(R) ER and Opana(R) are extended-release and immediate-release formulations of oxymorphone hydrochloride (HCl) that were approved by the U.S. Food and Drug Administration on June 22, 2006.

A new oral extended-release opioid analgesic treatment option for patients, Opana(R) ER is indicated for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. Opana(R) ER is not intended to be used on an as-needed basis. This is the first time oxymorphone will be available in an oral, extended-release formulation and will be available in 5mg, 10mg, 20mg and 40mg tablets. Opana(R) (the immediate release version) is indicated for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate and will be available in 5mg and 10mg tablets. Both Opana(R) ER and Opana(R) are available by prescription only.

This fall, Endo also plans to re-launch its injectable formulation of oxymorphone in the hospital setting under the new trade name. This will complete the “continuum of care” for Opana(R) by making it available in parenteral, short- and long- acting oral formulations.

“We are delighted to be able to provide physicians and patients with this new, much-needed option for patients with moderate-to-severe pain, and particularly for patients who have not found satisfaction with their current opioid treatment,” said Peter A. Lankau, President and Chief Executive Officer, “As a leader in pain management, we also take very seriously our responsibility of helping physicians and caregivers appropriately manage pain. We are confident that Endo’s PROMISE(TM) initiative, combined with our Risk Minimization Action Plan developed in conjunction with the FDA and other outside experts, will effectively minimize the inherent risks of opioid misuse, abuse and diversion through comprehensive education and support programs for both patients and physicians.”

Endo’s Commitment to Responsible Pain Management: PROMISE(TM)

Endo is committed to providing healthcare professionals and patients with safe and effective opioid analgesic medications and support programs that will better ensure their appropriate and responsible use. Through extensive experience with opioid analgesics and working with the FDA and industry experts, Endo has developed a comprehensive risk minimization action plan for Opana(R) ER and Opana(R). Evolving from the risk minimization plan is a new initiative to further help reduce the inherent risk of misuse, abuse and diversion of opioid analgesics: The Partnership for Responsible Opioid Management through Information, Support, and Education (PROMISE(TM)). The PROMISE(TM) initiative contains essential information and guidance to healthcare professionals so that they can prescribe opioids to patients responsibly and appropriately. PROMISE(TM) includes educational support and practical patient management tools. For patients, the program raises the level of knowledge of those suffering from moderate-to-severe pain and empowers them to manage their condition with the help of their healthcare professional. More information about the PROMISE(TM) initiative is available at http://www.endopromise.com/ .

About Opana ER and Opana(R) Tablets

Opana(R) ER and Opana(R) tablets were formulated using oxymorphone hydrochloride, a semisynthetic, pure microgram-opioid agonist that had been available previously only as an injectable formulation. Both products have been proven to achieve effective relief in multiple moderate-to-severe pain models, in opioid-naive and opioid-experienced patients.

Opana(R) ER’s clinical profile has demonstrated that it can be dosed consistently on a twice-daily basis and is well-tolerated when titrated effectively. Opana(R) ER has also shown maintenance of effective pain control at a stable dose over the three-month period of the pivotal clinical trials, which the company believes highlights the durability of its analgesic effect. Opana(R) ER utilizes a patented delivery system that was specifically developed to provide continuous delivery of medication over a 12-hour period, helping patients maintain a steady level of pain relief. Experts agree that patients suffering from moderate-to-severe chronic pain which is present much or all of the day need around-the-clock coverage with an analgesic agent to sustain pain relief.

Opana(R) ER has been studied in a wide range of chronic pain conditions, including low back pain, osteoarthritis pain, and cancer pain. Endo developed Opana(R) ER using Penwest Pharmaceuticals’ proprietary time-release technology, TIMERx(R).

Opana(R) has been studied in multiple post-operative pain models, including orthopedic and abdominal procedures. Immediate-release Opana(R) is a proprietary product developed by Endo.

Important Safety Information

Opana(R) ER and Opana(R) are opioid agonists and Schedule II controlled substances with an abuse liability similar to morphine. Opana(R) ER and Opana(R) can be abused in a manner similar to other opioid agonists, legal or illicit.

WARNING:

OPANA ER contains oxymorphone, which is a morphine-like opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics.

Oxymorphone can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing OPANA ER in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

OPANA ER is an extended-release oral formulation of oxymorphone indicated for the management of moderate to severe pain when a continuous, around-the- clock opioid analgesic is needed for an extended period of time.

OPANA ER is NOT intended for use as a prn analgesic.

OPANA ER TABLETS are to be swallowed whole and are not to be broken, chewed, dissolved, or crushed. Taking broken, chewed, dissolved, or crushed

OPANA ER TABLETS leads to rapid release and absorption of a potentially fatal dose of oxymorphone.

Patients must not consume alcoholic beverages, or prescription or non- prescription medications containing alcohol, while on OPANA ER therapy. The co-ingestion of alcohol with OPANA ER may result in increased plasma levels and a potentially fatal overdose of oxymorphone.

Opana(R) ER is not indicated for pain in the immediate post-operative period (12-24 hours following surgery), or if pain is mild or not expected to persist for an extended period of time.

Opana(R) ER and Opana(R) are contraindicated in patients with a known hypersensitivity to oxymorphone hydrochloride, morphine analogs such as codeine, or any of the other ingredients of Opana(R) ER and Opana(R); in patients with moderate or severe hepatic impairment or in any situation where opioids are contraindicated.

Respiratory depression is the chief hazard of Opana(R) ER and Opana(R), particularly in elderly or debilitated patients.

The most common adverse drug reactions (greater than or equal to 10%) in clinical trials for Opana(R) ER were nausea, constipation, dizziness, vomiting, pruritus, somnolence, headache, increased sweating, and sedation. The most common adverse drug reactions (greater than or equal to 10%) reported in clinical trials for Opana(R) were nausea and pyrexia.

   For full prescribing information, visit http://www.opana.com/ .    About Endo  

A wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc., Endo Pharmaceuticals Inc. is a fully integrated specialty pharmaceutical company with market leadership in pain management products. The company researches, develops, produces and markets a broad product offering of branded and generic pharmaceuticals, meeting the needs of healthcare professionals and consumers alike. More information, including this and past press releases of Endo Pharmaceuticals Holdings Inc., is available online at http://www.endo.com/ .

This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on management’s beliefs and assumptions, current expectations, estimates and projections. Statements that are not historical facts, including statements which are preceded by, followed by, or that include, the words “believes,””anticipates,””plans,””expects” or similar expressions and statements are forward-looking statements. Endo’s estimated or anticipated future results, product performance or other non- historical facts are forward-looking and reflect Endo’s current perspective on existing trends and information. Many of the factors that will determine the Company’s future results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and, therefore, actual results may differ materially from those expressed or implied by these forward-looking statements. The reader should not rely on any forward-looking statement. The Company undertakes no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise. Several important factors, in addition to the specific factors discussed in connection with these forward-looking statements individually, could affect the future results of Endo and could cause those results to differ materially from those expressed in the forward-looking statements contained in this press release. Important factors that may affect future results include, but are not limited to: market acceptance of the Company’s products and the impact of competitive products and pricing; dependence on sole source suppliers; the success of the Company’s product development activities and the timeliness with which regulatory authorizations and product launches may be achieved; successful compliance with extensive, costly, complex and evolving governmental regulations and restrictions; the availability on commercially reasonable terms of raw materials and other third party manufactured products; exposure to product liability and other lawsuits and contingencies; dependence on third party suppliers, distributors and collaboration partners; the ability to timely and cost effectively integrate acquisitions; uncertainty associated with pre- clinical studies and clinical trials and regulatory approval; uncertainty of market acceptance of new products; the difficulty of predicting FDA approvals; risks with respect to technology and product development; the effect of competing products and prices; uncertainties regarding intellectual property protection; uncertainties as to the outcome of litigation; changes in operating results; impact of competitive products and pricing; product development; changes in laws and regulations; customer demand; possible future litigation; availability of future financing and reimbursement policies of government and private health insurers and others; and other risks and uncertainties detailed in Endo’s filings with the Securities and Exchange Commission, including its Registration Statement on Form S-3 filed with the SEC on March 21, 2006. Readers should evaluate any statement in light of these important factors.

   CONTACTS:   Bill Newbould   Endo Pharmaceuticals   (610)558-9800    Jane Petrino   Cohn & Wolfe Healthcare   (212)798-9512  

Endo Pharmaceuticals Inc.

CONTACT: Bill Newbould of Endo Pharmaceuticals, +1-610-558-9800; JanePetrino of Cohn & Wolfe Healthcare, +1-212-798-9512, for Endo Pharmaceuticals

Web site: http://www.endo.com/http://www.opana.com/http://www.endopromise.com/

Europe swelters in heatwave, 20 dead in France

By James Mackenzie

PARIS (Reuters) – A heatwave in France has probably killed
more than 20 people, including a 15-month-old baby, officials
said on Friday, and the rest of Europe also sweltered with no
sign of temperatures dropping.

Temperatures were not as high as they had been on previous
days but authorities warned people to take precautions.

“Desert London,” a headline in Britain’s Evening Standard
newspaper said over a photo of a parched Hyde Park on Friday.

“This is not the Sahara or Serengeti — these remarkable
pictures show how London’s parks have been turned dry, brown
and dusty by the drought,” the newspaper said.

A severe drought, said to be the worst in a century in the
south of England, is making itself felt and temperatures hit a
July record of 36.3 Celsius (97.3 Fahrenheit) earlier this
week.

British farmers have begun harvesting wheat fields early
because of the dry weather.

In Spain, a sunbather died in Barcelona from the heat and a
37-year-old man died in hospital on Friday after collapsing
from heat exhaustion while working in a greenhouse in Almeria
on the south coast the day before.

Six people were reported dead from heat-related problems so
far this Spanish summer.

As in the last major heatwave in 2003, which in France
lasted less than a month but killed around 15,000 people, most
of the victims were elderly people or the infirm.

A health ministry official said a baby died in Paris where
temperatures hit 37 Celsius earlier this week, but provided no
further details.

Of the other victims, 10 were aged 80 or over, four
collapsed at their workplace, two died while playing sport, two
were homeless and one was an obese youth “in poor physical
condition.”

SET TO CARRY ON

Temperatures well above 30 Celsius have been registered
across France over the past week and weather forecasters say
the heatwave looks set to continue well into next week.

The high death toll stunned health authorities and local
officials have worked hard to try to improve their response to
heatwaves, supplying air conditioning to retirement homes and
broadcasting constant information on how to cope in the heat.

In Italy, temperatures pushed higher on Friday, reaching
nearly 39 degree Celsius in Florence, and were expected to
increase throughout the weekend. Many cities raised their alert
levels to avoid a repeat of 2003, when the heatwave killed
20,000 people.

Emergency workers in Rome said they were handing out water
to people standing in queues outside museums and art galleries
or waiting in the sun to catch their bus.

A worker collapsed and died of heat-related causes in the
island of Sardinia on Thursday, while health services received
thousands of calls from elderly people asking for help.

Southern and western Bosnia have been hit by a series of
fires as temperatures reached as high as 41 degrees, prompting
local fire fighters to ask the army for helicopter assistance.

(Reporting by European bureaux)

The Modified Bentall Procedure for Aortic Root Replacement

By Cherry, Cecile; DeBord, Starla; Hickey, Carol

ABSTRACT

* THE BENTALL PROCEDURE is a surgical repair of an ascending aortic or aortic root aneurysm in combination with aortic valve disease. Less commonly, it is used to repair aortic dissection affecting the aortic root and valve.

* DURING THE PROCEDURE, a composite aortic valve graft is used to replace the proximal ascending aorta and aortic valve. The procedure is performed through a median sternotomy during cardiopulmonary bypass.

* IN THIS MODIFICATION of the original procedure, coronary artery circulation is maintained by removing a full-thickness “button” of aorta surrounding the coronary ostia, making it easier to implant the proximal end of the coronary arteries into openings made in the aortic vascular graft. AORN J 84 (July 2006) 52-70.

AORN, Inc, 2006.

The Bentall procedure is a surgical repair of an ascending aortic aneurysm or an aortic root aneurysm that is accompanied by aortic valve incompetence. Less commonly, this procedure is used to repair aortic dissection affecting the aortic root and valve. The procedure uses a composite aortic graft (ie, a vascular tube graft with an attached mechanical or biologic valve) to replace the proximal ascending aorta and the aortic valve. Circulation to the coronary arteries is maintained by implanting the proximal end of the coronary arteries into openings made in the aortic graft.

This procedure was first described by H. H. Bentall, MD, and A. DeBono, MD, in 1968(1) and still is performed today with some modifications. Currently, a full-thickness “button” of aorta surrounding the coronary ostia (ie, where the proximal coronary arteries attach to the aorta) is removed, making it easier to implant the proximal coronary arteries into the aortic vascular graft.

ANATOMY AND PHYSIOLOGY

The heart is a muscular, fourchambered pump that provides the power to move blood through the circulatory system. The heart is about the size of an adult’s fist, located slightly to the left of the midline of the mediastinum, directly behind the sternum (Figure 1). The four chambers of the heart consist of the right and left atria and ventricles. Oxygenated blood from the heart exits through the aorta to enter systemic circulation.2

The aorta exits from the left ventricle, arches upward and then down through the thorax and abdomen, and branches into the iliac arteries. The diaphragm separates the thoracic and abdominal portions of the aorta. The thoracic aorta is subdivided further into the ascending aorta, aortic arch, and descending aorta.3

The aorta is the largest artery in the body, and it supplies blood to all major arteries in the body. Like all arteries, the aorta consists of three layers: the tunica intima, the tunica media, and the tunica adventitia. The tunica intima is the innermost layer, consisting of endothelial cells and elastic tissues that give the aorta its elasticity and strength.3 The tunica media is the middle layer that contains smooth muscle tissue and elastic fibers. The tunica adventitia is the outermost layer, consisting of connective tissue.4 The aortic root includes the section of the ascending aorta that exits from the heart, the aortic valve, and the coronary ostia (ie, openings where the coronary arteries enter the aorta). The left and right main coronary arteries branch off from the ascending aorta to supply the heart muscle with oxygenated blood (Figure 2).

THE HEART VALVES. The purpose of the heart valves is to ensure that blood flows through the heart in one direction. The valves open and close passively, as a result of differences in the pressure gradients between the heart chambers. As blood accumulates in the heart’s chambers, the pressure behind the valve increases until it is greater than pressure beyond the valve. The valve opens allowing blood to flow through the valve and then closes as the pressure in front of the valve rises.” There are four heart valves: the aortic and pulmonic valves (ie, semilunar valves) and the mitral and tricuspid valves (ie, atrioventricular valves).s The mitral valve has two cusps; the other three valves are each composed of three cusps. The aortic valve is attached to the aortic wall and left ventricular muscle.”

THE CARDIAC CYCLE. The term cardiac cycle refers to the contraction and relaxation cycle of one heartbeat. An average cardiac cycle is about 0.8 seconds. Systole is the phase of the cardiac cycle associated with ventricular contraction and ejection of blood into systemic circulation, which accounts for one-third of the cardiac cycle. The atria contract to complete filling of the ventricles that began passively filling during systole. As the aortic and pulmonic valves open, the mitral and tricuspid valves close, producing the first heart sound, Sl. The aorta stretches and expands, temporarily storing a portion of the blood ejected from the ventricle.7

Diastole is the relaxation phase of the cardiac cycle, accounting for two-thirds of the cardiac cycle.” During diastole, blood from the lungs and systemic circulation enters the heart. Relaxation results in negative pressure that passively draws blood into the chambers of the heart. The mitral and tricuspid valves open, and the aortic and pulmonic valves close, which produces the second heart sound, S2. Blood enters the coronary arteries during this phase. The aorta recoils to propel blood into systemic circulation.9

Figure 1 * The heart is about the size of an adulfs fist, located slightly to the left of the mldllne of the mediastinum, directly behind the sternum.

Figure 2 * The aortic valve has three cusps. It is attached to the aortic wall and left ventricular muscle.

Figure 3 * An aneurysm of the aortic root is caused by degeneration of the tunica media.

PATHOPHYSIOLOGY

Aneurysms are classified by location and can affect any segment of the thoracic or abdominal aorta, singly or in combination.5 The terms aneurysm and dissection often are used interchangeably. Although both conditions may exist in the same patient, the terms describe two very different types of pathology.

AORTIC ANEURYSM. The term aortic aneurysm refers to a localized dilation of the wall of the aorta and generally is defined by an aortic diameter greater than 3 cm. Aortic aneurysms are caused by degeneration of the tunica media, causing dilation of all three layers of the artery.10 The wall of the aorta becomes progressively weaker as the aneurysm enlarges. If the aneurysm is left untreated, it may rupture and cause death from cardiac tamponade.3

There is a strong link between aortic aneurysms and atherosclerosis, although the relationship is not understood. It is theorized that the atherosclerotic process reduces the aortic wall’s elasticity in addition to thinning the wall of the vessel.11 One study found an autosomal dominant genetic connection in patients with thoracic aortic aneurysms.12 Twentyone percent of the study population (ie, patients who had a thoracic aneurysm or aortic dissection) had a close relative who had an aneurysm, either diagnosed or suspected due to sudden death with cardiac-like symptoms (eg, chest pain, shortness of breath, diaphoresis, nausea).

The term annuloaortic ectasia refers to an aneurysm of the aortic root accompanied by dilation of the annulus of the aortic valve and aortic valve incompetence as the result of cystic medial degeneration (ie, the tunica media of the aorta becomes less elastic as fibers break down). This may be a result of the aging process; hypertension; connective tissue disorders, such as Marian’s syndrome; or other unknown factors.5,11 Annuloaortic ectasia frequently is the indication for surgical aortic root replacement.

The pathologic changes in the ascending aorta can cause aneurysmal dilation of the aortic root (Figure 3), which can affect the ability of the aortic valve cusps to close, leading to valve incompetence and aortic regurgitation. When the aortic valve is incompetent, the valve fails to close completely, causing a backflow of blood into the heart from the aorta and increasing the workload of the left ventricle. Left ventricular hypertrophy may result from the increased workload and progress to left heart failure if the aortic regurgitation is not treated.9,13,14

AORTIC DISSECTION. The term aortic dissection refers to a tear in the intimai wall of the vessel, creating a false lumen that allows blood to accumulate between the tunica intima and the tunica media. Systemic blood pressure forces more blood into this false lumen with each heartbeat, enlarging the area of dissection. Untreated, the dissection will continue to enlarge, creating possible complications, such as

* aortic thrombus formation,

* compromised systemic circulation,

* rupture of the weakened aortic wall, or

* cardiac tamponade.

Patients may present with signs of shock because of decreased circulating blood volume or sudden onset of stroke or paralysis as a result of disruption of blood flow to the brain or spinal cord. Dissections of the ascending aorta may alter the normal anatomical structure of the aortic root, resulting in dysfunction of the aortic valve and disruption of the flow of blood to the coronary arteries.15-7

TABLE 1

Factors Associated with Developin\g Aortic Aneurysm and Aortic Dissection1-3

INCIDENCE. The incidence of all thoracic aneurysms is estimated to be 10.4 cases per 100,000 people annually.18 Thoracic aortic aneurysms occur most frequently in the ascending aorta (ie, 50%), whereas only 40% occur in the descending aorta, and the remaining 10% occur in the aortic arch.5,15 Aortic dissection affects two in 100,000 people in the United States annually, most commonly men who are 40 to 70 years of age.19 Factors associated with developing an aortic aneurysm or aortic dissection are presented in Table 1.

SYMPTOMS. Often thoracic aortic aneurysms are asymptomatic and are discovered only by testing for other conditions. Symptoms may not occur until the aneurysm grows large enough to compress adjacent structures in the chest, at which point patients may complain of chest or back pain.3,18 Symptoms specific to aortic root aneurysm caused by aortic regurgitation include

* cough,

* diastolic murmur,

* dysphasia,

* dyspnea on exertion,

* fatigue,

* orthopnea,

* palpitations,

* paroxysmal nocturnal dyspnea, and

* widened pulse pressures.5,20

Symptoms of aortic dissection include sudden onset of severe chest pain, which may radiate to the back and often is described as a “ripping” or “tearing-like” pain. Clinical signs of acute aortic insufficiency or aortic regurgitation resulting from an aortic root dissection are the same as those caused by aortic root aneurysm.16

DIAGNOSIS

Chest radiography may reveal an aortic aneurysm, usually by the presence of a widened mediastinum; however, it is not always possible to distinguish an aortic aneurysm from a mass. In some patients, an aortic root aneurysm might be obscured by the cardiac silhouette and therefore not be visible on a chest x-ray.9 Patients with aortic incompetence may have an enlarged cardiac silhouette.18 Transthoracic or transesophageal echocardiography can be used to diagnose pathology of the aortic valve and aorta. Contrast-enhanced computed tomography can be used to diagnose the presence, location, and size of an aortic aneurysm. Cardiac catheterization with aortography provides accurate diagnosis of the presence and severity of an aortic root aneurysm. If coronary artery disease is demonstrated during the cardiac catheterization, the surgeon probably will elect to perform a coronary artery bypass at the time of the aneurysm repair.9

Aortic aneurysms also may be detected during diagnostic testing for another condition. If the aneurysm is asymptomatic, the patient’s health care provider may recommend regular followup to monitor the aneurysm’s growth before proceeding with surgical repair. The consensus of many cardiothoracic surgeons is that elective surgery to repair the aneurysm is indicated for

* an aortic diameter greater than 4.5 cm in patients with Marian’s syndrome,

* an aortic diameter greater than 5.5 cm to 6 cm,

* any symptomatic aneurysm, or

* patients who have a family history of a ruptured aortic aneurysm.15,21

Elective surgery also is indicated if the patient has symptomatic aortic valve regurgitation related to the aneurysm. Rupture of the aneurysm requires emergency surgery to prevent death from cardiac tamponade or exsanguination.9

PREOPERATIVE PATIENT PREPARATION

At University Hospital, Birmingham, Ala, the patient is admitted to the hospital on the day before the scheduled procedure. Patients with a symptomatic aortic root aneurysm accompanied by a low ejection fraction (ie, less than 350%)22 may be admitted to the cardiac intensive care unit (CICU) for preoperative placement of an intra-aortic balloon pump (IABP). The IABP provides counterpulsation that reduces the workload of the heart during the night before surgery. The decision to use the IABP depends on the aneurysm’s location and structural involvement; however, this device must be used with caution in the presence of an aortic aneurysm.

Patient teaching and discharge planning begin on admission. The preoperative nurse gives the patient and his or her family members a hospitalprepared patient teaching booklet that outlines what to expect during the hospital stay, both preoperatively and postoperatively, and includes postdischarge instructions. This booklet contains a simplified description of basic cardiac anatomy and physiology. The different roles of hospital staff members who will care for the patient (eg, nurse practitioner, chaplain, dietitian, case manager, physical therapist) also are described. Equipment that will be used during the patient’s CICU stay is described in detail (Figure 4). This booklet also contains information that family members may need, such as parking, dining, and lodging options.

The preoperative nurse instructs the patient that nurses will be using a oneto-10 rating scale to frequently assess postoperative pain. The nurse also explains that the patient will be NPO after midnight the night before surgery. On the morning of surgery, the patient’s body hair will be removed with clippers, if needed, and the patient will be instructed to shower using antibacterial soap.

FIGURE 4

Excerpt from the Cardiovascular Surgery Patient Teaching Booklet

TABLE 2

Equipment and Supplies Needed for the Modified Bentall Procedure

PREPARATON OF THE OR

The circulating nurse and scrub person gather all equipment, supplies, instruments, and medications for the procedure (Table 2). The OR team prepares for femoral arterial and venous cannulation for cardiopulmonary bypass (CPB) to avoid the risk associated with cannulation of the aneurysm-weakened aorta.2 The circulating nurse checks the inventory of aortic root implants (Table 3) to ensure that all sizes of each implant that might be used are available.

The circulating nurse goes to the preoperative holding area to greet the patient and perform the preoperative nursing assessment. The circulating nurse introduces himself or herself to the patient and verifies the patient’s identity verbally and with the patient’s hospital identification bracelet. The nurse then verifies the surgical procedure with the patient and the consent form, ensuring that the written consent is in agreement with the patient’s statement of the planned procedure and the surgeon’s preoperative progress note. The circulating nurse questions the patient regarding allergies and NPO status and verifies that any dentures; partial dentures; contact lenses; and jewelry, including body jewelry, are removed before the patient’s transfer to the holding area. The nursing assessment also includes gathering all data relevant to the patient’s care, including

* the presence of any metal implants (eg, pacemakers, implanted defibrillators, total joint implants);

* sensory impairments;

* preexisting skin conditions; and

* any special positioning needs that the patient might have (eg, accommodating for the presence of joint contractures).

The nurse reviews the patient’s chart for relevant laboratory test results and the presence of a consent form for administration of blood products. Using information obtained during the preoperative assessment, the nurse formulates the appropriate nursing diagnoses and develops an intraoperative plan of care for the patient (Table 4). The anesthesia care provider administers preoperative IV antibiotics to the patient as ordered by the surgeon while the patient is in the holding area. To comply with infection control recommendations, antibiotic prophylaxis is administered within 60 minutes of the surgical skin incision.23

TABLE 3

Types of Grafts Used in Aortic Root Replacement

INTRAOPERATIVE PATIENT CARE

The circulating nurse and anesthesia care provider transfer the patient into the OR on either a stretcher or the CICU bed and help the patient move onto the OR bed. The circulating nurse offers the patient warm blankets for comfort and remains close to the patient during induction of anesthesia to offer emotional support to the patient and assistance to the anesthesia care provider. After anesthesia induction, the circulating nurse or the RN first assistant (RNFA) places an indwelling urinary catheter with a temperature probe. The surgeon and anesthesia care provider place pressure monitoring lines (ie, radial arterial line, central line, pulmonary artery catheter) for hemodynamic monitoring during the intraoperative and immediate postoperative periods. The circulating nurse places the patient’s wrist with the arterial line on a padded disposable arm board to help maintain the correct position of the arterial catheter.

The circulating nurse, surgeon, anesthesia care provider, and RNFA place the patient in the supine position for the procedure, ensuring that correct body alignment is maintained. The anesthesia care provider places the patient’s head on a padded headrest. The circulating nurse places an electrosurgical unit (ESU) dispersive pad under the patient’s upper back. If the patient has an implanted pacemaker or internal defibrillator, the ESU dispersive pad is placed at an alternate well-muscled site. The circulating nurse pads both of the patient’s arms at the elbows, and then rucks the patient’s arms at his or her sides using the draw sheet, with the palmar surface of the patient’s hands against the patient’s body. Padded sleds are used, if necessary, depending on the size of the patient.

SURGICAL PROCEDURE

The circulating nurse cleans the patient’s skin with an iodine/ alcohol solution from chin to toes, prepping both legs and feet circumferentially, taking care to avoid pooling of the prep solution. After the prep solution dries completely, the scrub person, RNFA, and surgeon drape the patient, and the scrub person passes the CPB pump lines off the field before the skin incision is made. The circulating nurse initiates a surgical “time out” in which all members of the surgical team participate, verifying the patient’s identity and scheduled surgical procedure before the skin incision.

TABLE 4

Nursing Care Plan for Patients Undergoing Aort\ic Root Replacement

The surgeon uses a #10-knife blade to make a midline incision extending from the supraclavicular notch to just beyond the xiphoid process. The surgeon places a rake retractor in the upper end of the incision to expose the sternal notch. He or she uses curved Mayo scissors to separate the tissue above the transverse ligament and then places a Shallcross clamp under the ligament, using the monopolar ESU pencil to transect the ligament.

The surgeon uses the ESU pencil to cut through the subcutaneous tissue and pectoralis muscle to the sternum. He or she uses the ESU pencil to mark the sternum down the midline to prepare for sawing.

Using an electrically powered sternal saw, the surgeon performs a median sternotomy. He or she then uses electrosurgery to obtain hemostasis of the sternal edges and soft tissue. The surgeon and RNFA place a four-bladed self-retaining sternal retractor between the sternal edges.

The surgeon uses a #10-knife blade to open the pericardial sac, then uses electrosurgery to complete the dissection. If necessary, the surgeon places a 2-0 silk pericardial stay stitch on the surgeon’s side of the chest to expose the aorta and secure the patient’s subcutaneous tissue.

At the same time the surgeon is making the midline skin incision, the RNFA uses a #10-knife blade to make an incision in the groin to expose the fmoral artery for cannulation. Cannulating the femoral artery makes the entire ascending aorta available for replacement if necessary. After exposing the femoral artery, the RNFA uses electrosurgery to dissect through the subcutaneous tissue and places a self-retaining Weitlaner retractor to expose the femoral artery.

The RNFA uses dissecting scissors to separate and expose the vessel and uses a single-armed 4-0 monofilament polypropylene suture with an RB-I needle as a purse-string stitch. The RNFA cuts off the needle and threads the suture through a disposable tourniquet and secures it with a hemostat with shods.

The surgeon places a purse-string stitch of 3-0 polypropylene suture with a polytetrafluoroethylene (ie, Teflon) pledget in the inferior vena cava for venous cannulation. He or she threads the pursestring stitch through a disposable tourniquet and uses a hemostat with shods to secure the tourniquet.

The surgeon then places a second purse-string stitch in the superior vena cava using a 3-0 single-armed polypropylene suture. He or she secures the purse-string suture with a tourniquet and hemostat with shods.

Before cannulation, the scrub person measures the bypass tubing, cuts it into appropriate lengths, and places a 1/2-inch by 3-inch by 8-inch Y-shaped connector on the venous side of the tubing. There is no need for an arterial connector, because the percutaneous arterial cannula has a built-in arterial connector.

The surgeon inserts an 18-gauge, hollow needle into the femoral artery until blood is returned. He or she then inserts a guide wire into the needle and advances it up the aorta. The surgeon removes the needle and threads a series of dilators over the wire and into the artery to dilate the artery for insertion of the cannula. He or she then threads the femoral artery cannula over the wire and inserts it into the femoral artery. When arterial blood enters the cannula, the surgeon places a pump clamp across the cannula, removes the wire, and connects the cannula to the arterial pump tubing. If air is present, the surgeon attaches a 60-mL syringe to the connector and removes the air via the syringe. The RNFA then secures the cannula to the patient’s leg using a threaded 0-silk suture.

Using a #ll-knife blade, the surgeon performs venous cannulation by making a stab wound in the inferior vena cava. If necessary, the surgeon uses a Kelly clamp to dilate the opening in the inferior vena cava and inserts a metal-tipped, rightangled femoral venous cannula. The surgeon tightens the tourniquet and secures it with a hemostat with shods. The surgeon ties a #2-silk suture around the cannula and the tourniquet to maintain proper cannula placement. The surgeon then cannulates the superior vena cava in the same manner. He or she connects these venous cannulas to the Y-shaped connector on the venous tubing and initiates CPB. After CPB has been established, the surgeon dissects around the aorta with dissecting scissors to separate it from the pulmonary artery.

The surgeon places a 3-0 polypropylene suture with a Teflon pledget in the proximal myocardial fat to allow the proximal aorta to be exposed and to establish the location of the coronary ostia. The surgeon cross-clamps the ascending aorta as close to the distal end as possible using an 35-degree-angled DeBakey peripheral vascular clamp.

The surgeon then inserts a cardioplegia needle into the ascending aorta and infuses cold sanguineous cardioplegia solution into the aortic root. Cold saline slush is applied topically to the heart to assist in myocardial protection.

When asystole is achieved, the surgeon incises the aorta transversely, proximal to the innominate artery. He or she then removes the excess tissue.

The surgeon inspects the aortic valve and the openings of the coronary ostia in regard to their position to the annulus. The surgeon detaches the coronary ostia from the aorta with rims of aortic tissue using dissecting scissors. Using the ESU pencil, the surgeon obtains hemostasis of the surrounding soft tissues and also mobilizes each coronary ostia. He or she places a 3-0 polypropylene suture in each ostia for retraction and secures them with hemostats.

The surgeon excises the aortic valve leaflets and uses metal sizers to measure the annulus. When the appropriate annulus implant size is established, the circulating nurse delivers an appropriately sized composite graft to the sterile field.

The surgeon inserts the proximal (ie, valved) end of the composite graft into the annulus. He or she then places a continuous 3-0 polypropylene suture over externally placed Teflon-felt strips to secure the valve portion of the composite graft into the aorta.

Figure 4 The surgeon implants each coronary ostia with rims of aortic tissue into the graft and then anastomoses the distal portion of the tube graft to the distal aorta.

The surgeon measures the graft for length and cuts it to the appropriate length. He or she manipulates the coronary ostia using the 3-0 polypropylene-stay stitches for placement into the graft.

The surgeon uses a #ll-knife blade to make a stab hole into the graft. He or she makes a circular opening with the #ll-knife blade and tenotomy scissors and removes excess graft. The surgeon then repeats the process for the other ostia. Using a continuous double- armed 6-0 polypropylene suture, the surgeon implants each coronary ostia into the graft at the transfer sites (Figure 4).

When coronary circulation has been reestablished, the surgeon cuts the distal portion of the tube graft or tailors it and anastomoses it to the distal aorta using a continuous 3-0 polypropylene suture over externally placed Teflonfelt strips.

Before making the final stitches, the surgeon infuses carbon dioxide into the left ventricle and the aortic tube graft to displace any air that is present in the heart. The surgeon releases the aortic cross clamp and, using echocardiogram guidance, removes air from the heart by gently squeezing and massaging the heart.

When the air is eliminated, the surgeon removes the cardioplegia needle and closes the hole with a 3-0 polypropylene suture with Teflon pledgets. For extra security, the surgeon then wraps the distal anastomosis with polyethylene terephthalate that was prepared from the residual tube graft.

The CPB is discontinued gradually, and the surgeon removes the femoral artery cannula. The anesthesia care provider administers a heparin antagonist to reverse the anticoagulant effect of the heparin administered for the CPB phase of the procedure.

The surgeon removes the superior vena cava cannula and ties down the purse-string suture. The surgeon connects the aortic tubing to the inferior vena cava cannula for infusion of the residual volume in the CPB machine.

The surgeon places three temporary pacing wires on the heart-two on the right atrium and one on the right ventricle. He or she places a straight, 28-Fr chest tube and an angled, 24-Fr chest tube into the patient’s mediastinum, and the scrub person connects them to a closed, chest-drainage system for postoperative monitoring.

The surgeon inspects the surgical sites for bleeding and makes any needed repairs. To ensure that the sternum is not bleeding, the surgeon removes the retractor and visually inspects the bone. The surgeon uses electrosurgery to stop any bleeding and then applies a paste to the bone, which aids in hemostasis. The surgeon places two surgical towels over the bone edges and replaces the sternal retractor in the chest.

When the volume in the CPB machine is infused, the surgeon removes the inferior vena cava cannula and ties down the purse- string suture. The surgeon examines all the cannulation sites as well as the anastomoses sites for bleeding. If no repairs are needed, he or she closes the patient’s chest using #7 steel sternal wires.

The surgeon closes the fascia and subcutaneous tissue with O polypropylene and 2-0 polypropylene sutures respectively. He or she then closes the skin with 4-0 polydioxanone suture. The RNFA applies a sterile dressing over the incision.

The anesthesia care provider and circulating nurse transfer the patient to the CICU accompanied by the surgeon and RNFA. During transfer, the anesthesia care provider continues to monitor the patient’s electrocardiogram (ECG), arterial pressure, and oxygen saturation with a portable monitoring unit and ventilates the patient using a bag/mask device and a portable oxygen tank.

POSTOPERATIVE CARE

On arrival in CICU, the circulating nurse and anesthesia care provider report to the postanesthesia care unit (P\ACU) nurse who will be caring for the patient. A respiratory therapist connects the patient to the ventilator. The PACU nurse continuously monitors the patient’s physiologic parameters, such as ECG, oxygen saturation, arterial pressure, and pulmonary artery pressure. He or she also monitors the patient’s arterial blood gases, chest tube drainage, and urinary output. Initially, all patients are ventilated mechanically, with weaning performed as tolerated. After extubation, the PACU nurse helps the patient with using an incentive spirometer and deep breathing and coughing every one to two hours to help prevent postoperative respiratory complications.

After 24 hours in the CICU, if the patient’s respiratory and hemodynamic status are stable, he or she may be transferred to the telemetry unit for the remainder of the hospitalization. If the patient had a mechanical valve implanted, the telemetry nurse starts the patient on prophylactic anticoagulation therapy when the patient is able to tolerate oral fluids and nutrition well. The telemetry nurse or a physical therapist assists the patient with progressive ambulation.

Before discharge from the hospital, the patient and his or her family members watch a videotape that explains the discharge instructions and are given the opportunity to ask any questions they may have about postdischarge care. Discharge instructions include

* progressively increasing activity as tolerated,

* avoiding vigorous activity for 12 weeks after surgery, and

* not lifting more than 5 lbs in the first two weeks and no more than 20 lbs for three months after discharge.

If the patient received a mechanical valve, he or she will require lifelong anticoagulation therapy. The goal is to maintain the international normalized ratio (INR) for anticoagulant monitoring between 2.5 and 3.5. Normal INR in an uncoagulated patient is 1.0.20

The telemetry nurse instructs the patient and his or her family members in the care of the incision, which includes cleansing the incision site daily with an antibacterial soap. The nurse also instructs the patient to report to the surgeon’s office immediately if he or she has any signs or symptoms of infection, including

* chills;

* drainage from the incision;

* fever (ie, temperature higher than 101 F [38.3 C]);

* incisional redness; or

* increased incisional tenderness.

The nurse instructs the patient to follow up with the cardiologist as well as the cardiothoracic surgeon who performed the procedure.

POSSIBLE COMPLICATIONS ASSOCIATED WITH THE BENTALL PROCEDURE

Patients undergoing the Bentall procedure may experience the complications associated with any cardiac surgery that involves CPB, including

* air embolus,

* arrhythmias,

* atelectasis,

* bleeding,

* pneumonia,

* transient confusion, or

* wound infections.

Potential complications specific to the Bentall procedure include

* graft infection,

* stoke caused by embolization of atherosclerotic plaques during surgery, or

* coronary insufficiency secondary to a coronary artery implanted into the graft becoming kinked.9

RESULTS

Research studies have demonstrated good overall patient outcomes after surgery for aortic root replacement, with with an average 86% long-term survival after the procedure.24,25 The postoperative outcome for these patients depends largely on their preoperative condition. Furthermore, patients undergoing elective aortic root replacement have demonstrated better outcomes than patients who underwent the procedure on an emergent basis.13

Patients who had a poor overall state of health before the procedure are referred to a cardiac rehabilitation program. The objective of the cardiac rehabilitation program is to help patients improve activity tolerance by building muscle strength and stamina and provide patient and family education in stress reduction skills and nutrition for heart health. This program also offers education and support for smoking cessation to patients who smoke.

Patiente who had a good overall state of health before the procedure tend to recover more quickly than do patients who were debilitated as a result of advanced age or preexisting comorbid conditions.24 Typically, younger patiente have better outcomes after aortic root replacement surgery than do older adult patiente.” Most patiente who are in good overall health before the surgical procedure are able to fully resume their normal preoperative level of activity within six to eight weeks after the procedure.24,26

Examination

The modified Bentall procedure for aortic root replacement

1. The terms aneurysm and dissection define similar pathology and can be used interchangeably.

a. true

b. false

2. Aortic aneurysms are caused by degeneration of the tunica

a. adventitia.

b. intima,

c. media.

3. Annuloaortic ectasia may be a result of

1. atherosclerosis.

2. hypertension.

3. connective tissue disorders, such as Marian’s syndrome.

4. the aging process.

a. 1 and 3

b. 2 and 4

c. 1, 2, and 3

d. 2, 3, and 4

4. Failure of the aortic valve to close completely, causing a backflow of blood into the heart from the aorta and increasing the workload of the left ventricle is called aortic

a. dissection,

b thrombus formation,

c. valve annulus dilation,

d. valve incompetence.

5. Symptoms specific to aortic root aneurysms caused by aortic regurgitation include

1. “ripping” or “tearing-like” chest pain.

2. diastolic murmur.

3. dysphasia.

4. orthopnea.

5. paroxysmal nocturnal dyspnea.

6. sudden severe chest pain.

a. 1, 3, and 5

b. 2, 4, and 6

c. 2, 3, 4, and 5

d. 1, 2, 3, 4, 5, and 6

6. A diagnosis of aortic aneurysm may be made by

1. cardiac catheterization with aortography.

2. chest radiography.

3. contrast-enhanced computed tomography.

4. transthoracic or transesophageal echocardiography.

a. 1 and 3

b. 2 and 4

c. 2, 3, and 4

d. 1, 2, 3, and 4

7. A composite graft may be a

a. homograft of the ascending aorta with tissue aortic valve,

b. mechanical valve with an attached woven tube vascular graft,

c. xenograft aortic root with valve.

8. The following nursing interventions are appropriate for the nursing diagnosis “Risk for alteration in tissue perfusion.”

1. Collaborates in fluid management.

2. Monitors physiological parameters.

3. Evaluates postoperative cardiac and peripheral tissue perfusion.

4. Identifies patient’s accepted postoperative pain threshold.

5. Identifies nominal hazard zone.

6. Assesses skin integrity, sensory impairments, and musculoskeletal status.

a. 1, 2, and 3

b. 4, 5, and 6

c 1, 3, 4, and 5

d. 1, 2, 3, 4, 5, and 6

9. Cold saline slush is applied topically to the heart to

a. assist in myocardial protection,

b. improve visibility of the surgical site,

c provide hemostasis.

10. To displace air that may be present in the heart, before making the final stitches, the surgeon

1. infuses carbon dioxide into the left ventricle and the aortic tube graft.

2. installs saline through the coronary bypass machine.

3. releases the aortic cross clamp and gently massages the heart.

a. 2

b. 1 and 3

c. 2 and 3

d. 1, 2, and 3

AORN is accredited os a provider of continuing nursing education by the American Nurses Credentiating Center’s Commission on Accreditation, AOKN is provider-approved by the California Board of Registered Nursing, Provider Number CEP 13019. Check with your state board of nursing for acceptance of this activity for retlcensure.

Learner Evaluation

The modified Bentall procedure for aortic root replacement

Objectives

To what extent were the following objectives of this Home Study Program achieved?

1. Discuss the pathophysiology of aortic abnormalities.

2. List diagnostic tools used to identify aortic abnormalities.

3. Discuss nursing care of a patient undergoing aortic root replacement surgery.

4. Describe the aortic root replacement surgical procedure.

Content

To what extent

5. did this article increase your knowledge of the subject matter?

6. was the content clear and organized?

7. did this article facilitate learning?

8. were your individual objectives met?

9. did the objectives relate to the overall purpose/goal?

Test Questions/Answers

To what extent

10. were they reflective of the content?

11. were they easy to understand?

12. did they address important points?

Learner Input

13.Will you be able to use the information from this Home Study in your work setting?

a. yes b. no

14.1 learned of this Home Study via

a. the Journal I receive as an AORN member.

b. a Journal I obtained elsewhere,

c. the AORN web site,

d.the AORN Manager Resources web page.

15. What factor most affects whether you take an AORN Journal Home Study?

a. need for contact hours

b. price

c. subject matter relevant to current position

d. number of contact hours offered

What other topics would you like to see addressed in a future Home Study Program? Would you be interested or do you know someone who would be interested in writing an article on this topic?

Topic(s): ____________________

Author names and addresses: ____________________

This evaluation is used to determine the extent to which this Home Study Program net your learning needs. Rate these Items on a scale of 1 to 5.

Purpose/Soak To educate perioperative nurses about caring for patients undergoing the modified Bentatl procedure for aortic root replacement.

Ifan aneurysm is asymptomatic, the patient’s health care provider may recommend regular follow-up to monitor the aneurysm’s growth before proceeding with surgical repair.

After using the electrosurgical pencil to cut through the subcutaneous tissue and pectoralis muscle, the surgeon marks the sternum down the midline in preparation for sawing.

The surgeon inspects the aortic valve and the openings of the coronary ostia in regard to their position to the annulus and then detaches the coronary ostia from the aorta with rims of aortic tissue.

If the patient received a mechanical valve, he or she will require lifelong anticoagulation therapy.

NOTES

1. H H Bentall, A DeBono, “A technique for complete replacement o\f the ascending aorta,” Thorax 23 (July 1968) 338-339.

2. J Rothrock, Alexander’s Care of the Patient in Surgery, 12th ed (St Louis: Mosby, 2003).

3. D Klein, “Thoracic aortic aneurysms,” Journal of Cardiovascular Nursing 20 (July/August 2005) 245-250.

4. L Copstead, J Banasik, Pathophysiology: Biological and Behavioral Perspectives, second ed (Philadelphia: W B Saunders Company, 2000) 367.

5. P C Seifert, Cardiac Surgery: Perioperative Patient Care (St Louis: C V Mosby, Inc, 2002).

6. D McGiffin, J K Kirklin, “Management of the small aortic root,” in Advanced Therapy in Cardiac Surgery, second ed, K Franco, E Verrier, eds (Hamilton, Ontario: B C Decker, 2003) 241-247.

7. R E Klabunde, Cardiovascular Physiology Concepts (Philadelphia: Lippincott Williams & Wilkins, 2005).

8. V Piacentino, “Cardiac physiology,” in Cardiothoracic Surgical Nursing Secrets, ed B A Todd (St Louis: C V Mosby, Inc, 2005) 11.

9. C Anderson, R Rizzo, L Cohn, “Ascending aortic aneurysms,” in Cardiac Surgery in the Adult, second ed, L H Edmunds, L Cohn, eds (New York: McGraw-Hill, 2003) 1123-1144.

10. E Tseng, M Comacho, “Thoracic aortic aneurysm,” eMedicine.com (Dec 6, 2005), http://www.emedkine.com/med/topic2783.htm (accessed 5 May 2006).

11. S Beese-Bjurstrom, “Hidden danger: Aortic aneurysms & dissections,” Nursinv2004 34 (February 2004) 3641.

12. J Elefteriades, “Natural history of thoracic aortic aneurysms: Indications for surgery and surgical versus nonsurgical risks,” Annals of Thoracic Surgery 74 (November 2002) S1879.

13. T David, “Surgery of the aortic root and ascending aorta, in Sabiston & Spencer Surgery of the Chest, vol 2, seventh ed, F Sellke, S Swanson, P Nido, eds (St Louis: Saunders, 2005) 1115- 1132.

14. B Todd, K Higgins, “Recognizing aortic and mitral valve disease,” Nursing2005 35 (June 2005) 58-63.

15. B Finkelmeier, Cardiothoracic Surgical Nursing, second ed (Philadelphia: Lippincott Williams & Wilkins, 2000).

16. K Shaughnessy, “Aortic dissection,” in Cardiothoracic Surgical Nursing secrets, ed B A Todd (St Louis: C V Mosby, Inc, 2005) 61-64.

17. L Scheetz, “Aortic dissection,” American Journal of Nursing 106 (April 2006) 56.

18. N Kouchoukos et al, Kirklin/Banatt-Boyes Cardiac Surgery: Morphology, Diagnostic Criteria, Natural History, Techniques, Results, and Indications, third ed (Philadelphia: Churchill Livingstone, 2003).

19. “Aortic dissection,” MedlinePlus Encyclopedia, http:/ fwww.nlm.nih.gov/medline plus/ency/artide/000181.htm (accessed 10 May 2006).

20. B A Todd, V P Addinizio, “Valvular heart disease,” in Cardiothoracic Surgical Nursing secrets, ed B A Todd (St Louis: C V Mosby, Inc, 2005) 52.

21. B Lytle, “Ascending aortic aneurysm,” in Operative Cardiac Surgery, fifth ed, T J Gardner, T L Spray, eds (London: A Hodder Arnold Publication, 2004) 435-442.

22. M Bolgna, personal communication with the author, Birmingham, Ala, 19 April 2006.

23. D Bratzler, P Houck, “Antimicrobial prophylaxis for surgery: An advisory statement from the National Surgical Infection Prevention Project,” Chnical Infectious Diseases 38 (June 15, 2004) 1706-1715.

24. E Prifti et al, “Early and long-term outcome in patients undergoing aortic root replacement with composite graft according to the BentalTs technique,” European Journal of Cardio-Thoracic Surgery 21 (January 2002) 15-21.

25. J Christensen et al, “Bentall procedure using cryopreserved valved aortic homografts: Mid- to late-term results,” Texas Heart Institute Journal 31 no 4 (2005) 390.

26. S Goldberg, personal communication with the author, Birmingham, Ala, 22 March 2006.

Cecile Cherry, RN; Starla DeBord, RN; Carol Hickey, RN

Cedle Cherry, RN, MSN, CNOR, is a nurse clinician in the cardiothoracic OR at University Hospital, Birmingham, Ala.

Starla DeBord, RN, BSN, is a nurse clinician in the cardiothoracic OR at University Hospital, Birmingham, Ala.

Carol Hickey, RN, MSN, is an education coordinator in the cardiothoracic OR at University Hospital, Birmingham, Ala.

The authors thank A. D. Padfico, MD, division director of cardiovascular/thoracic surgery at the University of Alabama at Birmingham, Birmingham, Ala; and Steven Goldberg, MD, resident in cardiothoracic surgery at the University Hospital, University of Alabama at Birmingham, for their assistance with preparing this manuscript.

Editor’s note: Teflon is a registered trademark of DuPont, Wilmington, Del.

Copyright Association of Operating Room Nurses, Inc. Jul 2006

(c) 2006 Association of Operating Room Nurses. AORN Journal. Provided by ProQuest Information and Learning. All rights Reserved.

Antibiotics not advised for treating runny nose

LONDON (Reuters) – Children suffering from a common cold
and persistent runny noise should not be treated initially with
antibiotics, researchers said on Friday.

They suggested antibiotics, which can sometimes cause side
effects such as vomiting, diarrhea and abdominal pain, should
only be prescribed if the youngsters do not improve.

“Most patients will get better without antibiotics,” Bruce
Arroll of the University of Auckland in New Zealand said in a
report in the British Medical Journal.

The overuse of antibiotics has lead to concerns about the
emergence of so-called superbugs that are resistant to the most
powerful antibiotics.

Arroll and his colleague Tim Kenealy reviewed seven studies
that looked at the effectiveness or harm of treating acute
purulent rhinitis, a runny nose with a colored discharge, with
antibiotics.

Although the drugs are probably effective for the problem,
they found that for each patient that will benefit from the
drugs six others will not.

“Our summation would be to suggest initial management by
non-antibiotic treatments or “watchful waiting” and that
antibiotics should be used only when symptoms have persisted
for long enough to concern parents or patients,” they said in
the report.

The researchers said their findings support current “no
antibiotic as first line” advice.

Kids Risk Early Deafness with MP3 Players

LONDON (Reuters) – Teenagers and young adults who listen to MP3 players too loudly and too often risk going deaf 30 years earlier than their parents’ generation, a charity warned on Thursday.

Deafness Research UK said a national survey in Britain showed that 14 percent of 16-34 year-olds use their personal music players for 28 hours a week.

More than a third of the 1,000 people questioned in the poll said they had ringing in the ear, a sign of damage to hearing, after listening to loud music.

“We are warning young people that they are putting themselves at risk of going deaf 30 years earlier than their parents’ generation,” said Vivienne Michael, chief executive of Deafness Research UK.

Young people are exposed to loud noise from MP3 players, sophisticated sound systems in homes, clubs and cars but many are unaware of the damaging effect it can have on hearing.

Nearly 40 percent of the people questioned in the poll said they did not know that listening to loud music on a personal music player or in clubs or cars could damage their hearing.

Twenty-eight percent said they went to noisy bars, pubs or nightclubs once a week.

“Hearing loss can make life unbearable. It cuts people off from their family and friends and makes everyday communication extremely difficult,” Michael said in a statement.

The charity advises people to follow the 60-60 rule. Do not listen to your MP3 player at more than 60 percent of maximum volume and do not listen to it for more than 60 minutes at a time.

It also added that if the music from a headset is loud enough for the people around to hear, then it is loud enough to cause hearing damage.

Noise levels exceeding 105 decibels can damage hearing if endured for more than 15 minutes, according to Britain’s Health and Safety Executive.

Normal conversation is about 60 decibels. Heavy traffic is about 85 decibels and loud personal music players are 112 decibels.

Defining a Methodology for Bloodstain Pattern Analysis

By Gardner, Ross M

Abstract:

Articulating a Concise Scientific Methodology for Bloodstain Pattern Analysis [1] exposed and attempted to explain, in an easy- to-understand manner, the steps involved in reaching a conclusion. This article attempts to further explain the application of scientific method to bloodstain pattern analysis, detailing additional steps and the specific questions posed in that process.

Introduction

In an environment where lawyers routinely attack the tenets of every forensic discipline, it is absolutely imperative that students, instructors, and practitioners of the various disciplines know and apply functional methodologies. Although these methodologies may vary in minor ways across the spectrum of practitioners, the fact that individuals follow some form of established process enhances the probability that analysts (whatever their expertise) will stay a course and arrive at defensible conclusions. The use of a structured methodology helps limit much of the thunder from any lawyer’s attack of a discipline.

In the past, the discipline of bloodstain pattern analysis has suffered needlessly in terms of reputation within the legal system. In many ways, bloodstain pattern analysts have been their own worst enemy. Examples include the failure to define an effective taxonomy for bloodstain classification which has resulted in unnecessary ambiguity and the fact that too often students leave a basic course reciting only three phrases (“low”, “medium” and “high velocity”) and then fail to understand the application of these classifications fully. Worse yet, in documents written for defense counsel, individuals purporting themselves as experts in the area of bloodstain pattern analysis have literally claimed the discipline as subjective, writing: “Seen in this light, blood stain analysis is more of an art than a science and is always open to interpretation.”[2]

How is it possible that a discipline with a 150-year consistent history can be labeled an “art” and suffer from such issues?

The answer in large part is attributed to a published methodology, or lack thereof. Methodology is not taught in most bloodstain pattern analysis courses. Budding analysts are taught all of the skills applied in bloodstain pattern analysis: recognition of patterns, impact angle determination, and area of origin determinations, to name a few. But few instructors teach students how to apply these skills by providing a methodology that would keep the analyst within the confines of the discipline and help him or her reach valid conclusions. This results in analysts’ being unable to explain how they “analyzed”, which leaves the legal profession perceiving the discipline as without foundation. If the rank-and- file analyst cannot explain how he or she goes about the analysis, then how can the discipline hope to escape being labeled unscientific? The problem is not a lack of procedure, but rather a failure to articulate that procedure.

When pressed on issues of procedure, analysts routinely cite the use of scientific method; some even point to the ACEV technique as a functional methodology. Although valid statements, the discipline has failed to effectively describe how to apply these broad concepts when approaching the bloodstained crime scene. Articulating a Concise Scientific Methodology for Bloodstain Pattern Analysis [1] was an excellent start toward resolving this problem. Saviano put forth an eight-step process: (1) data collection, (2) case review, (3) isolation/description of patterns, (4) formulation of hypothesis, (5) testing of hypothesis, (6) formulation of theories, (7) testing of theories, and (8) conclusions and results [1]. But even this excellent article fell short in one important area: the isolation and analysis of the individual patterns, which is the key to all subsequent effort.

As a discipline, bloodstain pattern analysis purports to define “information specific to the events that occurred during the [bloodshed] incident” using information derived from “dispersion, shape, volume, pattern [characteristics], the number of bloodstains, and their relationship to the surrounding scene” [3]. Individual pattern recognition and analysis is the core of bloodstain pattern analysis and thus it must follow scientific method as well; but what does that really mean?

Scientific method, research method, whatever one might call it, seeks to answer specific questions using a standard process. As Saviano explained, the specific articulation of the steps of scientific method varies from author to author [1]. At its core, no matter who the author is, scientific method relies on an ability to define discrete objective questions, seek and find answers to those questions, and ultimately apply the answers from those questions to solve larger more complex questions. Posing and answering questions is the heart of scientific method, which begs the question. What should be asked in bloodstain pattern analysis? The ultimate question of bloodstain pattern analysis is, How was this stain created? To achieve an answer, the analyst must first ask and answer a number of far more discrete questions.

Application of Scientific Method to Bloodstain Pattern Analysis

In some fashion, instructors of bloodstain pattern analysis must articulate a process of what to do and in what order, associating it to the more philosophical aspect of scientific method. If the student of bloodstain pattern analysis docs not know what questions to ask and in what order to ask them, how then can he or she apply scientific method? A practical approach that resolves this problem can be articulated in seven steps. The bloodstain pattern analyst should:

1. Become familiar with the entire scene.

2. Identify the discrete patterns among the many bloodstained surfaces.

3. Categorize these patterns based on an established taxonomy.

4. Evaluate aspects of directionality and motion for the pattern.

5. Evaluate angles of impact, points of convergence, and areas of origin.

6. Evaluate interrelationships among patterns and other evidence.

7. Evaluate viable source events to explain the pattern, based on all of the above [4].

These steps effectively solve the issue of what questions need to be asked in bloodstain pattern analysis. Consider what these seven steps entail and the questions associated with each.

Step 1 – Become Familiar with the Entire Scene

This step involves the most basic questions posed in crime scene processing and crime scene analysis: What is the extent of the scene? What is present in it? If the analyst only considers certain areas, he or she may be missing critical stains or evidence. One never begins any type of scene analysis without first assessing the limits of the scene and knowing generally what is contained within it. Before any other action, the analyst seeks to familiarize himself or herself with the scene using whatever means are available. This entails many of the actions Saviano described in his steps 1 and 2 [1].

Step 2 – Identify Discrete Patterns

Bloodshed often involves multiple events that are ongoing in an area, resulting in stains that are deposited on or around other stains. For instance, multiple blows from a weapon may deposit impact spatter in several iterations onto the same surface, with limited movement of the victim. Or spatter from a cast-off event may occur simultaneously with impact spatter. These patterns tend to merge, making it difficult, if not impossible, to distinguish between them.

In this second step the analyst answers simple, but often elusive, questions: Where are the patterns that I intend to evaluate? What stains belong together? Consideration of the individual stain’s size, shape, position, and directionality are all aspects that help the analyst determine what stains will entail a pattern. Saviano offers this action as a part of his step 3. which he combined with classification [1].

Step 3 – Categorize the Patterns

This is the core step in bloodstain pattern analysis. The questions are, What kind of stain is this? Is this contact or spatter? Is it impact spatter or projected spatter? To answer these questions, the analyst must first have established criteria with which to compare the stain. Note that definitions abound in bloodstain pattern analysis, but definitions are not the same as criteria. For example, a definition of a cast-off stain as “a stain created when blood is flung or projected from an object in motion or one that suddenly stops some motion” does nothing to explain what characteristics were used by the analyst to conclude that the stain was cast-off in the first place. Besides articulating a methodology, the greatest difficulty affecting bloodstain pattern analysis today is the lack of a standard taxonomy.

A taxonomic classification system articulates the physical characteristics (e.g., shape, size, volume, number, dispersion, orientation) that must be present according to the analyst, in order to define something as belonging to a particular classification. In the example of the cast-off, these characteristics might be articulated as:

* a series of circular or elliptical stains (stains resulting from blood in free flight)

* that are positioned in a linear or curvilinear orientation

* with individual stains that have consistent direct\ional or gamma angles to the path of overall pattern.

The failure to teach and use an established taxonomy is why many analysts seem to believe that bloodstain pattern analysis is open to interpretation. If the analyst has no established criteria to look for before assigning a stain to a classification, then, in effect, any stain can be claimed as anything, by anyone. Even though the discipline has yet to create a standardized taxonomy, nothing prevents the individual analyst from having his or her own taxonomy or, at the very least, being prepared to describe his or her idea of these specific criteria. From analyst to analyst, some aspects may vary, but the basic idea of what creates a cast-off, an impact pattern, or a projected pattern is generally understood even if it has not been articulated well in the references.

Classification is the true key to successful objective analysis. Before the analyst can ever begin to consider a hypothesis in the context of the crime, he or she must know what kind of patterns he or she has. As Saviano pointed out, the focus is on the pattern itself with no attempt to infer the broader meaning of the pattern in the context of the scene [1].

These first three steps are accomplished in sequential order. The analyst first familiarizes himself or herself with the entire scene, so he or she knows where all the bloodstains are. The analyst then attempts to distinguish discrete patterns among the various bloodstained surfaces. Once this is accomplished, these discrete patterns may be categorized using a viable (physical characteristic- driven) classification system. Steps 4 and 5 follow and are accomplished as needed and in varying orders, depending upon the situation.

Step 4 – Evaluate Aspects of Directionality and Motion for the Pattern

In this step, the questions are relatively simple: From which direction did the stains being considered originate? What path were they traveling when they were deposited? Information of this nature will be significant at later stages when considering the flow of events and actions in the crime scene. Evaluating directionality is an integral step in establishing area of origin for impact spatter patterns, thus it is often evaluated simultaneously with Step 5. Nevertheless, direction and motion are not solely issues for spatter patterns; various drip, contact, and flow patterns require this consideration as well.

Step 5 – Evaluate Point of Convergence and Area of Origin

Using the mathematical techniques taught in basic a nil advanced courses, the analyst asks and attempts to answer questions relating to impact spatter: Can an impact angle be determined for this stain? If so. what is it? Is there a point of convergence for a group of related stains? C’an the area of origin be defined? If so, where is it? Although the importance of the mathematics of bloodstain pattern analysis is often overstated (most analysts spend less than 10% of their time evaluating these considerations), the answers to these questions can weigh heavily on the ability to evaluate a subsequent hypothesis about where these events occurred.

Step 6 – Evaluate Interrelationships among Patterns and Other Evidence

In this step, the analyst begins to look at the patterns in relation to one another and in relation to other items of evidence. In Step 3. the perspective was on the individual pattern under scrutiny. Here the analyst looks at the scene with a broader perspective. The questions posed include but are not limited to. Are these stains related? Are they the result of a common bloodshed event (e.g., a cast-off emanating from a spatter pattern)? Do patterns on loose items of evidence suggest a specific orientation at the time of the event? Is there evidence of sequence between different stains? Are a number of patterns present on different surfaces actually a single pattern (e.g., impact spatter dispersed over a wall and floor)? Consideration and refinement of these answers will often alter initial conclusions made in Step 2.

Step 7 – Evaluate Viable Source Events in an Effort to Explain the Pattern

Using all of the information derived from the analysis in steps 1 through 6, the stains and patterns must be considered in the context of the scene and incident in an effort to answer. What happened and in what order did it happen’.’ This final step effectively leads us back to Saviano’s steps 4 through 8, where the application of scientific method is directed at the broader investigative issues. Saviano eloquently described how the analyst moves from individual hypothesis to larger more encompassing theories, testing each objectively along the way [1]. This step may entail empirical experimentation in an attempt to determine whether a specific event or event sequence can re-create stains similar to those observed. Thus, the bloodstain data defines conclusions about specific events and, through an understanding of individual events, theories of what happened can be formulated and tested.

Conclusions

Despite all that has been written on bloodstain pattern analysis during its 150-year history, many in the legal profession continue to deride the discipline as unscientific and without objective foundation. Such misinformation is furthered in its cause by a failure of this discipline to adequately prepare rankand-file analysts to either conduct or explain bloodstain pattern analysis using a structured practical approach. And for those who do follow a structured process, as good as they are, many are simply not prepared to articulate that approach to the court. This has to change.

A practical systematic procedure or methodology is the basis of any good analysis. It should be taught and adopted at the most basic stage of bloodstain training and reinforced over time. The use of such a methodology ensures that the bloodstain pattern analyst follows accepted procedure in day-to-day activities. It does not guarantee the outcome, but lacking a methodology can certainly affect the validity of any conclusions drawn. The specifics of how that methodology can or should be written are debatable. As Saviano explained, which procedure is adopted is probably a moot point, as they will all follow a similar path [1]. But introducing a basic procedure into all bloodstain pattern training is a must. And once trained, every bloodstain pattern analyst should be prepared to effectively describe these steps to the court.

Received September 19, 2005; accepted November 22, 2005

References

1. Saviano, J. Articulating a Concise Scientific Methodology for Bloodstain Pattern Analysis. J. For. Ident. 2005, 55 (4), 461-470.

2. Akin, L. Interpretation of Blood Spatter for Defense Attorneys and Investigators: Part I, The Champion, May 2005, 26.

3. Bevel, T.; Gardner. R. Bloodstain Pattern Analysis With cm Introduction to Crime Scene Reconstruction, 2nd ed.; CRC Press: Boca Raton, FL, 2002; p 2.

4. Gardner, R. M. Practical Crime Scene Processing and Ivestigation; CRC Press: Boca Raton, FL, 2004; pp 267-268.

Ross M. Gardner

Gardner Forensic Consulting

Lake City, GA

For further information, please contact:

Ross M. Gardner

Gardner Forensic Consultirm

905 Windmill Court

Jonesboro, GA 30236

gard ner [email protected]

Copyright International Association for Identification Jul/Aug 2006

(c) 2006 Journal of Forensic Identification. Provided by ProQuest Information and Learning. All rights Reserved.

Mayo Clinic Offers New Genetic Test to Help Manage Treatment for Patients With Depression

ROCHESTER, Minn., July 18 /PRNewswire-FirstCall/ — Mayo Clinic is offering a new genetic test to help physicians identify patients who are likely to have side effects from drugs commonly used to treat depression.

Mayo has obtained a nonexclusive license from Pathway Diagnostics, Inc. to test for a key genetic marker that identifies people who respond differently to antidepressants, including selective serotonin reuptake inhibitors (SSRI). SSRIs act specifically by binding to the serotonin transporter, and increase the concentration of the neurotransmitter serotonin in the synapse. These medications include fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), citalopram (Celexa) and escitalopram (Lexapro).

The test will be offered to patients nationwide through Mayo Medical Laboratories (MML), the reference laboratory for Mayo Clinic.

A 2003 study in the Journal of Clinical Psychiatry estimated the annual economic impact of depression in the Unites States at $83.1 billion, and one of six Americans will have at least one depression episode in their lifetime. Treatment choices are complicated because it often takes several weeks to determine whether a drug is having a therapeutic effect.

The 5HTTLPR biomarker has potential to improve management of patients with major depression and others who benefit from SSRI treatment. It provides unique information relating to drug response: side effect and compliance.

The Long/Long (L/L) genotype confers compliance to a SSRI whereas the Short/Short (S/S) genotype indicates an increased compliance with a noradrenergic and specific serotonergic antidepressant (e.g., mirtazapine).

“The serotonin transporter genotype assists the physician in making a better choice of antidepressant medications for their specific patient,” said Dennis O’Kane, Ph.D., director of the Nucleotide Polymorphism Laboratory at Mayo Clinic that validated the serotonin transporter testing. “Patients can be prescribed antidepressants that have a greater probability of being effective in their individual case, based upon their serotonin transporter genotype used in conjunction with CYP450 genotyping testing. Depending upon genotypes, some patients should respond well to SSRIs, some may respond to SSRIs but more slowly, and some patients may respond more effectively to non- SSRI antidepressants.”

“Depressive disorders affect over 18 million American adults,” says Wally Narajowski, president and CEO of Pathway Diagnostics. “Prescribing the right antidepressant therapy at the right dose is a medication management challenge. We are pleased to work with Mayo Medical Laboratories to provide tools that will help address this challenge.”

Published studies in the medical literature have estimated that 30 percent of patients treated with the existing antidepressant medications do not improve. In addition, 90 percent experience side effects and 30 to 40 percent do not respond to the first drug regimen. “Prescribing a correct antidepressant for the specific patient may increase the likelihood of patient compliance and decrease the loss of patients to follow-up,” says Dr. O’Kane.

The 5HTTLPR test is among the growing list of pharmacogenomic tests Mayo offers to help physicians personalize treatment options. Pharmacogenomics individualizes drug selection and dosing based on a person’s genomic makeup; pharmacogenomic testing can help determine which patients should receive which doses of which medications to avoid adverse drug reactions.

Mayo offers these proven diagnostic technologies to more than 5,000 health care institutions around the world through MML. Working with the Department of Neurology at Mayo Clinic, the Department of Laboratory Medicine and Pathology refined and validated this 5HTTLPR genotype test for use by its physicians, and will offer it to other health care organizations through MML. Mayo will offer education to providers on the benefits of this important screening test to ensure that patients everywhere have access to it.

The Department of Laboratory Medicine and Pathology at Mayo Clinic maintains an active diagnostic test development program. These activities also incorporate discoveries, such as the 5HTTLPR biomarker, made elsewhere. Revenue from MML testing and technology licensing is used to support medical education and research at Mayo Clinic.

To obtain the latest news releases from Mayo Clinic, go to http://www.mayoclinic.org/news . MayoClinic.com ( http://www.mayoclinic.com/ ) is available as a resource for your health stories.

Mayo Clinic

CONTACT: Lee Aase of Mayo Clinic, +1-507-284-5005 (days), or+1-507-284-2511 (evenings), or [email protected]

Web site: http://www.mayo.edu/http://www.mayoclinic.org/http://www.mayoclinic.com/

Alzheimer’s drug slow brain shrinkage

WASHINGTON (Reuters) – The Alzheimer’s drug Aricept not
only improves memory and understanding in patients but appears
to slow the characteristic shrinkage of the brain, researchers
reported on Monday.

Magnetic resonance imaging or MRI images of the brains of
131 patients with mild cognitive impairment showed less
shrinkage of the hippocampus, a structure key to memory
function, in patients who got the drug compared to those who
got a placebo, researchers told a meeting.

“No drug has been shown to slow brain atrophy for patients
with mild cognitive impairment,” said Dr. Clifford Jack of the
Mayo Clinic in Rochester, Minnesota.

Aricept, which is known generically as donepezil, is
marketed by Pfizer and Japan’s Eisai Co. Ltd..

“Our study results seem to imply that donepezil does more
than provide symptom relief — it has an effect on a measure of
brain health. Our findings also show that MRI measures can have
usefulness in future studies of mild cognitive impairment.”

Mild cognitive impairment can lead to Alzheimer’s disease,
but not always.

Jack’s team found the effects only in people with the
apolipoprotein E4 (APOE 4) gene, a genetic variation that has
long been known to put people at higher risk of Alzheimer’s.

Why is unclear, he said.

“One possibility is that APOE 4 carriers were more likely
to have definite Alzheimer’s disease than noncarriers in the
study who appear to have symptoms of early Alzheimer’s disease,
yet turn out to have a different diagnosis when an autopsy is
performed after death,” he said.

Jack’s study was presented to the International Conference
on Alzheimer’s Disease and Related Disorders in Madrid, Spain.

An estimated 12 million people worldwide suffer from
Alzheimer’s disease, but international researchers predict the
number of people suffering from dementia worldwide could reach
81 million by 2040 as the “baby boom” generation ages.

There is no cure for Alzheimer’s, which begins as mild
memory loss and can progress quickly to complete loss of any
ability to care for oneself.

The brain becomes clogged with proteins known as plaques
and tangles of nerve fibers. And it shrinks.

“In extreme cases, the brain of an Alzheimer’s patient
might weigh half of what a normal person’s brain does at peak
health,” Jack said.

Experts are looking for ways to prevent Alzheimer’s from
developing, or to slow its fatal progression. They are also
looking for better ways to diagnose the disease in patients
using imaging scans such as MRI or PET.

Amgen Announces EVOLVE Trial(TM) To Investigate Impact of Sensipar(R)/Mimpara(R) (Cinacalcet HCl) on Mortality and Cardiovascular Morbidity in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease Receiving Dialysis

— New Data Showed Earlier Intervention With Sensipar/Mimpara

Improved Ability to Achieve K/DOQI(TM) Secondary HPT Treatment

Guidelines in Dialysis Patients —

Amgen (Nasdaq:AMGN), the world’s largest biotechnology company, announced today the initiation of the largest prospective, randomized clinical trial planned to date in patients with stage five chronic kidney disease (CKD). EVOLVE (EValuation Of Cinacalcet Therapy to Lower CardioVascular Events)(TM) is a Phase 3 international, clinical outcomes study designed to determine whether Sensipar(R)/Mimpara(R) (cinacalcet HCl) can effectively reduce the risk of mortality and cardiovascular morbidity in patients with secondary hyperparathyroidism (secondary HPT) and CKD undergoing maintenance dialysis. EVOLVE was announced at the 2006 European Renal Association – European Dialysis and Transplant Association (ERA-EDTA). Cinalcalet HCl is marketed as Sensipar in the United States, Canada and Australia and as Mimpara in the European Union.

Amgen’s decision to initiate EVOLVE is supported by a recent post-hoc analysis of four pooled, prospective, randomized, placebo-controlled clinical trials that showed treatment with cinacalcet HCl in patients with secondary HPT and CKD receiving dialysis resulted in improvement of clinical outcomes, including cardiovascular hospitalization, parathyroidectomy, fracture and health-related quality of life.(1)

“Recent data have shown a relationship between poorly controlled secondary HPT and increased mortality and morbidity in CKD patients receiving dialysis,” said Willard Dere, MD, senior vice president for global development and chief medical officer at Amgen. “Until EVOLVE, no robust prospective, clinical trial has definitively determined whether treating secondary HPT reduces the risk of cardiovascular events. The results of the EVOLVE will be invaluable to nephrologists in deciding how to optimally manage secondary HPT.”

EVOLVE is expected to enroll approximately 3,800 patients in 500 clinical sites throughout the world, including the United States, Latin America, Canada, Australia, Russia and the European Union. Amgen has gained acceptance of the study design with global regulatory authorities and enrollment is expected to begin in the second half of 2006.

At ERA-EDTA, Amgen also announced new cinacalcet HCl data from the OPTIMA Study (An OPen-label, Randomized Study Using Cinacalcet To IMprove Achievement of K/DOQI(TM) Targets in Patients with ESRD). This study showed that initiation of cinacalcet HCl at the earlier stages of secondary HPT at intact parathyroid hormone (iPTH) levels of 300-500 pg/mL enabled greater achievement of the National Kidney Foundation’s (NKF) Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines for secondary HPT targets than if treatment was initiated at higher iPTH levels. The K/DOQI guidelines are evidence-based clinical practice guidelines for kidney dialysis patients. Additionally, cinacalcet HCl helped more patients achieve K/DOQI(TM) targets for iPTH and calcium-phosphorous product (Ca x P) levels compared to conventional therapy (with unrestricted vitamin D and phosphate binder use). Control of both PTH and Ca x P was greatest in patients with lower baseline PTH and was achieved with lower cinacalcet HCl doses.(2)

“Use of Mimpara in dialysis patients enables patients and physicians to achieve greater control of secondary HPT, especially when adequate treatment is initiated in the early stages of this progressive metabolic disorder,” said Martin Wilkie, MD, Northern General Hospital, Sheffield, United Kingdom. “In our study, we found that the greatest reductions in Ca and P were in those patients receiving Mimpara in combination with lower doses of vitamin D sterols. Furthermore, large Phase 3 outcomes clinical studies are needed to determine Mimpara’s benefits in improving patients’ lives and preventing disease progression.”

About EVOLVE and Amgen Cardiovascular Clinical Trials Program

Amgen has initiated an extensive clinical trials program to study the effect of treating CKD complications or anemia on cardiovascular outcomes in different populations. In addition to EVOLVE, Amgen initiated TREAT (Trial to Reduce Cardiovascular Events with Aranesp Therapy)(TM), which is an ongoing trial in diabetic patients with chronic kidney disease and anemia not requiring dialysis, and the RED-HF(TM) Trial (Reduction of Events with Darbepoetin alfa in Heart Failure) to evaluate treatment of anemia with Aranesp on morbidity and mortality in patients with symptomatic heart failure.

About OPTIMA Data Presented At ERA-EDTA

The study involved 552 dialysis patients with baseline (BL) iPTH 300-800 pg/mL, randomized to receive either cinacalcet HCl or conventional therapy (CT) in a ratio of 2:1. Cinacalcet HCl patients were initiated at 30 mg/day and titrated to achieve iPTH Less Than or Equal to 300 pg/mL. After reaching iPTH target, vitamin D dose was decreased if necessary to achieve Ca x P target. In the CT arm, physicians had full freedom to treat patients with unrestricted vitamin D and phosphate binder use in an attempt to reach treatment targets. All patients were assessed during an efficacy assessment phase (weeks 17 to 23). More cinacalcet HCl patients with moderate BL iPTH levels (300 – 500 pg/mL) met both iPTH and Ca x P targets (65 percent) than cinacalcet HCl patients with high BL iPTH levels (500 – 800 pg/mL; 55 percent) and CT patients (16 percent). Mean daily dose of cinacalcet HCl was also lower among patients with moderate than high BL iPTH levels (42 mg vs. 60 mg).(2)

Secondary HPT, Chronic Kidney Disease and Cardiovascular Disease

There are approximately 1.3 million patients worldwide currently on dialysis to treat kidney failure(3) and nearly all of them also have secondary HPT.(4) Secondary HPT is characterized by increased levels of parathyroid hormone (PTH), calcium and phosphorus. If left untreated, patients with secondary HPT may develop severe bone disease, including bone pain and fractures.(4)

Abnormalities in PTH, calcium and phosphorus are also associated with an increased risk of hospitalization and death, often due to cardiovascular disease.(4) According to the NKF, cardiovascular disease is the leading cause of death among dialysis patients.(5)

About Sensipar/Mimpara (cinacalcet HCl)

In clinical trials in secondary HPT patients on dialysis, cinacalcet HCl was well-tolerated and effective in reducing PTH, Ca, P, Ca x P in a broad range of patients regardless of age, gender, dialysis method (hemo- or peritoneal dialysis), years on dialysis or disease severity.(6)

In a clinical trial in patients with hypercalcemia due to parathyroid carcinoma, cinacalcet HCl significantly lowered calcium levels in the majority of patients.(7)

Studies have shown that cinacalcet HCl lowers Ca, based on its mechanism of action, so it should not be initiated if a patient’s Ca levels are below the lower limit of the normal range.(7) During dose titration, Ca levels should be monitored frequently and if levels decrease below the normal range, appropriate steps should be taken to increase Ca levels. The threshold for seizures may be lowered by reductions in Ca levels and, infrequently, seizures have been reported. The most commonly reported side effects are nausea and vomiting.(7)

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Forward-Looking Statement

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in Amgen’s Form 10-K for the year ended December 31, 2005, and in Amgen’s periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify side effects or manufacturing problems with our products after they are on the market. In addition, sales of our products are affected by the availability of reimbursement and the reimbursement policies imposed by third party payors, including governments, private insurance plans and managed care providers, and may be affected by domestic and international trends toward managed care and healthcare cost containment as well as possible U.S. legislation affecting pharmaceutical pricing and reimbursement. Government regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that it will be able to produce commercially successful products or maintain the commercial success of our existing products.

Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the FDA for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

 (1)Cunningham J, Danese M, Olson K, Klassen P, Chertow G.M. Kidney    Int.: 1793-1800, 2005.  (2)Messa P, Villa G, Braun J, et al. European Renal Association -    European Dialysis and Transplant Association (ERA-EDTA)  (3)Lameire N., Jager K., van Biesen W., et al: Chronic kidney disease.    Kidney Int,.68:99:30-38, 2005  (4)De Francisco AL. Clin Ther 2004; 26: 1976-1993.  (5)National Kidney Foundation. Available at:  http://www.kidney.org/professionals/kdoqi/guidelines_cvd/overview.htm  (6)Moe SM, et al. Kidney Int.: 2005; 760-771  (7)Mimpara(R) Summary of Product Characteristics 

Russia titanium town hopes for Kremlin boost

By Aleksandras Budrys

VERKHNAYA SALDA, Russia (Reuters) – Horse-drawn carts still
ply the streets of the Russian town where most of the world’s
titanium is made.

A sprawling, Soviet-built plant has been upgraded to supply
state-of-the-art products to luxury airliners being built by
Boeing and Airbus, but living conditions in this Ural mountains
town of 40,000 people are still basic.

This could be about to change.

The world’s top titanium maker, VSMPO-Avisma, plans to
transform the region into a “Titanium Valley” by building 11
workshops to make titanium products.

The project has been boosted by a joint venture to supply
Boeing with components for its new Dreamliner jets, and by the
Kremlin’s interest in acquiring a stake in VSMPO-Avisma.

Russia’s government, an increasingly confident and wealthy
player on the world stage and keen to consolidate strategic
mineral assets under its control, sees VSMPO-Avisma as an
integral part of a national aerospace and military powerhouse.

State-owned arms trader Rosoboronexport has declared its
intent to acquire at least a blocking stake — 25 percent plus
one share under Russian law — and sources involved in the
talks have said a deal could be struck within a month.

VSMPO-Avisma’s general director Vladislav Tetyukhin and
chairman Vyacheslav Bresht have both said they would be willing
to sell to the state at the right price.

It could be good news for this neglected town, about 1,050
miles east of Moscow, but the Kremlin’s overtures have raised
fears among some analysts that exports from VSMPO-Avisma could
be cut back, especially as Russia develops a civil and military
aerospace industry of its own.

“I foresee problems if the state changes the management,”
said Vladimir Katunin, metals analyst at Aton brokerage.

“I don’t think the new managers will immediately sever
contracts with Boeing and others,” he said. “But there is a
risk these contracts might be revised.”

FEARS UNFOUNDED

Tetyukhin, a 73-year-old metallurgist, says such fears are
unfounded.

“The state understands that we are an international
company, and we have a gigantic responsibility for the world
aircraft sector,” he said.

“They understand what it would mean to disrupt supplies to
Boeing or Airbus. This would be a mighty international scandal
and these people aren’t about to commit suicide.”

Tetyukhin and Bresht, who each have a fortune of $690
million according to Forbes magazine ranking them among
Russia’s top 75 richest men, together own 60 percent of the
company.

“The government has decided the company should get proper
attention,” Tetyukhin said.

“Titanium is used in submarines and in surface vessels, in
aircraft, spaceships and nuclear power stations — all sectors
of the economy that guarantee the survival of the state.”

Until now, however, that strategic importance of titanium
hasn’t been reflected on the streets of Verkhnaya Salda.

“ABSURD SITUATION”

The Titanium Valley project would give VSMPO-Avisma
significant tax breaks that, local officials say, would allow
the company to invest in improving facilities.

“We have either adopted, or are discussing, a series of
laws granting tax breaks to companies, in particular on
property tax,” said local government official Vladimir
Tereshkov.

“We are ready to cut by 50 percent the tax on newly built
assets,” said Tereshkov, chairman of the budget, tax and
finance committee of the lower chamber in the Sverdlovsk
regional legislative assembly.

He said another law recently adopted by the regional
parliament would cut VSMPO-Avisma’s tax on any investments it
makes in its production facilities.

That is welcome news for the company.

“We are able to finance our development, but we are unable
to take responsibility for the whole of the social
infrastructure,” said Tetyukhin.

“It’s an absurd situation. Our taxes have risen several
times. In the capital of the region, Yekaterinburg, new houses
are rising like mushrooms after rain. Here, nothing happens.”

VSMPO started making aluminum parts for aircraft engines
near Moscow in 1933. As Nazi troops pushed toward the Russian
capital in the 1940s, production was moved to Verkhnaya Salda.

By the 1950s, the firm was the monopoly supplier of
titanium to the Soviet aerospace and military industries. But
after the break-up of the Soviet Union, a drastic fall in
military spending and civil aircraft production dragged VSMPO
to the brink of bankruptcy.

Now VSMPO-Avisma — formed when VSMPO merged with the
Avisma titanium sponge and magnesium unit in 2005 — aims to
invest $650 million by 2010 to raise output of titanium
products to 35,900 tonnes, and an overseas share listing is
planned for next year.

(Additional reporting by Natalya Shurmina in Yekaterinburg)

House backs voting rights extension

By Amanda Beck

WASHINGTON (Reuters) – The U.S. House of Representatives on
Thursday overwhelmingly approved a 25-year extension of the
1965 Voting Rights Act, preserving for another generation a law
that opened voting booths to minorities.

Often described as the crown jewel of the civil rights era,
the Voting Rights Act outlawed poll taxes, literacy tests and
other obstacles that had prevented African Americans and other
minorities from exercising their rights to vote. Since then,
minorities have voted in larger numbers, and more have been
elected to local and national office.

Most of the act is permanent, but portions of it expire if
not renewed periodically. The House vote was 390-33, and the
Senate is expected to give the bill, backed by President George
W. Bush, similar bipartisan support later this year.

House leaders had hoped to pass the bill, named for civil
rights heroines Fannie Lou Hamer, Rosa Parks and Coretta Scott
King, in June but were forced into a last-minute cancellation
when conservative Republicans argued it was time to change some
provisions. They said that southern states are not being given
full credit for the changes they have made since the civil
rights era.

Controversy centered on two issues — extra scrutiny for
mostly southern states with a legacy of voting discrimination
against minorities and a requirement to provide bilingual
ballots to citizens whose English is poor. Amendments that
would have softened those provisions were defeated.

(Additional reporting by Joanne Kenen)

Bush, Merkel slice into roast pig at German barbecue

By Steve Holland

TRINWILLERSHAGEN, Germany (Reuters) – President Bush put
Middle East tension, violence in Iraq and Iran’s nuclear
program behind him on Thursday to feast on a wild boar roasting
on a spit.

“Laura and I come from Texas,” Bush told his host German
Chancellor Angela Merkel on a warm summer evening. “One of the
greatest compliments you can pay a guest is to have a
barbecue.”

The barbecue was a much-anticipated highlight of Bush’s
visit to Merkel’s political home base in northeastern Germany,
a grilling he had been looking forward to all day.

Merkel greeted Bush wearing faded blue jeans as the U.S.
president and his wife, Laura, arrived in the tiny Baltic town
north of Berlin aboard the Marine One helicopter.

They walked past a red-coated band playing a medley of
songs like “Hooray for the Red, White and Blue,” and Bush
plucked the conductor’s wand from his hand and led the band for
a few notes.

Then he and Merkel posed for pictures with the band as its
members played on, Bush startling a woman playing a flute by
poking her on the shoulder.

Nearby, three creatures were turning slowly over flaming
beds of coals, one of them a wild boar hunted down by
restaurant owner Olaf Micheel.

After both leaders spoke to the crowd, Bush said: “Thanks
for having us. Let’s go eat.”

Someone handed Bush a long knife and fork and as he
prepared to pierce the meat, members of another band lifted
their horns and began to play on cue.

Bush cut several slices from the shoulder and Merkel did
the same from a haunch, and the eating began.

At a joint news conference with Merkel earlier in
Stralsund, Bush kept mentioning a wild boar, slaughtered and
roasted the traditional way, that he planned to share at the
dinner.

“I’m looking forward to the feast you’re going to have
tonight. I understand I may have the honor of slicing the pig,”
Bush told Merkel.

A few minutes later — after discussing Iran, the Middle
East, the merits of press freedoms in Russia and progress on
the Doha round of free trade talks — Bush returned to the
boar.

“Thank you for having me,” he told Merkel. “Looking forward
to that pig tonight.”

Bush answered a few more questions but kept coming back to
the boar for a third, then a fourth time.

Leg length linked to heart disease risk

NEW YORK (Reuters Health) – Having longer legs may put you
at lower risk of heart disease, new findings show.

In an analyses of data from 12,254 men and women aged 44 to
65, Dr. Kate Tilling of the University of Bristol in the UK and
colleagues found a direct association between leg length and
intimal-medial thickness (IMT), a measurement of the thickness
of blood vessel walls used to detect the early stages of
atherosclerosis, or hardening of the arteries.

The longer a person’s legs, they found, the thinner their
carotid artery walls were, indicating less buildup of deposits
within these blood vessels and a lower risk of heart disease
and stroke.

Leg length is strongly affected by early life factors,
Tilling and her team point out in their article in the American
Journal of Epidemiology. For example, studies have linked
breastfeeding, high-energy diets at age two and four years, and
affluent childhood circumstances to longer leg length.

To investigate whether leg length might also be related to
early signs of heart and blood vessel disease — which would in
turn support a connection between early life factors and heart
attack and stroke risk — the researchers compared leg length
to IMT of the carotid artery in a group of men and women
participating in a large study of atherosclerosis risk. They
estimated leg length by subtracting a person’s height when
seated from his or her total height.

Leg length was directly linked to IMT, the researchers
found, with the relationship being strongest for black men and
weakest for black women.

The study “provides some support for the hypothesis that
early life factors, such as breastfeeding and childhood
nutrition, which are associated with greater prepubertal linear
growth, may reduce cardiovascular disease risk,” Tilling and
her colleagues conclude.

SOURCE: American Journal of Epidemiology, July 15, 2006.

Controlling Infectious Diseases

By Kent, Mary M; Yin, Sandra; Fontaine, Olivier; Boschi-Pinto, Cynthia

The 20th century was a triumph for human health and longevity. An Indian born in 1900 had a life expectancy of 22 years; an American baby born that year could expect to live about 49 years. By century’s end life expectancy had soared to unprecedented levels even in many poor countries. In 2005, average life expectancy at birth in the United States was 78 years; in India it was 62 years.1

The falling death toll from infectious diseases-primarily among infants and young children-led to these spectacular improvements in human life expectancy. For most of human history, communicable diseases such as malaria, smallpox, and tuberculosis (TB) were leading causes of death. TB was the second-highest cause of death in the United States in 1900, and malaria was a major problem in southeastern U.S. states. These diseases were effectively controlled in the United States and declined throughout much of the world in the 20th century. One major disease-smallpox-was virtually wiped out; another-polio-may be close to eradication.2

Improvements in sanitation and the development of vaccines and antibiotics accelerated the decline of infectious and parasitic diseases (IPDs) in the 20th century.

But, with a few exceptions, communicable diseases have not been vanquished. The microbes that cause these diseases continue to evolve, sometimes requiring new drugs and methods to combat them. New pathogens emerge, or make the jump from infecting animals to infecting humans. The most recent global estimates show that communicable diseases cause about one-third of all deaths (see Figure 1). Pneumonia and other lower respiratory diseases are the largest group, followed by HIV/AIDS, diarrheal diseases, TB, and malaria.

Communicable diseases impose vastly different health burdens on the wealthy and poor. They are the primary reason why a baby born in Somalia today is 30 times more likely to the in infancy than a baby born in France.3 Most of these diseases-including measles, HIV, TB, and malaria-are preventable and treatable using proven and often surprisingly low-cost health interventions. But control of communicable diseases will require additional financial investments, fundamental improvements in health delivery, and longer-term political commitments.4 International and national organizations such as the U.S. Agency for International Development (USAID), the World Health Organization (WHO), the World Bank, and UNICEF-aided by private funders such as the Bill & Melinda Gates Foundation-have spearheaded major efforts to attack infectious diseases.

Figure 1

Global Deaths by Leading Cause, 2002

Large-scale vaccination campaigns, for example, save millions of lives from measles and whooping cough each year. Other diseases- such as malaria-have proved more difficult to control. Although greatly diminished worldwide, malaria has resurged in many countries and continues to be a leading cause of childhood deaths in Africa and a drag on health in several other regions. Likewise, TB, which lost its hold on Europe and the United States by the mid-20th century, continues to devastate the health of millions in developing countries-especially where HIV/AIDS is prevalent. TB is re-emerging in many Eastern European countries where HIV is rapidly increasing.

Some of the miracle drugs that suppressed major diseases have lost their magic as viruses and parasites develop resistance to them. The mosquitoes that transmit malaria, dengue fever, and other diseases have become immune to some common insecticides. The parasites carried by mosquitoes have developed a resistance to drugs formerly used to treat them. Medical researchers are in a race to develop new weapons against diseasecarrying pests, viruses, and parasites before the current arsenal is obsolete.

In the late-20th century, the world was also hit with a new pandemic-HIV-that infects more than 40 million people today and causes at least 3 million deaths annually. HIV undermines the immune system-causing AIDS and making it harder for HIV-infected individuals to fight other diseases. It has increased death and disability from other IPDs, especially TB.

Other infectious diseases have emerged that have proved especially lethal-including Ebola and hantaviruses. While outbreaks tend to be highly localized, some bioterrorism professionals fear these viruses could be used as weapons.5 Influenza experts warn that we are likely to experience a worldwide influenza pandemic with the potential of causing millions of deaths, as did the Spanish Flu pandemic in the early 20th century. No one can predict when this might occur, or how deadly the next flu pandemic will be. The public health community is currently focused on the H5N1 avian flu, which is spreading around the world. H5N1 has not been transmitted person- to-person so far, but it could evolve into a major human health threat.6

Aspects of life in the 21st century-frequent travel, population migration, international trade, even climate change-all favor the spread and persistence of infectious and parasitic disease (IPDs). Dengue fever probably arrived in Latin America in recent decades as larvae in tire shipments from Asia, and cholera may have been carried in the holding tanks of freighters.7 Both are now major health concerns in parts of Latin America. If average temperatures continue to rise throughout the world, the range of disease- carrying mosquitoes will expand, exposing more people to malaria and dengue, among other diseases.8

This Population Bulletin explores the major health threats from infectious and parasitic diseases, with a special focus on malaria, diarrheal diseases, and TB. It examines recent trends and obstacles to prevention and treatment. It will also look at the potential threats from new pandemics and what the international health community and national governments are doing about them.

Demographic Dimension

For much of human history, populations grew slowly, if at all, because high birth rates were matched by high death rates from infectious diseases and other hazards. Major epidemics, such as the black plague that killed off one-third of Europe’s population in the 13th century, and smallpox, which decimated the indigenous population of the Americas in 16th and 17th centuries, were extreme examples.9 But tuberculosis, measles, pneumonia, and diarrheal diseases (including cholera and typhus) were constant threats. Living conditions improved in Europe after the 18th century because of a confluence of economic, political, and social developments, and a long stretch of moderate weather that made food more plentiful. But basic knowledge of what caused infectious disease was minimal. It wasn’t until the late 19th century that medical researchers accepted the idea that invisible microorganisms transmitted dis ease through water, pests, food, or close personal contact.10 On average, mortality remained quite high until the late 19th and early 20th centuries. After that time, several factors greatly reduced the mortality from IPDs, and ushered in an epidemiological transition to lower mortality:

* People learned the importance of better hygiene; especially washing hands and safely handling food, as knowledge of the “germ theory” of disease spread;

* Antibiotics and vaccines effective against IPDs became available; and

* Governments invested in clean water and sanitation systems.

Figure 2

Increase in Life Expectancy in Four World Regions, 1950-2005

These developments occurred at different times in different countries-better hygiene and sanitation practices helped IPDs fall markedly in developed countries even before antibiotics and vaccines were widely available, for example.11

Death rates declined, but birth rates remained high in many countries, creating an unprecedented surplus of births over deaths and causing growth rates to surge. Birth rates began to decline as families realized that more of their babies would survive to adulthood, especially as families moved away from farming and other livelihoods in which having many children might be an advantage. As birth rates declined, population growth rates subsided in many countries throughout the world, especially in Europe and North America.

But infant and child mortality from infectious diseases is still too high in many developing countries and among disadvantaged groups in nearly every country. This is the primary reason for the life expectancy gap between low mortality Western Europe and highermortality sub-Saharan Africa and South-Central Asia (see Figure 2). Progress against IPDs in many lowincome countries has lagged or stagnated because of a lack of resources, political instability, and corruption, among other barriers. HIV/AIDS epidemics have blocked progress in many sub-Saharan African countries.

The demographic toll of infectious diseases is reflected in the age and sex structure of high mortality countries. Except for AIDS and TB, the young are disproportionately affected by IPDs. Although children under age 15 account for one-quarter of all deaths in low- and middleincome countries, they account for one-half of the deaths from infectious and parasitic diseases, including lower respiratory infections (see Figure 3). More than 7 m\illion children under age 15 die each year from IPDs, at least 85 percent die before their fifth birthday.

As IPDs are controlled, infant and child mortality rates could fall quickly, as they did in many countries in the 1950s and 1960s. This welcome improvement in child survival could produce other demographic effects: a bulge in the number of children in high- mortality countries and a spike in population size. The magnitude and length of any surge in population growth will depend on whether couples in those countries want to limit their childbearing and whether they have easy access to family planning services. We are not likely to see a repeat of the rapid global population growth of the 1960s and 1970s, in part because the remaining high mortality countries make up less than 10 percent of world population. Sustained and rapid growth is also unlikely because fertility in most countries is lower than it was in the 1960s and because family planning is more acceptable and available.

Figure 3

Percent of all Deaths and Deaths From Infectious Diseases by Age in Low- and Middle-Income Countries, 2001

Geographic Disparities

The geographic disparities in the toll from infectious and parasitic diseases are most evident for children. In more developed regions, IPDs cause just 5 percent of deaths of children under age 5 (see Figure 4, page 6). This contrasts sharply with the percentages in lower-and middle-income countries. More than three-fourths of child deaths in Africa were attributed to infectious diseases around 2001, more than one-half in Southeast Asia, and just over one-third in Eastern Europe and in Latin America and the Caribbean.

Sub-Saharan Africa is the region plagued by the worst death and disability from IPDs, led by HIV/AIDS. Because of HIV, average life expectancy in southern Africa declined from 62 to 48 between the early 1990s and the early 2000s, reversing hard-won gains in life expectancy in the previous three decades.12 HIV/AIDS is the largest single cause of illnesses and deaths in the region, accounting for 19 percent of deaths in 2001. Five other IPDs accounted for another 34 percent of deaths: malaria, lower respiratory diseases, diarrheal diseases, measles, and TB.13

Sub-Saharan Africa also suffers the most death and disability from communicable tropical diseases such as onchocerciasis (river blindness), trypanosomiasis (sleeping sickness), and helminth infections.14

South Asia-including Bangladesh and India-is the other major world region where poverty is widespread and where infectious diseases are a major health problem (see Table 1). The tropical and semitropical climates, poverty, and lack of adequate infrastructure and health care have hindered the fight against preventable infectious diseases in this region.

The leading IPDs in South Asia are lower respiratory diseases and diarrheal diseases, which especially target children. Other IPDs in the top 10 causes of death are TB and HIV/AIDS, which especially affect working-age adults. The HIV/AIDS epidemic has been another setback for disease control. Although HIV prevalence has remained far below the levels in southern Africa, it is a growing problem.

Figure 4

Percent of Child Deaths From Infectious Diseases in Selected Regions, 2000-2003

Table 1

Top 10 Causes of Death in Low- and Middle-Income Countries, Selected Regions, 2001

Countries in Latin America and the Caribbean have made more progress in controlling infectious diseases. IPDs caused less than 15 percent of all deaths, and 38 percent of deaths of children under age 5 in the region around 2001. The incidence of measles deaths, for example, has fallen markedly throughout the region, and, except for Haiti, HIV has not exceed 1 percent in most countries in the region.15

Some parasitic diseases, such as schistosomiasis, are endemic in parts of Latin America, and dengue fever and its more serious complication, dengue hemorrhagic fever, actually increased in urban areas during the 1990s.

Differences by Age

Pneumonia, diarrheal diseases, and malaria are the major causes of death for children under age 15-with the vast majority succumbing before age 5. Children who survive until their fifth birthdays have already fought off a number of childhood infections and have a good chance of living until age 15. The 5-to-l4 age group in high- mortality countries tend to be a healthier group-they developed resistance to many IPDs and they are not yet subject to most of the health problems that harm adults, including complications of pregnancy and childbirth, TB, HIV, and such noncommunicable diseases such as cancer and cardiovascular diseases.

HIV/AIDS, TB, and lower respiratory infections (especially pneumonia) are the top three infectious diseases that strike those ages 15 to 59. People age 60 or older are most likely to die of a noncommunicable disease, including heart disease, cancer, and stroke, but older people also succumb to infectious diseases. Pneumonia is a major cause of death to the elderly in all countries. Older people often have several health problems that make them less able to recover from respiratory infections. People whose immune systems are compromised by TB and malaria and other parasitic infections are especially vulnerable. In low- and middleincome countries, lower respiratory diseases, TB, and HIV are the top three causes for people age 60 or older.

Childhood Diseases

A relatively small number of infectious diseases are responsible for 62 percent of deaths to children under age 5 in low- and middle- income countries.16 Children rarely the from these causes in more developed countries because of widespread vaccination, greater access to health care, and better hygiene and sanitation. Less developed countries have made great strides in combating IPDs, and infant mortality rates have declined in most regions. But the gap between rich and poor countries remains substantial.

In 1974, WHO launched the Expanded Programme of Immunization (EPI), with the aim of vaccinating all children against six major childhood killers: whooping cough (pertussis), diphtheria, tetanus, polio, measles, and childhood tuberculosis. Three doses of the vaccines for pertussis, diphtheria, and tetanus are required during the child’s first year of life for full protection-meaning three separate visits with health-care workers. The polio vaccine also requires additional doses. By 2004, at least three-fourths of children in less developed countries were protected by at least one of the EPI vaccines, and coverage was above 90 percent in some regions. Yet maintaining these high coverage rates for each new generation of children is an ongoing challenge in resource- constrained countries.

Vaccination rates are still quite low in many countries. Fewer than one-half of the children in the Dominican Republic, Haiti, and Jordan were protected from all six EPI target diseases, as were fewer than onefifth of children in Chad, Ethiopia, and Nigeria.17 Within countries, children living in rural areas are often much less likely to have received all their vaccinations. In Jordan, just 7 percent of children in rural areas were vaccinated in 2002, compared with 34 percent of urban children. In Vietnam, the rural rate was 62, compared with 87 in urban areas (see Figure 5). In Bangladesh, in contrast, the gap between urban and rural is smaller and the overall percentage fully vaccinated is much higher, demonstrating that low-income and largely rural countries can achieve high vaccination rates.

Infant and child mortality is greater in rural areas of most countries. In Bolivia, 81 infants died per 1,000 births in rural areas around 2003, for example, compared with 57 deaths per 1,000 births in urban areas.18

But the WHO immunization programs have saved millions of lives and have nearly eliminated polio. Around 2001, measles was still claiming at least 676,000 lives per year, but vaccine coverage had averted more than 1 million deaths (see Table 2, page 8). The pertussis vaccine averted more than another 1 million deaths, according to estimates.

EPI has been expanded and additional vaccines are being developed and administered. In particular, many less developed countries are vaccinating children against hepatitis B, yellow fever, and a deadly strain of influenza (Haemophilus influenzae type b, or Hib). A vaccine to protect children against the rotavirus-which causes severe diarrhea-may soon be available in less developed countries, with the potential of saving thousands of lives each year. Vaccines against meningitis and pneumococcal disease may also become available, further cutting the disease burden from IPDs.19

Figure 5

Percent of Children Fully Vaccinated, by Residence, Selected Countries, 2002-2005

Table 2

Vaccine-Preventable Childhood Diseases, 2001

Disability and III Health

While the IPDs cause excess and often preventable deaths, their total effect on global health is much greater. Infectious diseases affect physical and mental growth in childhood, which can cause life- long disabilities that impair a person’s ability to support themselves and their families. Pneumonia, which is responsible for about one-fifth of deaths of children under age 5, can permanently damage lungs. Measles can lead to blindness, polio to crippling, and hepatitis to liver cancer, for example. Malaria in pregnant women can cause low birth-weight babies, which can lead to a host of developmental problems. Malaria and other parasitic diseases often produce severe anemia, which can render their victims unable to work. Skin diseases can disfigure or disable victims, affecting their ability to function normally in society.20

Many people suffer from more than one IPD, which may be exacerbated by other health problems-especially malnutrition. WHO estimates that malnutrition is the underlying cause of more than one- half of the deaths among children under age 5.

Helminth infections caused by parasitic worms are exa\mples of IPDs that rarely cause death directly but undermine health in ways that can affect all aspects of an individual’s life. Some helminth infections are transmitted by close contact with soil or water containing the parasites, which links them to poor living conditions. They tend to thrive in warm climates in tropical and subtropical areas. The persistence of some helminths, such as schistosomiasis, has been attributed to building of dams and other construction projects that alter the flow of waterways in ways that promote the growth of the snail that is integral to the parasites life cycle. As such, an increase in schistosomiasis can be an unintended consequence of economic development.

Helminth infections can thwart educational advancement and hinder economic development. The severe anemia triggered by helminth infections in children can stunt physical growth, undermine physical fitness, and cause behavior-related problems. These infections can also cause chronic urinary and kidney problems in adults. Disability, pain, and undernutrition hinder individuals’ ability to contribute to society and the economy. Such infestations can be prevented by using clean water, handwashing, and disposing of human wastes adequately. Routine deworming programs in schools have proved highly effective against some of the most common parasitic infections.21

The total health burden of a disease can be estimated by combining the estimated years of life lost prematurely by people who died of the disease, and the number of years of disability caused by the disease. Malaria, for example, caused an estimated 2 million deaths in 2002, but was responsible for the loss of 46 million disability-adjusted life years, or DALYs (see Table 3). The DALYs lost because of schistosomiasis in 2002 were more than 100 times the number of deaths from the disease. Each DALY represents one lost year of health.

Table 3

Deaths and DALYs Caused by Selected Communicable Diseases, 2002

Conclusion

Reducing the health burden from communicable diseases is a top priority for the international community. Two of eight millennium development goals (MDGs) embraced by all members of the United Nations in 2000 deal specifically with infectious diseases:

* Reduce the child mortality rate to two-thirds the 1990 level by 2015. Because IPDs causes at least one-half of deaths to children under age 5, this cannot be achieved without drastic reduction in communicable diseases.

* Combat HIV, malaria, and TB, among other diseases. This MDG not only calls for halting the spread of these diseases, but for reducing their incidence in the population by 2015.

Because health affects and is affected by so many aspects of life, the fight against communicable diseases is advanced by efforts to meet all the MDGs, including eradicating poverty and hunger, achieving universal primary education, promoting gender equality, improving maternal health, and ensuring environmental sustainability.

The means for preventing or controlling the major infectious diseases already exist-and are affordable even in poor countries. The most cost-effective health interventions have been documented by the monumental Disease Control Priorities Project and released in 2006.22 If these measures are implemented around the world-for example fully vaccinating children, providing insecticide-treated bednets to combat malaria, and improving basic health services for children-the health burden from infectious diseases could be drastically reduced. And, new vaccines and drugs offer hope in the fight against the most pernicious communicable diseases.

The control of IPDs is an ongoing endeavor. We can eliminate unnecessary death and disability, but we will always face the threat of new and evolving microbes. As American historian William McNeill has stated:

“Ingenuity, knowledge, and organization alter but cannot cancel humanity’s vulnerability to invasion by parasitic forms of life. Infectious disease which antedated the emergence of humankind will last as long as humanity itself… “23

References

1 Carl Haub, 2005 World Population Data Sheet of the Population Reference Bureau (Washington, DC: Population Reference Bureau, 2005); United Nations (UN), Population of India: Country Monograph Series, no. 10 (New York: UN, 1982): 137; and Elizabeth Arias, “United States Life Tables, 2003,” National Vital Statistics Reports 54, no. 14 (2006): table 11.

2 S. Jay Olshansky et al., “Infectious Diseases-New and Ancient Threats to World Health,” Population Bulletin 52, no. 2 (1997).

3 Haub, 2005 World Population Data Sheet.

4 Dean T. Jamison et al., ed., Priorities in Health (New York: Oxford University Press, 2006).

5 U.S. Centers for Disease Control and Prevention, Emergency Preparedness: Bioterrorism, accessed online at www.bt.cdc.gov, on April 24, 2006.

6 World Health Organization (WHO), Epidemic and Pandemic Alert and Response: Pandemic Preparedness, accessed online at www.who.int, on May 1, 2006; and Lone Simonsen et al., “Pandemic Influenza and Mortality,” in The Threat of Pandemic Influenza, ed. Stacey Knobler et al. (Washington, DC: The National Academies Press, 2005): 89- 114.

7 Olshansky et al., “Infectious Diseases”; and WHO, Media Centre: Dengue and Dengue Haemorrhagic Fever, accessed online at www.who.int, on April 28, 2006.

8 Anthony J. McMichael, Planetary Overload (Cambridge, UK: Cambridge University Press, 1993): 132-69.

9 William H. McNeill, Plagues and Peoples (New York: Anchor Press, 1989): 209-15; and Jorge A. Brea, “Population Dynamics in Latin America,” Population Bulletin 58, no. 1 (2003).

10 Ian R. H. Rockett, “Population and Health: An Introduction to Epidemiology,” 2d ed., Population Bulletin 54, no. 4 (1999): 7-8.

11 Olshansky et al., “Infectious Diseases.”

12 UN, World Population Prospects: The 2004 Revision (New York: UN, 2005): xxii; and Peter R. Lamptey, Jami L. Johnson, and Marya Kahn, “The Global Challenge of HIV and AIDS,” Population Bulletin 61, no. 1 (2006).

13 Colin D. Mathers, Alan D. Lopez, and Christopher J. L. Murray, “The Burden of Disease and Mortality by Condition: Data, Methods, and Results for 2001,” in Global Burden of Disease and Risk Factors, ed. Alan D. Lopez et al. (New York: Oxford University Press, 2006): table 3.10.

14 See the following chapters from Dean T. Jamison et al., eds., Disease Control Priorities in Developing Countries, 2d ed. (New York: Oxford University Press, 2006): Jan H.F. Remme et al., “Tropical Diseases Targeted for Elimination: Chagas Disease, Lymphatic Filariasis, Onchocerciasis, and Leprosy”; Pierre Cattand et al., “Tropical Diseases Lacking Adequate Control Measures: Dengue, Leishmainiasis.and African Tryponosomiasis”; and Peter J. Hoetz et al., “Helminth Infections: Soil-Transmitted Helminth Infectious and Schistosomiasis”: 433-483; and Donald G. McNeil Jr., “Dose of Tenacity Wears Down a Horrific Disease,” The New York Times, March 26, 2006.

15 Lamptey, Johnson, and Kahn, “HIV and AIDS.”

16 Mathers, Lopez, and Murray, “The Burden of Disease and Mortality”: table 3.1.

17 ORC Macro, Stat Compiler, accessed online at www.measuredhs.org, on April 12, 2006.

18 ORC Macro, Stat Compiler, accessed online at www.measuredhs.org, on May 15, 2006.

19 UNICEF, The State of the World’s Children 2006 (New York: UNICEF, 2005): table 3; GAVI, GAVI Fact Sheets, accessed online at www.vaccinealliance.org, on April 12, 2006; Logan Brenzel et al., “Vaccine-Preventable Diseases,” in Disease Control Priorities in Developing Countries, 2d ed., ed. Dean T. Jamison et al. (New York: Oxford University Press, 2006): 397.

20 Disease Control Priorities Project, In Brief. Factsheet, Infectious Diseases, accessed online at www.dcp2.org, on April 25, 2006.

21 Disease Control Priorities Project, In Brief. Factsheet, Infectious Diseases.

22 The publications and related information for the Disease Control Priorities Project are available at www.dcp2.org.

23 McNeill, Plagues and People: 295.

SPECIAL SECTION: Diarrheal Diseases

by Olivier Fontaine and Cynthia Boschi-Pinto

Two decades ago diarrhea was responsible for around 5 million deaths of children under age 5 each year. Now diarrheal diseases account for less than 2 million child deaths a year, thanks to major public health efforts to prevent and treat dehydration, the main cause of death from diarrheal disease.

Diarrhea causes severe loss of water and electrolytes (sodium, chloride, potassium, and bicarbonate). Children can become dehydrated when these losses are not replaced adequately. The early stages of dehydration present no signs or symptoms. As dehydration increases, children may exhibit thirst, restless or irritable behavior, sunken eyes, and less elastic or supple skin.1 In infants, the soft boneless areas in the skull may be sunken.

These symptoms become more pronounced in a child (or adult) suffering severe dehydration, and the child may go into shock, which may be characterized by diminished consciousness, lack of urine output, cool moist extremities, a rapid and feeble pulse, and low or undetectable blood pressure. If the child is not rehydrated promptly, death quickly ensues. Dehydration from diarrhea can be prevented by providing the child more fluids than usual, and/or increased frequency of breastfeeding, during acute episodes.

Decreased food intake, decreased nutrient absorption, and increased nutrient requirements during diarrhea episodes often combine to cause weight loss and failure to grow: The child’s nutritional status declines and any preexisting malnutrition is made worse. In turn, malnutrition contributes to even more severe and frequent diarrhea. One can prevent the nutritional consequences of diarrhea by ensuring that children continue to feed during diarrhea and increasing food intake afterward.2

Increasing the intake of fluids a child would normally drink, supplemented by oral rehydration salts (ORS) to treat dehydration together with continued feeding to prev\ent malnutrition have proven to be powerful interventions for the prevention of childhood deaths from diarrhea.

In many countries, the decline in diarrhea mortality observed over the years is linked to the increased use of oral rehydration therapy (ORT), defined as “increased administration of fluids plus continued feeding,” the public health intervention recommended by WHO and UNICEF.3 However, diarrheal diseases remain a leading cause of preventable death, especially among children under age 5 in developing countries.

The Scope of the Problem

Of the 10.6 million child deaths a year globally, 1.9 million, or 18 percent, are related to diarrheal diseases. Almost all (98 percent) of the 1.9 million diarrheal deaths occur in low- and middle-income countries. Forty percent of all diarrheal deaths are in Africa and 32 percent in South and Southeast Asia. Moreover, country-specific estimates have revealed that just 15 countries (eight in sub-Saharan Africa and four in South and Southeast Asia) account for about 70 percent (1.3 million) of all diarrheal deaths worldwide. In the developing world, mortality rates are about twice as high in infants than in children ages 1 to 4.4

While the estimated number of deaths due to diarrhea have declined markedly over the last two decades, the incidence of diarrhea has declined very little. Between the 1980s and 2000, there were between two and three episodes of diarrhea per child under 5 per year. Since 1990, some studies show a slight increase in diarrhea incidence rates.5 Morbidity rates have been consistently greatest among infants ages 6 to 11 months.6

Of the 1.9 million deaths due to diarrhea, 61 percent are associated with undernutrition.7 Diarrhea and malnutrition reinforce one another in a potentially deadly spiral: Frequent and prolonged episodes of diarrhea can lead to malnutrition, and malnutrition can facilitate the evolution of diarrhea towards death. Children living in poor households are more likely to be exposed to health risks, less resistant to disease, and less likely to receive appropriate care from a health provider.8 In addition, the main risk factors for developing diarrheal disease-poor access to water and sanitation, improper hygiene and feces disposal practices at home, poor housing, and crowding-are intrinsically linked to poverty. In the African region, where the proportion of diarrhea deaths is highest, approximately one-half of the population has no access to safe water and two-thirds lack access to hygienic sanitation.9 Disparities within countries also illustrate income inequalities: Diarrhea prevalence in some countries is almost twice as high among the poorest 20 percent of the population as it is among the richest 20 percent (see figure).

The long-term consequences of diarrheal diseases remain poorly understood. However, repeated diarrheal episodes can affect a person’s overall intellectual capacity and concentration.10 In addition, early childhood malnutrition-a common consequence of repeated episodes of diarrhea-reduces physical fitness and work productivity in adults.11

Successful Preventive Interventions

Strategies to control and treat diarrheal diseases have remained relatively unchanged since the 1980s. Seven effective interventions continue to be high priorities:

* Breastfeeding;

* Improvement in weaning practices;

* Rotavirus immunization;

* Cholera immunization;

* Measles immunization;

* Improvement of water supply and sanitation facilities; and

* Promotion of personal and domestic hygiene.

Promoting Exclusive Breastfeeding

Breastfed children under age 6 months are six times less likely to die of diarrhea than infants who are not breastfed.12 In 1984, researchers estimated that exclusive breastfeeding could reduce diarrheal deaths by 24 percent to 27 percent in the first six months of life.13 Based on this evidence, exclusive breastfeeding for the first six months of life has been promoted as an important weapon against diarrhea. Breastfeeding is encouraged-and early bottlefeeding discouraged-through hospital policies and actions; counseling and education by peers or health workers, mass media campaigns, community education, and mothers’ support groups; and implementation of the International Code of Marketing of Breastmilk Substitutes. This code is designed to ensure adequate information about the importance of breastfeeding young infants and appropriate marketing and distribution of breast milk substitutes. Increases in exclusive breastfeeding as a result of education and promotion have been associated with a significant reduction in the risk of diarrhea.14

Complementary Feeding

Complementary feeding, in which an infant transitions from exclusive breastfeeding to normal family foods, typically occurs between 6 months and 18 to 24 months of age. It is a very vulnerable period for infants’ health. All infants should start receiving foods in addition to breast milk after 6 months of age. The complementary foods should be at least as nutritious as breast milk, they should provide enough calories for a developing child, and they should be appealing enough for the child to eat. To minimize the risk of contamination with pathogens, all food should be prepared and served under hygienic conditions.

Improved complementary feeding practices to prevent or treat malnutrition could save as many as 800,000 lives per year. 15 While the increased incidence of diarrhea associated with the introduction of foods in addition to breast milk feeding has been recognized for a long time, two key risk factors have not received sufficient attention: feeding with contaminated foods, and failing to provide appropriate nutrients during and after a diarrheal episode.16 Several interventions have been proposed to reduce microbial contamination of common foods, including education, improved household storage of foods, reduced pathogen multiplication in food (such as food fermentation), and the use of probiotics, nonpathogenic organisms (Lactobacillus GG) that colonize the gut and create an environment that resists infection by pathogens.17 However, the effectiveness of these techniques has not been adequately evaluated.

While mothers and other caregivers are told to introduce infants to the foods eaten by the whole family, it is practically impossible to meet all of an infant’s essential micronutrient requirements with unfortified foods, especially in places where meat, fish, and dairy products are limited.18 While vitamin A supplementation may not significantly reduce the incidence of diarrhea and other common childhood illness, it may reduce the incidence of severe diarrhea and mortality due to gastroenteritis.19 Adding zinc to the diet can also reduce the incidence of diarrhea.20

Diarrhea Prevalence in Under-5 Children by Socioeconomic Status in Selected Countries, 2002

Advances in Management

Two recent advances in managing diarrheal diseasenewly formulated oral rehydration salts (ORS) containing lower concentrations of glucose and salts, and zinc supplementation-can drastically reduce the number of child deaths. These new advances, used in addition to prevention and treatment of dehydration with appropriate fluids, breastfeeding, continued feeding and selective use of antibiotics, will reduce the incidence, duration, and severity of diarrheal episodes.

New Oral Rehydration Salts (ORS) solution

To improve acceptance of ORS solution by mothers and health workers, researchers developed an ORS solution that could not only prevent or treat dehydration from all types of diarrhea, but provide other important clinical benefits. Reducing the solution’s salt and glucose content reduced stool output, vomiting, and especially, the need for intravenous fluids. Rehydration salts with lower salt and glucose content could substantially reduce childhood deaths from diarrhea (except for cholera), especially in areas where intravenous fluids or the skills to administer them are not available.21 Based on this finding, WHO and UNICEF launched the new ORS solution in May 2002 and included it in the WHO model list of essential medicines in March 2003. Since January 2004, the new ORS formulation is the only one procured by UNICEF.

Zinc Supplementation

When a zinc supplement is given during an episode of acute diarrhea, it reduces the episodes duration and severity.22 In addition, zinc supplements given for 10 to 14 days lower the incidence of diarrhea in the following two to three months.23 Using zinc to manage diarrhea could save 300,000 children each year.24 Accordingly, WHO and UNICEF have issued new recommendations for the clinical management of diarrhea. Along with increased fluids (ORS solution or home-made fluids) and continued feeding, all children with acute diarrhea should be given zinc supplements for 10 to 14 days.25

There is now good evidence that the promotion of oral rehydration therapy with other key preventive and curative interventions have played a large role in the welcome reduction in childhood deaths caused by diarrhea.26 To reach the United Nations Millennium Development Goal (MDG) of reducing the 1990 mortality rate among children under 5 by two-thirds by 2015, the challenge for the next decade will be to increase or ensure universal coverage of these interventions in developing countries.

To meet this challenge, health worker capacity must be maintained to ensure that all mothers and caretakers are taught:

* To prevent dehydration through early administration of increased amounts of appropriate fluids available in the home (and ORS solution, if on hand);

* To continue feeding (or increase breastfeeding) during the episode and increase all feeding after the episode;

* To recognize the signs of dehydration and the need for medical care; and

* To provide children with 20 milligrams per day of zinc for 10 to 14 days.

Over the long term, the most promising improvements in child health will come from integrating health care \through initiatives such as the Integrated Management of Childhood Illness (IMCI), which promotes the accurate identification of childhood illnesses, ensures appropriate combined treatment of all major illnesses, strengthens the counseling of caretakers, and speeds up the referral of severely ill children. However, in lowresource settings, immediate action may be still be necessary to quickly reduce the high disease burden of diarrhea.

References

1 Skin turgor is visible when a fold of skin that is pinched and then released holds a tent-like shape for a few seconds instead of flattening out immediately.

2 To help prevent dehydration, home fluids, which are normally made at home and do not require special ingredients, should always be available. Depending on the local culture, such fluids might include soup, rice water, or yoghurt drinks.

3 Sofia Villa et al., “Seasonal Diarrhoeal Mortality Among Mexican Children,” Bulletin of the World Health Organization 77, no. 5 (1999): 37580; Peter Miller and Norbert Hirschhorn, “The Effect of a National Control of Diarrhoeal Diseases Program on Mortality: The case of Egypt,” Social Science at Medicine 40, no. 10 (1995): S1- S30; Cesar G. Victora et al., “Falling Diarrhoea Mortality in Northeastern Brazil: Did ORT Play a Role?” Health Policy and Planning 11, no. 2 (1996): 132-41; Cesar G. Victora et al., “Reducing Deaths from Diarrhoea Through Oral Rehydration Therapy,” Bulletin of the World Health Organization 78, no. 10 (2000): 1246- 55; and Jane C. Baltazar, Dinah P. Nadera, and Cesar G. Victora, “Evaluation of the National Control of Diarrhoeal Disease Programme in the Philippines, 1980-93,” Bulletin of the World Health Organization 80, no. 8 (2002): 637-43.

4 Jennifer Bryce et al., “WHO Child Health Epidemiology Reference Group. WHO Estimates of the Causes of Death in Children,” Lancet 365, no. 9465 (2005): 1147-52; World Health Organization (WHO), World Health Report 2005: Make Every Mother and Child Count (Geneva: WHO, 2005); and Margaret Kosek, Caryn Bern, and Richard L. Guerrant, “The Global Burden of Diarrhoeal Disease, as Estimated From Studies Published Between 1992 and 2000,” Bulletin of the World Health Organization 81, no. 3 (2003): 197-204.

5 Claudio Lanata, comment at WHO rotavirus meeting in Geneva, Nov. 30 to Dec. 1, 2005.

6 Kosek, Bern, and Guerrant, “The Global Burden of Diarrhoeal Disease”: 197-204; John D. Snyder and Michael H. Merson, “The Magnitude of the Global Problem of Acute Diarrhoeal Disease: A Review of Active Surveillance Data,” Bulletin of the World Health Organization 60, no. 4 (1982): 605-13; and Caryn Bern et al., “The Magnitude of the Global Problem of Diarrhoeal Disease: A Ten-Year Update,” Bulletin of the World Health Organization 70, no. 6 (1992): 705-14.

7 Laura E. Caulficld et al., “Undernutrition as an Underlying Cause of Child Deaths Associated With Diarrhea, Pneumonia, Malaria, and Measles,” American Journal of Clinical Nutrition 80, no. 1 (2004): 193-98.

8 Cesar G. Victora et al. “Applying an Equity Lens to Child Health and Mortality: More of the Same is Not Enough,” Lancet 362, no. 9379 (2003): 233-41.

9 WHO/UNICEF/WSSCC, Global Water Supply and Sanitation Assessment 2000 (Geneva: WHO, 2000).

10 Mark D. Niehaus et al., “Diarrhea is Associated With Diminished Cognitive Function 4 to 7 years Later in Children in a Northeast Brazil Shantytown,” American Journal of Tropical Medicine and Hygiene 66, no. 5 (2002): 590-93.

11 John Dobbing, “Early Nutrition and Later Achievement,” Proceedings of ‘the Nutrition Society 49, no. 2 (1990): 103-18.

12 WHO Collaborative Study Team, “Effect of Breastfeeding on Infant and Child Mortality Due to Infectious Diseases in Less Developed Countries: A Pooled Analysis,” Lancet355, no. 9202 (2000): 1104.

13 Richard G. Feachem and Marjorie A. Koblinsky, “Interventions for the Control of Diarrhoeal Diseases Among Young Children: Promotion of Breastfeeding,” Bulletin of the World Health Organization 62, no. 2 (1984): 271-91.

14 Marcia F. Westphal et al., “Breastfeeding Training for Health Professionals and Resultant Institutional Changes,” Bulletin of the World Health Organization 73, no. 4 (1995): 461-68; J. Sikorski et al., “Support for Breastfeeding Mothers,” Cochrane Database of Systematic Reviews 1 (2002): CDOOl 141; F. Barras et al., “The Impact of Lactation Centers on Breastfeeding Patterns, Morbidity, and Growth: A Birth Cohort Study,” Acta Paediatrica 84, no. 11 (1995): 1221-26; Rukhsana Haider et al., “Breastfeeding Counselling in a Diarrhoeal Hospital,” Bulletin of the World Health Organization 74, no. 2 (1996): 173-79; and Nita Bhandari et al., “Infant Feeding Study Group: Effect of CommunityBased Promotion of Exclusive Breastfeeding on Diarrhoeal Illness and Growth: A Cluster Randomised Controlled Trial,” Lancet 361, no. 9367 (2003): 1418-23.

15 Gareth Jones et al., “How Many Child Deadis Can We Prevent This Year?” Lancet 362, no. 9377 (2003): 65-71.

16 MGM Rowland, “The Weanling’s Dilemma-Are We Making Progress?” Acta Paediatrica Scandinavica 323 (1986 suppl): 33-42; Sujit K. Mondai et al., “Occurrence of Diarrhoeal Diseases in Relation to Infant Feeding Practices in a Rural Community in West Bengal, India,” Acta Paediatrica 85, no. 10 (1996): 1159-62; Kare Molbak et al., “Risk Factors for Diarrhoeal Disease Incidence in Early Childhood: A Community Cohort Study From Guinea-Bissau,” American Journal of Epidemiology 146, no. 3 (1997): 273-82; and Salma Badruddin et al., “Dietary Risk Factors Associated With Acute and Persistent Diarrhoea in Karachi, Pakistan,” American Journal of Clinical Nutrition 54, no. 4 (1991): 745-49.

17 Katharine S. Guptill et al., “Evaluation of a Face-to-Face Weaning Food Intervention in Kwara State, Nigeria: Knowledge, Trial, and Adoption of a Home-Prepared Weaning Food,” Social Science & Medicine 36, no. 5 (1993): 665-72; Ruth M. English et al., “Effect of Nutrition Improvement Project on Morbidity From Infectious Diseases in Preschool Children in Vietnam: Comparison With Control Commune,” British Medical Journal 315, no. 7116 (1997): 1122-25; Joel E. Kimmons et al., “The Effects of Fermentation and/or Vacuum Flask Storage on the Presence of Coliforms in Complementary Foods Prepared for Ghanaian Children,” International Journal of Food Sciences & Nutrition 50, no. 3 (1999): 195-201; and SJ. Alien et al., “Probiotics for Treating Infectious Diarrhea,” Cochrane Database Systematic Reviews 2 (2004): CD003048.

18 Georgia S. Guldan et al., “Culturally Appropriate Nutrition Education Improves Infant Feeding and Growth in Rural Sichuan, China,” Journal of Nutrition 130, no. 5 (2000): 1204-11; K. Dewey and K. Brown, “Update on Technical Issues Concerning Complementary Feeding of Young Children in Developing Countries and Implications for Intervention Programmes,” food and Nutrition Bulletin 23 (2003): 5-28; K. Brown, K. Dewey, and L. Alien, Complementary Feeding of Young Children in Developing Countries: A Review of Current Scientific Knowledge (Geneva: WHO, 1998); and Pan American Health Organization (PAHO), Building Principles for Complementary Feeding of the Breastfed Child (Washington, DC: PAHO, WHO, 2003).

19 G.H. Beaton et al., “Effectiveness of Vitamin A Supplementation in the Control of Young Child Mortality in Developing Countries,” Nutrition Policy Discussion Paper no. 13 (Geneva: 1993); Usha Ramakrishnan and Reynaldo Martorell, “The Role of Vitamin A in Reducing Child Mortality and Morbidity and Improving Growth,” Salud Publica de Mexico 40, no. 2 (1998): 189-98; Mauricio L. Barreto et al., “Effect of Vitamin A Supplementation on Diarrhoea and Acute Lower Respiratory-Tract Infections in Young Children in Brazil,” Lancet 344, no. 8917 (1994): 228-31; and David A. Ross et al., “Child Morbidity and Mortality Following Vitamin A Supplementation in Ghana: Time Since Dosing, Number of Doses, and Time of Year,” American Journal of Public Health 85, no. 9 (1995): 1246-51.

20 Z.A. Bhutta et al., “Prevention of Diarrhoea and Pneumonia by Zinc Supplementation in Children in Developing Countries: Pooled Analysis of Randomized Controlled Trials,” Journal of Pediatrics 135, no. 6 (1999): 689-97.

21 Christopher Duggan et al., “Scientific Rationale for a Change in the Composition of Oral Rehydration Solution,” Journal of the American Medical Association 291, no. 21 (2004): 2628-31.

22 Robert E. Black, “Zinc Deficiency, Infectious Disease and Mortality in the Developing World,” Journal of Nutrition 133, Suppl. 1, no. 5S (2003): 1485S-89S; and Mary E. Penny et al., “Randomized Controlled Trial of the Effect of Daily Supplementation With Zinc or Multiple Micronutrients on the Morbidity, Growth, and Micronutrient Status of Young Peruvian Children,” American Journal of Clinical Nutrition 79, no. 3 (2004): 457-65.

23 Bhutta et al., “Prevention of Diarrhoea and Pneumonia by Zinc Supplementation.”

24 Jones et al., “How Many Child Deaths Can We Prevent This Year?”

25 WHO and UNICEF, WHO-UNICEFJoint Statement on the Clinical Management of Diarrhoea (Geneva and New York, 2004).

26 Victora et al., “Reducing Deaths”: 1246-55.

SPECIAL SECTION: Malaria

by Sandra Yin

In 1955, malariologist Paul Russell wrote in the preface to Man’s Mastery of Malaria that one could be confident that “malaria is well on its way towards oblivion.”1

His prediction was too optimistic. While large-scale insecticide spraying and the widespread use of the miracle drug chloroquine freed millions of people from the grip of malaria in the decades after World War II, this relief was halted in many areas. The emergence of drug resistance, widespread resistance to available insecticides, and deterioration of national control programs suggest we are losing the battle. Malaria is reappearing in areas of the world formerly deemed disease-free.2

Each year, malaria kills up to 3 million people. It threatens close to one-half the world’s population, and more than 1 million children die e\ach year of complications related to malaria. Almost 5 billion clinical episodes resembling malaria occur each year, with more than 90 percent of the burden occurring in Africa.3

Malaria can be debilitating for people who live with the disease. It is characterized by extreme exhaustion and associated with high fever, sweating, shaking chills, and anemia.4 Through chronic malaria-induced anemia and time lost or wasted in the classroom due to illness, malaria can have long-term effects on a child’s cognitive development.

Malaria also causes and perpetuates poverty. Couples may have more children than they otherwise would because diey fear losing a child to the disease. People living with the disease are less productive and earn less household income. Regions with endemic malaria have substantially lower economic growth rates than neighboring regions where malaria has been controlled. Fear of malaria has blocked foreign investment, tourism, and trade.

Who Is Most at Risk?

Malaria is an infection caused by a parasite of the genus Plasmodium. Of the four species of Plasmodium that infect humans, P. falciparum causes most of the severe disease and deaths attributable to malaria. It is most prevalent in sub-Saharan Africa and in certain parts of South Asia, Southeast Asia, and the Western Pacific.

The mosquito vector plays a crucial role in the malaria parasite’s life cycle. The disease is transmitted when female Anopheles mosquitoes that carry the malaria parasite bite humans.5

Climate and ecology determine the distribution of the mosquitoes that carry the malaria parasites, and in turn the prevalence and severity of the disease. Malaria is endemic only in tropical and subtropical zones-in parts of Asia, Africa, Central and South America, Oceania, and some Caribbean islands (see figure).

Adults living in regions where malaria is endemic develop immunity, but pregnancy reduces a woman’s immunity, raising her risk of death or severe anemia. Malaria infection in a pregnant woman may also result in spontaneous abortion, neonatal death, and low birthweight babies.

Malaria accounts for 1 in 5 childhood deaths in Africa. About three-fourths of all deaths due to malaria infections occur in African children younger than 5 who are infected with P. falciparum.

Patterns of malaria transmission and disease vary markedly among regions and within individual countries due to variations among malaria parasites and mosquito vectors, ecological conditions that affect malaria transmission, and quality of housing. Malaria disproportionately affects the poorest of the poor within those countries: 58 percent of the cases occur in the poorest 20 percent of the world population.6

The increase in human population worldwide over the past century has influenced the percentage of the human population exposed to malaria risk. Despite human activities that reduced by half the land area supporting malaria, demographic changes resulted in a 2 billion increase in the total population exposed to risk of malaria because of continued population growth in malaria-endemic areas.7 The population at risk in Africa grew from 60 million to 650 million. Southeast and South Asia, which is dominated by India, saw even more dramatic growth, from 200 million to 1.5 billion people at risk.

Malaria’s Comeback

In the 1950s and 1960s, DDT spraying, elimination of mosquito breeding sites, and the use of antimalarial drugs freed more than 500 million people from the threat of malaria.8 But the use of DDT to control malaria became highly controversial, and many countries banned or reduced its use beginning in the 1970s. Evidence of DDTs harmful effects on wildlife, including thinning eggshells in birds and reproductive or endocrine deformities in reptiles, raised fears that long-term use would harm human health and destroy some animal species. Much of the developed world banned most uses of DDT by 1972. Many international donors were reluctant to fund DDT-spraying programs in developing countries.9 The abandonment of DDT was followed by a resurgence of malaria in some areas.

Countries at Risk of Malaria Transimssion, 2001

During the 1980s and 1990s, malaria increased in Africa for several reasons, including increased resistance to chloroquine, the most commonly used antimalarial drug; the deterioration of primary health services in many areas; and the emerging resistance of mosquitoes to insecticides. New breeding grounds for mosquitoes were created by dams and irrigation projects. During the past decade, malaria also resurged or intensified in South and Southeast Asia after eradication efforts were interrupted. It has reemerged in several Central Asian republics and in other former Soviet republics due in part to weakened public health infrastructure.10

Prevention

Long before the 19th century, when researchers discovered that mosquitoes spread malaria, people developed ways to avoid mosquito bites. In the 5th century B.C.E., Egyptians who lived in marshy lowlands slept under fishing nets steeped in fish oil to repel mosquitoes.11

Centuries later, during World War II, American forces in the South Pacific dipped bed nets and hammocks in DDT. After DDT use was discouraged or banned, bed nets were treated with biodegradable insecticides called pyrethroids.

Pyrethroid-treated nets paired with antimalarial drugs halved mortality in children younger than 5 in the Gambia. The nets are credited with saving many lives in Kenya, Ghana, and Burkina Faso.

ITNs have some drawbacks. At $2 to $6 each, nets are too expensive for many of the people who need them most. Nets usually have to be redipped every six to 12 months to remain effective. Some newly developed nets, however, promise longer-lasting protection. The nets are impregnated with an insecticide that lasts four to five years.

Indoor residual spraying can be a highly effective method for malaria vector control. It reduces human and mosquito contact by repelling some mosquitoes before they enter a dwelling and killing others that alight on treated walls after a blood meal. Such spraying can achieve a rapid reduction in transmission during epidemics and other emergency situations, provided it is well-timed and has wide coverage.

Public health officials in malarious countries see the reintroduction of DDT as integral to malaria controlparticularly as they confront a growing resistance to other, more costly pesticides and hardier, more drugresistant parasites. Health officials say the current use indoor spraying of DDT for disease vector control releases only tiny amounts of DDT, compared with more destructive wide-area crop spraying of the 1950s.12

WHO currently recommends indoor residual spraying of DDT for malaria vector control. In some parts of the world, this long- lasting toxin offers the best hope for reining in malaria.

The dwindling availability of low-risk and cost-effective insecticides poses an ongoing challenge to malaria control. In areas of intense malaria transmission, use of insecticidetreated nets is more sustainable.

In areas of high and stable transmission of falciparum malaria, intermittent preventive treatment (IPT) is recommended for pregnant women. It usually consists of two curative doses of antimalarial treatment given during prenatal care visits. IPT can significantly reduced the incidence of severe maternal anemia and low birthweight births.13

Treatment

The most effective drug treatments vary depending on a host of factors including the type of malaria parasite involved and how stable the transmission of malaria is. All malarious countries and territories have national malarial treatment policies. Ideally, health workers monitor the effectiveness of drugs closely and change treatments when parasite resistance to chloroquine and other drugs emerges. In many malaria-endemic areas, ongoing obstacles to speedy diagnosis and effective drug treatment persist. Among them: unreliable microscopy, widespread distribution and use of substandard and counterfeit drugs.

Drug Resistance

Antimalarial drug resistance presents one of the biggest challenges in malaria control.

While the former “miracle drug,” chloroquine, is losing effectiveness against ever more robust forms of the malaria parasite, it remains a top-selling antimalarial drug in Africa. The next most affordable drug in Africa, sulfadoxine-pyrimethamine, is also coming up against ever more hardy and resistant strains of P. falciparum.

In response to widespread resistance of P. falciparum to monotherapy, or single drug therapies, with conventional antimalarial drugs such as chloroquine, WHO now recommends combination therapies as the treatment policy for falciparum malaria. Malaria experts believe combinations of drugs will work, especially if they include a form of artemisia annua, a medicinal herb once used as a fever remedy in ancient China. Artemisinins fight malaria parasites more quickly than any other treatment and also block malaria’s spread from humans to mosquitoes. If used alone, the artemisinins will cure falciparum malaria in seven days. In combination with certain synthetic drugs, artemisinin-based combination therapies (ACT) produce high cure rates in three days. They can also retard the development of resistance to the partner drug. But artemisinins cost 10 to 20 times more than weaker malaria drugs, including chloroquine. And the global supply of ACTs is tight.

Since 2001, WHO has recommended that artemisinin be used only in combination with other antimalarials to prevent the malaria parasite from developing artemisinin resistance. In January 2006, the head of WHOs malaria section warned that using artemisinin alone could leave the world with no effective weapon against malaria. “We can’t afford to lose artemisinin,” said Arata Kochi, head of WHOs Roll Back Malaria department. “If we do, it will be at least 10 years before a drug that good is discovered.”14

Kochi, a physician who earlier headed WHO\’s TB program against tuberculosis, said he was trying to prevent a repeat of what happened to TB-the emergence of strains that are resistant to all drugs. By mid-May 2006, 13 drug companies agreed to comply with WHOs recommendation to phase out single-drug artemisinin medicines and focus on producing ACTs.15

In an ideal world, countries where malaria is endemic could institute policies that include insecticidetreated nets, indoor residual spraying, and IPT. But the cost of mounting such a campaign could be too high. In resource-poor areas, insecticide-treated nets would be the most cost-effective preventive measure.

While malaria has attracted both funding and the attention of international organizations, it remains a major global problem that exacts a heavy toll on the health and economic life of the world’s poorest communities. Before the battle against malaria is over, more research is needed to improve existing interventions and develop new weapons to fight malaria.

In 1958, WHO, the Pan American Sanitary Bureau, and other international organizations aided governments in a fight against malaria. The goal was to wipe malaria off the face of the earth in 10 years. Today’s goals are more limited. There’s no talk of eradicating malaria. The Millennium Development Goal accepted by 190 countries in 2000 calls for a halt the spread of malaria and progress in reversing its incidence by 2015.

References

1 Simon Hay et al., “The Global Distribution and Population at Risk of Malaria: Past, Present, and Future,” The Lancet Infectious Diseases 4, no. 6 (June 2004): 327.

2 Clive Shiff, “Integrated Approach to Malaria Control,” Clinical Microbiology Reviews 15, no. 2 (April 2002): 278-93.

3 Joel G. Breman et al., “Conquering Malaria,” in Disease Control Priorities in Developing Countries, 2d ed., ed. Dean T. Jamison et al. (New York: Oxford University Press, 2006): 413-32.

4 WHO, Malaria, accessed online at www.who.int, on May 2, 2006.

5 Roll Back Malaria, WHO, and UNICEF, World Malaria Report 2005 (Geneva: WHO and UNICEF, 2005): 11.

6 Joel G. Breman, Martin S. Alilio, and Anne Mills, “Conquering the Intolerable Burden of Malaria: What’s New, What’s Needed: A Summary,” The American Journal of ‘Tropical Medicine and Hygiene 71, no. 2suppl. (2004): 1-15.

7 Hay et al., “The Global Distribution and Population at Risk of Malaria: Past, Present, and Future”: 327-35.

8 Claire P Dunavan, “Tackling Malaria,” Scientific American (December 2005): 78.

9 Donald R. Roberts et al., “DDT, Global Strategies, and a Malaria Control Crisis in South America,” Emerging Infectious Diseases 3, no. 3 (July-September 1997): 300.

10 Roll Back Malaria, WHO, and UNICEF, World Malaria Report 2005: xii.

11 Dunavan, “Tackling Malaria”: 80.

12 Donald Roberts et al., “DDT, Global Strategies.”

13 Breman et al., “Conquering Malaria”: 420.

14 Donald G. McNeil Jr., “Drug Makers Get a Warning From the U.N. Malaria Chief,” The New York Times, Jan. 20, 2006.

15 WHO, Who Announces Pharmaceutical Companies Agree to Stop Marketing Single-Drug Artemisinin Malaria Pills, accessed online at www.who.int, on May 25, 2006.

SPECIAL SECTION: Tuberculosis

by Sandra Yin

Humans have had a long relationship with TB: Evidence of TB has been found in ancient mummies in Egypt and Peru. As late as 1900, TB was the second most common cause of death in the United States. Although TB is no longer a major killer in most developed countries, it remains the worlds deadliest curable infectious disease. One- third of the world population is currently infected with the bacillus that causes TB. People infected with latent TB have a 10 percent to 20 percent risk of developing active TB, which, untreated, can lead to debilitating illness and death. Although drugs to cure TB have been around since the 1940s, approximately 2 million people died from TB in 2004; another 3.9 million new cases of the most infectious form of TB appeared that year.1

Developing countries bear the brunt of the TB epidemic. An estimated 95 percent of TB cases and 98 perent of TB deaths occur in the developing world. Just five countries-Bangladesh, China, India, Indonesia, and Pakistan-account for nearly half die new cases each year.2

The incidence of TB worldwide is growing by roughly 1 percent a year, driven primarily by the HIV epidemic. Accordingly, TB is spreading fastest in areas hardest hit by HIV/AIDS-sub-Saharan Africa and Eastern Europe. Between 1990 and 2004, TB incidence in Africa more than doubled, from 153 cases to 356 cases per 100,000 people. In the former Soviet bloc countries of Eastern Europe, TB incidence per capita rose through the 1990s, but has eased since 2001. Incidence rates may still be increasing in some Central Asian republics such as Tajikistan and Uzbekistan.3

What Makes TB So Deadly?

The bacteria that cause TB usually attack the lungs, but can spread to other parts of the body. Symptoms may include fever, cough, night sweats, weight loss, fatigue, and coughing up blood.

Most people infected with TB bacilli will not become sick. The immune system may wall off the TB bacilli in a thick waxy coat that allows them to lie dormant inside the body for decades. People with latent TB infection do not feel sick, do not have any symptoms, and cannot spread the disease. But, between 5 percent and 10 percent will develop TB in the future.4

TB spreads through the air, like the common cold. Only people who are sick with TB in their lungs or throat are infectious. People who have TB in other parts of their body are not infectious. When infectious people cough, sneeze, spit, or j

Diners Fret as the Sun Sets on Foie Sras in Chicago

By Brad Dorfman

CHICAGO — In a few weeks it will be illegal to sell foie gras in Chicago; but fans of the delicacy are not going quietly into the night.

On a recent evening more than 100 of them paid $150 each to dine on grilled foie gras with cherry chutney and peppercorn brioche; salt and herb cured foie gras with lamb prosciutto; ravioli of foie gras, pheasant and apple and other treats as chefs talked of overturning the ban.

“It does bother me the way it’s raised, but then my grandfather raised cattle in Kansas, so I’m very aware of what farm life is like,” said Pati Heestand, a retired graphic designer and foie gras aficionado.

Chicago’s City Council in April voted to make the city the first in the country to ban the restaurant sale of foie gras, which detractors argue is inhumanely produced by force-feeding ducks and geese through a tube to fatten their livers.

The ban is to take effect August 22 when restaurants found selling foie gras will face a $500 fine.

Foie gras proponents argue that the feeding of the high protein diet through a tube is not inhumane because the fowl do not have a gag reflex like humans. They say the extreme amount of feeding is somewhat similar to what the birds do in the wild anyway to store energy before long migrations.

“I’ve been to a foie gras farm,” said Dean Zanella, executive chef at 312 Chicago. “They seem very happy. I’ve never seen one (bird) being mistreated.”

The foie gras ban prompted praise by some and ridicule by others worldwide, with Chicago’s own Mayor Richard Daley suggesting the council could better spend its time focusing on more serious issues.

The chefs at this week’s gathering agreed and contemplated strategies to combat the ban, including filing a lawsuit, or trying to get around the ban of the sale by foie gras by giving it away for “free” along with, say, a markedly overpriced $20 plate of lentils or $40 glass of wine.

‘CONSUMER CHOICE’ VS ‘EGREGIOUS CRUELTY’

Michael Tsonton, executive chef at Copperblue in Chicago and a founder of Chicago Chefs for Choice, a group formed after the ban was approved in April, said the free market should determine whether foie gras is sold.

He noted that when consumers boycotted tuna because dolphins caught in tuna nets were harmed, the tuna fishing industry changed its practices.

“If you don’t like it, you don’t buy it. It’s a consumer choice issue,” Tsonton said. “It’s not an issue for legislation.”

A lawsuit planned to try to void the ordinance is in the works, though restaurateurs, who need city licenses to operate, first want assurances they won’t be punished for going to court, he said.

Joe Moore, the alderman who sponsored the ordinance, discounted the thought by some that once foie gras is banned other foods raised under practices animal rights activists decry, including commercially raised chickens, would be next.

“It’s the most egregious example of cruelty to animals in order to produce a product that is at best a luxury,” Moore said, adding that he received hundreds of comments when the measure passed, with about 60 percent in favor of the ordinance.

Still, the chefs worried that the organizations who pushed for the foie gras ban would target other foods.

“They want to ban eggs, they want to ban veal, they want to ban lobster, they want to ban everything,” Allen Sternweiler, executive chef at Allen’s The New American Cafe, where the dinner was held, said.

Using TV as Reward May Get Kids to Exercise

NEW YORK — Overweight children may be more inclined to get outside and get moving when their TV time depends on it, a new study shows.

Researchers found that when parents made TV and video games a reward for exercise, their overweight children increased their physical activity by 65 percent. The plan also cut children’s TV time by nearly two hours a day, and reduced their snacking.

According to the study authors, the findings suggest that by changing household rules, “committed and motivated” families can help their overweight children get moving and shed pounds.

The researchers, led by Dr. Gary S. Goldfield of the University of Ottawa in Canada, report the results in the journal Pediatrics.

Experts believe that the growing problem of childhood obesity has much to do with the increasing amount of time kids are spending in front of TV and computer screens — often with high-calorie snacks in hand.

Goldfield and his colleagues were interested in what would happen if children’s TV time was contingent upon exercise time.

The researchers randomly assigned 30 overweight 8- to 12-year-olds to one of two groups: an intervention group where the children won TV and video game time by exercising; or a “control” group in which children were encouraged to exercise but could watch TV when they wanted.

The intervention required some technological help. Children wore small monitors that gauged their activity levels, and the family TV was outfitted with a device that prevented it from being turned on unless “tokens” were inserted.

Children won these tokens by exercising; when they got the equivalent of roughly one hour of moderate walking, they earned an hour of TV.

After eight weeks, children in this group had bumped up their overall activity levels by nearly two-thirds, and were getting 10 extra minutes of moderate-to-vigorous exercise each day. In contrast, children in the control group showed only a small change in overall exercise levels.

The change in the intervention group’s TV viewing was even greater, the researchers found. On average, these children were spending about 45 minutes a day in front of the TV, versus nearly three hours at the beginning of the study.

Along with that reduction came a decline in snacking, which lowered the children’s overall intake of calories and fat. This finding, the researchers note, supports the notion that excessive TV time promotes weight gain not just by making kids sedentary, but also by encouraging them to snack more.

Making TV contingent upon exercise, they conclude, could help overweight children improve both their exercise and eating habits.

SOURCE: Pediatrics, July 2006.

Pot may indeed lead to heroin use, rat study shows

By Anne Harding

NEW YORK (Reuters Health) – Teens who experiment with
marijuana may be making themselves more vulnerable to heroin
addiction later in life, if the findings from experiments with
rats are any indication.

“Cannabis has very long-term, enduring effects on the
brain,” Dr. Yasmin Hurd of the Mount Sinai School of Medicine
in New York, the study’s lead author, told Reuters Health in an
interview.

Whether or not trying marijuana is a ‘gateway’ to use of
so-called harder drugs like heroin and cocaine has been hotly
debated, she and her colleagues note in the journal
Neuropsychopharmacology.

To investigate whether pot smoking could cause brain
changes that might predispose an individual to later drug use,
Hurd and her team looked at rats exposed to the active
ingredient in marijuana, THC, during a developmental period
similar to human adolescence. To mimic the relatively small
amount used by most teens experimenting with pot, the rodents
received periodic, small doses of THC.

As young adults, the animals were fitted with catheters
that allowed them to self-administer heroin. The researchers
compared the amount and frequency of their drug use with that
of rats that had not been given THC previously.

The THC-exposed rats were more sensitive to the effects of
heroin, the researchers found, and also consistently used
larger amounts of the drug.

The researchers also found that the THC-exposed rats showed
disturbances in the brain’s endogenous opioid system, which is
often popularly referred to as the “reward system” of the brain
and, in humans, is involved in experiencing pleasure.

“I was really surprised at how specific and enduring the
effects of cannabis were,” Hurd said.

She and her colleagues conclude: “The current findings
provide direct evidence in support of the gateway hypothesis
that adolescent cannabis exposure contributes to greater heroin
intake in adulthood.”

SOURCE: Neuropsychopharmacology

Nancy Marie Valentine, RN, PhD, MPH, FAAN, FNAP, Named Chief Nursing Officer for Main Line Health

BRYN MAWR, Pa., July 12 /PRNewswire/ — Main Line Health is pleased to announce that Nancy Marie Valentine, RN, PhD, has been named chief nursing officer for the non-profit health system. Dr. Valentine will assume her position effective September 18, 2006.

Dr. Valentine’s career in nursing spans more than 35 years and includes successful positions in clinical nursing, nursing and hospital administration, academics and research, and the development of nursing policy and practice on a national level. Dr. Valentine served as the enterprise-wide chief nursing officer for the Department of Veterans Affairs in the 1990s, and was part of the leadership at the VA Hospitals that implemented extensive quality initiatives now viewed as a national model for patient safety. While at the VA, Dr. Valentine also served as Special Assistant, Health Affairs to the Secretary of the VA and Advisor to the VA Undersecretary for Health.

Dr. Valentine was also instrumental in setting the early groundwork for the VA to meet the standards of the American Nurse Credentialing Center’s Magnet Program, the designation that identifies the finest hospital-based nursing programs in the country. The acute care hospitals of Main Line Health – Lankenau, Bryn Mawr, and Paoli – attained Magnet status last year.

After the VA, she served as the national senior nursing executive for CIGNA Healthcare, headquartered in Hartford, CT, an experience that allowed Dr. Valentine to see healthcare from the payers’ perspective.

“In searching for a chief nursing officer, Main Line Health sought someone with a national profile within the nursing profession, who would bring strong experience in nursing leadership, innovation, research, and education,” said John J. Lynch, III, president and chief executive officer of Main Line Health. “In Nancy Valentine, we have found all these qualities. We are thrilled that she will bring her expertise to our hospitals – and more importantly, to our nurses and patients.”

Dr. Valentine grew up in the Somerton section of Philadelphia and received her nursing degree from the Rutgers University College of Nursing, followed by a Master’s in Nursing from the University of Pennsylvania and a Master’s in Public Health from the Harvard University School of Public Health. She received her doctorate in Economics and Health Policy from Brandeis University in 1991. She has held academic and teaching appointments at leading institutions such as Georgetown University and Catholic University in Washington, DC; Harvard Medical School in Cambridge, MA; Northeastern University in Boston, and Fairfield University in Fairfield, CT. In 2001, she received the Eagle Award for outstanding graduate from George Washington High School in Philadelphia.

Much of Dr. Valentine’s clinical practice and research has focused on psychiatric nursing and issues related to treating nurses and other healthcare practitioners suffering from substance abuse and mental illness. As an administrator, she has focused on issues related to quality, innovative applications of evidenced-based research, and the development of the nursing workforce through education, research, and emphasis on clinical excellence.

“Main Line Health is poised for really taking its excellent nursing to a new level,” Dr. Valentine said. “There are already well-developed leaders here, with strong teams in place. I am very excited to be returning to my roots in the Philadelphia area and look forward to working with a great group of nurses, doctors, and the entire team at Main Line Health. The system’s friendliness, energy and drive for excellence attracted me to this position.”

Dr. Valentine will assume the chief nursing officer position from Barbara Tachovsky, who has held that role in addition to her responsibilities as president of Paoli Hospital. Ms. Tachovsky will focus full time on overseeing the Hospital’s major expansion project. “Through Barbara’s leadership, the nursing program at Main Line Health is as strong as it has ever been, as demonstrated by the Magnet recognition we achieved last year,” said Mr. Lynch. “We are fortunate that Barbara will remain at Paoli to oversee its growth and to collaborate with Dr. Valentine as she transitions into her role here.”

Main Line Health is a non-profit health system serving portions of Philadelphia and its western suburbs. Founded in 1985, MLH includes Bryn Mawr Hospital, Lankenau Hospital, and Paoli Hospital; Bryn Mawr Rehabilitation Hospital; the Lankenau Institute for Medical Research; Main Line Clinical Laboratories; Great Valley Health, physician network; the Wayne Center, a skilled nursing facility; and Mid County Senior Services. The mission of Main Line Health is to provide a comprehensive range of health services, complemented by appropriate educational and research activities, that meets community needs and improves the quality of life in the communities we serve.

Main Line Health is part of Jefferson Health System (JHS), founded in 1996, whose members also include Thomas Jefferson University Hospital, the Albert Einstein Healthcare Network, Frankford Health System, and Magee Rehab.

Main Line Health

CONTACT: Richard Wells, Vice President, Public Affairs, Main LineHealth, Office: +1-610-526-8310 or Cell: +1-610-842-9025 or [email protected]

Hypercalcemia-Induced ST-Segment Elevation Mimicking Acute Myocardial Infarction

By Nishi, Shawn P E; Barbagelata, Nestor A; Atar, Shaul; Birnbaum, Yochai; Et al

Abstract

We describe a patient who presented with abdominal pain radiating to the chest and ST elevation in the precordial leads, mimicking acute myocardial infarction. Urgent coronary angiography revealed normal coronary arteries and his serum troponin has not increased. Subsequently, he was found to have severe hypercalcemia. ST segment elevation resolved after correction of hypercalcemia. This phenomenon of ST elevation secondary to hypercalcemia has been described only two times in the English literature to date.

2006 Elsevier Inc. All rights reserved.

Keywords: Hypercalcemia; Myocardial infarction; ST elevation; QTc interval; ECG; Arrhythmia

Introduction

It is well established that hypercalcemia causes shortening of the QT interval. However, other electrocardiographic (ECG) changes related to hypercalcemia have been less characterized. Review of literature suggested that hypercalcemia may cause ST-segment elevations, arrhythmias, atrioventricular blocks, and a variety of T- wave changes, including flattening, inversions, and notchings. We report a patient with severe hypercalcemia presented with chest pain and ST-segment elevation mimicking acute myocardial infarction.

Case report

A 31-year-old male Vietnamese was admitted for 5-day complaint of nausea, vomiting, lethargy, and diffuse abdominal pain radiating to his precordium. Medical history includes poorly controlled stage 2 hypertension that had been diagnosed and treated medically 5 years before admission, a recent diagnosis of hyperparathyroidism for which the patient had undergone parathyroidectomy 1 week before admission, and chronic kidney disease. The patient denied any other significant cardiac history of coronary artery disease, diabetes, or hyperlipidemia.

The patient presented to the emergency department in obvious distress. On evaluation, his blood pressure was 200/90 mm Hg, heart rate of 78 beats per minute, respirations at 18/min, and temperature of 36.2C. There was no jugular venous distension, lungs were clear to auscultation bilaterally, and cardiac auscultation yielded no murmur or friction rub. The abdomen was benign. An initial ECG showed normal sinus rhythm with marked ST elevations in leads VI through V5 and QTc of 415 milliseconds (Fig. 1). Chest x-ray revealed an enlarged heart with clear lungs.

Given the ECG findings and patient presentation, management included intravenous administration heparin, nitroglycerin, and β-blocker, and the patient was taken to the catheterization laboratory for urgent coronary angiography. Coronary angiography revealed normal coronary arteries.

Subsequently, the first set of cardiac enzymes showed elevated creatine kinase (337 U/L), mildly elevated creatine kinase-MB fraction (6.3 ng/mL), and normal troponin I levels (0.16 ng/mL). All other laboratory values were within normal range except for a serum calcium level of 17.8 mg/ dL, creatinine of 3.28 mg/dL, and serum urea nitrogen of 41 mg/dL. The second and third set of cardiac enzymes revealed serum creatine kinase of 218 and 114 mg/dL, respectively; serum creatine kinase-MB of 3.9 and 2.3 ng/ mL, respectively; and troponin I of 0.07 and 0.04 ng/mL, respectively.

Repeat ECGs showed persistent marked ST elevation in the precordial leads. Transthoracic echocardiographic examination demonstrated moderate left ventricular hypertrophy with normal left ventricular function, mild right ventricular hypertrophy, mild aortic dilation, and dilated left coronary sinus of Valsai va. The ejection fraction was 50% to 55% and without regional wall motion abnormalities. There was no pericardial effusion and the pericardium appeared normal.

Fig. 1. Initial ECG with serum calcium level of 17.8 mg/dt. showing diffuse ST elevations in V^sub 2^ through V^sub 5^ with QTc of 415 milliseconds.

The patient was treated with aggressive hydration and diuresis for hypercalceinia with a decrease in serum calcium to 10.1 mg/dL. Repeated ECG performed 3 weeks after discharge from the hospital showed resolution of the ST elevation without T-wave inversion or abnormal O waves. The QTc interval increased to 476 milliseconds (Fig. 2). At that time, his serum calcium level was 8.6 mg/dL.

Discussion

The patient presented with chest pain and ST-segment elevation compatible with ST-elevation acute myocardial infarction. However, coronary angiography revealed normal coronary arteries without obstruction and subsequent serum troponin I levels were within normal range. Moreover, ST-segment elevation resolved only after correction of his hypercalcemia. without evolution of abnormal Q waves or inverted T waves, and transthoracic echocardiogram did not show regional wall motion abnormalities or pericardial effusion. Thus, in our patient, ST-segment elevation was probably not caused by myocardial ischemia or acute pericarditis.

Fig. 2. Follow-up ECG of patient aller serum calcium levels normali/ed to preadmissions levels (serum calcium, 8.6 mg/dL) and QTc of 476 milliseconds.

Although hypercalccmia has been well characterized to shorten the QT interval, few authors have been reported transient ST-segment elevation mimicking acute myocardial infarction in patients with hypcrcalcemia.'”4 Ashizawa et al5 described a similar “high takeoff of the ST segment” in leads Vl and V2 in a patient with hypercalcemia due to vitamin D intoxication, simulating an acute myocardial infarction. In addition, they reported flattened and biphasic/notched T waves that were not seen in our patient.’ Turhan et al1 reported on a patient with ST-segment elevation in leads I, II, and Vl through V^sub 2^. In addition, they observed transient Q waves in V^sub 2^ through V^sub 3^ with normal serum troponin T and creatine kinase-MB and no regional wall motion abnormalities by echocardiography.6 Others have observed that the T waves flatten, invert, or appear biphasic/notched in configuration, and the T-wave amplitude was shown to be inversely correlated with serum calcium levels.7,8

The characteristic electrocardiography changes found in association with hypercalcemia are prolongation of the PR interval and shortening of the QT interval mainly due to shortening of the ST segment. Ahmed and Hashiba1 further classified QT intervals due to the effect of the shortened ST segment and revealed the intervals Q- oTc (the interval from the beginning of the QRS complex to the beginning of the T wave) of less than 0.18 second, and Q-aTc of less than 0.30 second (measured from the beginning of the QRS complex to the apex of the T wave) as reliable indicators of clinically moderate to severe hypercalcemia. Ashizawa et al5 also showed that hypercalcemia caused shortening of the Q-aTc. Hypercalcemia decreases ventricular conduction velocity and shortens the effective refractory period. This property of shortened QT intervals can prove useful in distinguishing ST elevations of acute myocardial infarction from ST manifestations of hypercalcemia. However, other studies have found that shortening of the QT interval is an unreliable index of clinical hypercalcemia due to the wide distribution of normal values 9,10. In our patient, although the QTc interval prolonged after correction of hypercalcemia, it was still within normal range on presentation (Fig. 1 ).

A spectrum of other ECG findings associated with hypercalcemia have also been reported. Carpenter and May11 reported on a patient with hypercalcemia (serum calcium, 13-18 mg/dL) who developed a “tachycardiabradycardiaMike syndrome with episodes of sinus arrest and bouts of paroxysmal supraventricular tachycardia and first- degree atrioventricular block. Correction of the calcium levels led to resolution of the tachycardia-bradycardia syndrome; however, the atrioventricular block persisted. Rosenqvist12 went on to show a correlation between the severity of hypercalcemia and the degree of atrioventricular block. Kiewiet 13 first documented the development of ventricular fibrillation in a patient with hypercalcemic crisis and no other explanation. Others have also uniquely reported a normothermic Osborne or prominent J waves in at least 5 reported cases of hypercalcemia.8,14-16

Conclusions

In summary, we report a case of severe hypercalcemia with chest pain in which ECG changes mimicked myocardial and slowly resolved with correction of serum calcium. At least 2 other documented cases of hypercalcemic ST elevations mistaken for myocardial ischemia have also been reported in the English literature.5’6 Short QT intervals in low-risk patients with ST-segment elevation may suggest the diagnosis of hypercalcemia. However, normal QT intervals do not necessarily exclude the diagnosis as in our case report.

References

1. Ahmed R, Hashiba K. Reliability of QT intervals as indicators of clinical hypercalcemia. CHn Cardiol 1988; 11:395.

2. Douglas PS, Carmichael KA, Palevsky PM. Extreme hypercalcemia and electrocardiographic changes. Am J Cardiol 1984;54:674.

3. Nierenberg DW, Ransil BJ. Q-aTc interval as a clinical indicator of hypercalcemia. Am J Cardiol 1979;44:243.

4. Saikawa T, Tsumabuki S, Nakagawa M, Takakura T, Tamura M, Maeda T, et al. QT intervals as an index of high serum calcium in hypercalcemia. CHn Cardiol 1988; 11:75.

5. Ashizawa N, Arakawa S, Koide Y, Toda G, Seto S, Yano K. Hypercalcemia due to vitamin D intoxicationwith clinical features mimicking acute myocardial infarction. Intern Med 2003;42:340.

6. Turhan S, Kilickap M, Kilinc S. ST segment elevation mimicking acute myocardial infarction in hypercalcaemia. Heart 2005;91:999.

7. Ahmed R, Yano K, Mitsuoka T, Ikeda S, Ichimura M, Hashiba K.. Changes in T wave morphology during hypercalcemia and its relation to the severity of hypercalcemia. J Electrocardiol 1989;22:125.

8. Topsakai R, Saglam H, Arinc H, Eryol NK, Cetin S. Electrocardiographic J wave as a result of hypercalcemia aggravated by thiazide diuretics in a case of primary hyperparathyroidism. Jpn Heart J 2003; 44:1033.

9. Wortsman J, Frank S. The QT interval in clinical hypercalcemia. CHn Cardiol 1981;4:87.

10. Rumancik WM, Denlinger JK, Nahrwold ML, FaIk Jr RB. The QT interval and serum ionized calcium. JAMA 1978;240:366.

11. Carpenter C, May ME. case report: cardiotoxic calcemia. Am J Med Sci 1994;307:43.

12. Rosenqvist M, Nordenstrom J, Andersson M, Edhag OK. Cardiac conduction in patients with hypercalcaemia due to primary hyperparathyroidism. CHn Endocrinol (Oxf) 1992;37:29.

13. Kiewiet RM, Ponssen HH, Janssens EN, Pels PW. Ventricular fibrillation in hypercalcaemic crisis due to primary hyperparathyroidism. Neth J Med 2004;62:94.

14. Otero J, Lenihan DJ. The “normothermic” Osborn wave induced by severe hypercalcemia. Tex Heart Inst J 2000;27:316.

15. Mitsunori M, Yoshinori K, Eitorah K, Yoshiyuki H, Hirotsugu A, Takao K, et al. Osborn waves: history and significance. Indian Pacing Electrophysiol J 2004;4:33.

16. Sridhara MR, Horan LG. Electrocardiographic J wave of hypercalcemia. Am J Cardiol 1984;54:672.

Shawn P.E. Nishi, MD, Nestor A. Barbagelata, MD, Shaul Atar, MD, Yochai Birnbaum, MD (Edward D. and Sally M. Futch Professor of Medicine, Medical Director)*, Enrique Tuero, MD

Division of Cardiology. Department of Internal Medicine, University of Texas Medical Branch, Galveston. TX 77555-0553, USA

Received 9 September 2005

* Corresponding author. Tel.: +1 409 772 2794; fax: +1 409 772 4982.

E-mail address: [email protected] (Y. Birnbaum).

Copyright Churchill Livingstone Inc., Medical Publishers Jul 2006

(c) 2006 Journal of Electrocardiology. Provided by ProQuest Information and Learning. All rights Reserved.

Second-generation airbags safer for kids

NEW YORK (Reuters Health) – A new study confirms that newer
airbags designed to be less hazardous to children and small
adults are indeed safer for young children, without putting
adults at greater risk.

The first generation of air bags, built to protect an
average-size male, “have been lethal for children and adults in
some crashes,” Dr. Carin M. Olson of the University of
Washington in Seattle and her colleagues note in the July 15
issue of the American Journal of Epidemiology.

Second-generation air bags developed to deal with this
problem were included in most cars built in 1998 and nearly all
passenger cars of subsequent model years, they add. These air
bags include depowered air bags, which inflate with less force,
and advanced air bags.

Concerns have been raised that depowered air bags could be
unsafe for larger people, and may “represent a tradeoff between
decreasing the risk of death for some occupants and increasing
the risk for others, such as unrestrained adults,” the
researchers note.

To investigate, Olson and her team analyzed data from fatal
accidents occurring between 1990 and 2002 involving passenger
cars of model years 1987 to 2003, including a total of 151,297
people and 62,333 cars. Second-generation airbags were
installed in most autos of model year 1998 and in all in later
years.

Overall, compared to no air bags, first-generation air bags
reduced the risk of a front-seat occupant’s death within 30
days of a crash by 10%, while second-generation air bags
reduced the risk by 11%, the researchers found.

For children under age 6, first-generation airbags
increased the risk of death by 66% compared to no air bags.
There was a 10% increased risk of death among young children
with the second-generation air bags compared to no air bag,
which was not statistically significant.

There was also no evidence that second-generation air bags
were less safe than first-generation air bags for any subgroup
of car occupants, including men not wearing seatbelts, the
researchers note.

They conclude: “Consumers, policy makers and manufacturers
can be assured that the increased safety of second-generation
air bags for children was not offset by less protection for
older occupants.”

SOURCE: American Journal of Epidemiology, July 15, 2006.

Largest Hospital System in North Texas Names New Chief Financial Officer

ARLINGTON, Texas, July 10 /PRNewswire/ — Texas Health Resources (THR) announced today that Ronald R. Long has joined the system as executive vice president and chief financial officer. THR is the largest health care system in North Texas and includes Arlington Memorial Hospital, Harris Methodist Hospitals and Presbyterian Healthcare System.

Long assumes the CFO position vacated last spring when long-time CFO Ron Bourland retired. He will begin work in early November and will report to Doug Hawthorne, president and chief executive officer of THR.

“Ron understands THR’s commitment to be good stewards of community-based assets,” said Doug Hawthorne. “He brings a wealth of experience in the financial management of health care organizations in a variety of settings including rural, suburban, large urban academic centers, integrated and regional health systems, managed care organizations, joint ventures, and physician group practices.”

Long will be responsible for finance, business operations, tax and compliance, managed care, and oversight of the Harris Methodist Health Foundation and the Presbyterian Healthcare Foundation.

“Ron is joining a strong team,” said Hawthorne. “We expect his contributions and leadership will help preserve the financial strength and stability that enables THR to fulfill its mission to improve the health of the people in the communities we serve.”

Long is active in a variety of health care industry financial management groups, and his participation at the national level will strengthen THR’s efforts in advocating for development of a national health care policy.

“I look forward to joining Texas Health Resources. It is an organization which is highly regarded in the industry and is strategically positioning itself for the future”, Long said.

Long’s health care career spans more than 20 years. He comes to THR from Cincinnati, Ohio, where he currently serves as executive vice president and CFO for Health Alliance of Greater Cincinnati, a position he has held since 2001. Previously, Long has served as senior vice president of finance and health plans for Saint Mary’s Health Network in Nevada. He also served in various financial capacities with Legacy Health System in Portland, Oregon and with the Central Oregon District Hospital in Redmond, Oregon. He began his healthcare career while serving as a senior auditor with Arthur Young & Company in Portland, Oregon.

Long, a Certified Public Accountant licensed in Oregon, earned his Bachelor of Science degree from the University of Portland. An active member of the Healthcare Financial Management Association, he served as the National Chairman in 2001-2002.

About Texas Health Resources

Texas Health Resources is one of the largest faith-based, nonprofit health care delivery systems in the United States. The 13-hospital system is the largest in North Texas in terms of patients served and includes Harris Methodist Hospitals, Arlington Memorial Hospital and Presbyterian Healthcare System. For more information about Texas Health Resources, visit http://www.texashealth.org/ .

Texas Health Resources

CONTACT: Reace Alvarenga Smith of Texas Health Resources,+1-817-462-6390, or [email protected]

Web site: http://www.texashealth.org/

Limo driver gets big tip from rider — a kidney

CHICAGO (Reuters) – As tips go, Chicago limousine driver
Abdul Faraj got a priceless one this week when one of his
regular customers offered up a kidney, media reports said.

Faraj and Minnesota businessman Dave Baker underwent
transplant surgeries at Chicago’s Northwestern Memorial
Hospital.

“He gave me part of his body. He saved my life,” Faraj, a
diabetes sufferer whose kidneys were failing despite a
three-times-a-week dialysis regime, told area television
stations.

Baker has used Faraj, a native of Lebanon, as his driver on
trips to Chicago for several years. Making small talk months
ago, Baker learned of Faraj’s poor health and struggle to find
a kidney donor with a matching blood type.

“At that time, he tells me, ‘What’s your blood type?’ I
tell him O-positive,” Faraj said. “He said, ‘I’m 0-positive.
I’ll give you one.”‘

Baker is out of the hospital and expected to fully recover
within weeks.

“This was an opportunity to stop, slow down, take a look
around and try to help someone,” Baker told local television.

Millions of Cameroon girls suffer “breast ironing”

By Tansa Musa

YAOUNDE, Cameroon (Reuters) – Worried that her daughters’
budding breasts would expose them to the risk of sexual
harassment and even rape, their mother Philomene Moungang
started ‘ironing’ the girls’ bosoms with a heated stone.

“I did it to my two girls when they were eight years old. I
would take the grinding stone, heat it in the fire and press it
hard on the breasts,” Moungang said.

“They cried and said it was painful. But I explained that
it was for their own good.”

“Breast ironing” — the use of hard or heated objects or
other substances to try to stunt breast growth in girls — is a
traditional practice in West Africa, experts say.

A new survey has revealed it is shockingly widespread in
Cameroon, where one in four teen-agers are subjected to the
traumatic process by relatives, often hoping to lessen their
sexual attractiveness.

“Breast ironing is an age-old practice in Cameroon, as well
as in many other countries in West and Central Africa,
including Chad, Togo, Benin, Guinea-Conakry, just to name a
few,” said Flavien Ndonko, an anthropologist and local
representative of German development agency GTZ, which
sponsored the survey.

“If society has been silent about it up to now it is
because, like other harmful practices done to women such as
female genital mutilation, it was thought to be good for the
girl,” said Ndonko.

“Even the victims themselves thought it was good for them.”

However, the practice has many side-effects, including
severe pain and abscesses, infections, breast cancer, and even
the complete disappearance of one or both breasts.

The survey of more than 5,000 girls and women aged between
10 and 82 from throughout Cameroon, published last month,
estimated that 4 million women in the central African country
have suffered the process.

“You ask me why I did it?” said Moungang. “When I was
growing up as a little girl my mother did it to me just as all
other women in the village did it to their girl children. So I
thought it was just good for me to do to my own children.”

COMMON IN TOWNS

The practice is now more common in urban areas than in
villages, because mothers fear their children could be more
exposed to sexual abuse in towns and try to suppress outward
signs of sexuality, the survey said.

Its findings have prompted a nationwide campaign to educate
mothers about its dangers and to try to eradicate it. A similar
campaign some years ago helped drastically to reduce rates of
female genital mutilation in Cameroon.

“A girl…has to be proud of her breasts because it is
natural. It is a gift from God. Allow the breasts to grow
naturally. Do not force them to disappear or appear,” said a
leaflet from the campaign.

Moungang said she stopped ironing her daughters’ breasts
after one girl developed blisters and abscesses.

“I took her to the hospital and the doctor scolded me and
advised never to do it again because it could ruin my
daughter,” she said.

“When Mariane married and delivered her first baby, it took
a long time — about a month — for her breasts to start
producing milk and the child almost died. I was told it was
because I had ironed her breasts. I was frightened.”

The younger a girl develops, the more likely she is to have
her bosom ironed — 38 percent of girls developing breasts
under the age of 11 had undergone the procedure.

The practice is most common in the Christian and animist
South of the country, rather than in the Muslim North and Far
North provinces, where only 10 percent of women are affected.

The survey found that in 58 percent of cases breast ironing
was carried out by mothers worried that the onset of puberty
could provoke sexual harassment, inhibit their daughters’
studies or even stunt their growth.

Many mothers were alarmed because an improvement in
nutrition and living conditions had caused young girls’ breasts
to develop earlier than ever.

BREASTS DESTROYED

“Massaging the breasts with hot objects is painful, very
painful, and can completely destroy the breasts,” said Bessem
Ebanga, executive secretary of women’s rights group RENATA,
herself a former victim.

“Some girls could be traumatized throughout their lives and
their sexual behavior could be disturbed forever.”

Thirteen-year-old Geraldine Mbafor could not hold back her
tears as she narrated her ordeal.

“I had just finished doing my homework when my mother
summoned me to the kitchen. She boiled water and in the water
she put a grinding stone. She then removed the stone holding it
with a thick cloth to protect her hands, and placed it my
breasts and started ironing them,” she stated.

“I felt so much pains that I started crying. After that she
bandaged my breasts with a band called breast-band … She did
this to me for 2-1/2 months.”

According to 14-year-old Amelia, who would not give her
family name, her breasts started developing when she was 9. Her
elder sister decided to massage them every evening with a towel
soaked in hot water.

“This was very painful, and every evening before I slept,
she would put a big elastic belt well fastened round my chest
to flatten my breasts.”

“Six months later the flesh that held my breasts was
already weak. At 10, I already had fallen breasts and each time
I undress I’m ashamed and it is a big complex.”

Nevertheless, support for and opposition to the tradition
remains evenly balanced. According to the survey, 39 percent of
women opposed it, while 41 percent expressed support and 26
percent were indifferent.

For Ndonko, the campaign is a battle to respect the
physical integrity of young girls — with broader implications
for human rights.

“If nothing was done today, tomorrow the very parents may
even resolve to slice off the nose, the mouth or any other part
of the girl which they think is making her attractive to men.”

Poor in England More Likely than Rich to Die in 50s

By Patricia Reaney

LONDON — The poorest in England are over 10 times more likely to die in their 50s than richer people despite receiving similar healthcare, researchers said.

Obesity and smoking, two of the leading causes of preventable death, are more common in lower economic groups but Professor Michael Marmot of University College London said psychological factors and social position can also have an effect on health.

“There is an intricate relationship between wealth and health,” said Marmot, the principal investigator of the English Longitudinal Study on Aging (ELSA).

ELSA follows the health, wealth, relationships, retirement and other issues of 8,780 people born before 1952 who are interviewed every two years.

“For each age group the richer had a lower risk of dying,” Marmot told a news conference.

Wealthier people were also less likely to suffer from 17 common chronic diseases including high blood pressure and diabetes. But the quality of healthcare did not vary by wealth which suggests other factors are also important.

About twice as many people in the poorest as opposed to the richer group felt isolated often or some of the time. Living alone was also more common in people on the lower economic levels.

“Adult social position has a clear effect on health,” said Marmot, adding that in older people social isolation kills.

But according to the study, 60 percent of 75-year-olds are young at heart and did not think of themselves as old.

Marmot said studies done in European countries and the United States revealed similar findings linking health and wealth.

He added that the redistribution of wealth is not the answer to the problem, adding that a better understanding of the causal relationship is needed.

“The challenge is not to abolish hierarchies. It is to understand better what links your position in the hierarchy to your health,” he said.

When earlier results of the ELSA study were compared with similar research in the United States it showed that Americans are not as healthy as the English. Americans had more illness in all income and education levels for six serious medical conditions than their neighbors across the Atlantic.

NASA Satellites Find Balance in South America’s Water Cycle

For the first time, NASA scientists using space-based measurements have directly monitored and measured the complete cycle of water movement for an entire continent.

Using satellite data from three Earth-orbiting NASA missions — Quick Scatterometer (QuikScat), Gravity Recovery and Climate Experiment (Grace), and Tropical Rainfall Measuring Mission (TRMM) — a science team at NASA’s Jet Propulsion Laboratory, Pasadena, Calif., directly observed the seasonal cycling of water into and out of South America. Their research confirmed that the amount of water as rain or snow flowing into the continent from the marine atmosphere is in balance with the estimated amount of water returned to the ocean by the continent’s rivers.

The findings are significant because until now there had been no direct way to monitor continental water balance. Scientists had been estimating the balance through regional ground-based measurements and computer models. The findings are published in Geophysical Research Letters.

“Having a better understanding of the processes in which water is transported from Earth’s oceans to continental land masses is important to a variety of climate and ecology studies,” said Dr. Timothy Liu, science team leader at JPL. “We’ll have greater understanding of floods and drought, surface and ground water quality, and the availability of freshwater resources for agriculture and ecosystems.”

To calculate the continent’s overall water balance equation, Liu’s team compared the amount of water coming into the continent with that going out. A statistical method was developed to estimate water transport using QuikScat’s surface wind data and atmospheric water vapor data from microwave radiometers. Rainfall data from NASA’s TRMM were used to measure the rainfall over the continent. Water going out from the continent was measured by combining data from river flow gauges with projections from models that predict the amount of water discharged at the rivers’ mouths.

The river discharge rates were collected over periods ranging from a few years to a century, depending on the river basin and locality, and were averaged to determine an annual cycle. Scientists compared that estimate with the monthly changes in South America’s mass over two annual cycles, from August 2002 to July 2004, as measured by Grace. They determined that the seasonal mass change is dominated by changes in the amount of surface and underground water.

Liu said the large-scale geographic patterns of rainfall and mass change rates follow an apparent counterclockwise annual march over the northern half of South America. With relatively small amounts of evaporation, and small or slow surface water outflow, the mass change over a certain region is primarily driven by rainfall. The team found the annual variation of rainfall in the Amazon and La Plata basins — the two largest drainage basins in South America — correlates closely with the Grace measurements of their mass change. In addition, measurements of the flow of moisture across relevant segments of the continent’s Pacific and Atlantic coasts were found to correspond with measurements of the annual cycle of rainfall in the two basins and the Andes Mountains.

Liu said the study strongly validates the credibility of space-based measurements to study continental water balance, but is only a beginning. “Planned reprocessing of QuikScat, Grace and TRMM data to improve the data quality and resolution, when combined with data from planned future missions, promises to further enhance our understanding of water balance on a global basis,” he said. Those planned future missions include NASA’s Global Precipitation Measurement Mission, the European Space Agency’s Soil Moisture and Salinity Sensor and NASA’s Aquarius satellite.

Grace is a joint partnership between NASA and the Deutsches Zentrum fur Luft- und Raumfahrt. The identical twin Grace satellites are managed by JPL. Grace tracks changes in Earth’s gravity field, primarily caused by the movement of water. The University of Texas Center for Space Research has overall mission responsibility. GeoForschungsZentrum Potsdam, Potsdam, Germany, is responsible for German mission elements. Science data processing, distribution, archiving and product verification are managed jointly by JPL, the University of Texas and GeoForschungsZentrum Potsdam.

QuikScat, managed by JPL, measures ocean surface winds by transmitting high-frequency microwave pulses to Earth’s ocean surface and measuring the strength of the radar pulses that bounce back to the instrument. These ocean surface winds drive Earth’s oceans and control the exchange of heat, moisture and gases between the atmosphere and the sea.

TRMM is a joint mission between NASA and the Japan Aerospace Exploration Agency that monitors and studies tropical rainfall. It is managed by NASA’s Goddard Space Flight Center, Greenbelt, Md.

An animation illustrating the annual variation of South America’s water balance as detected by Grace is available at: http://airsea.jpl.nasa.gov/movie/sa.qt .

For more information on Grace, QuikScat and TRMM on the Web, visit: http://www.csr.utexas.edu/grace ; http://winds.jpl.nasa.gov ; and http://trmm.gsfc.nasa.gov/ .

JPL is managed for NASA by the California Institute of Technology.

Canada, Mexico, US Agree to Protect Butterflies

By Maggie Fox, Health and Science Correspondent

WASHINGTON (Reuters) – Wildlife officials in Mexico, the United States and Canada have agreed to work together to protect the Monarch butterfly, which makes a spectacular migration every year from Canada to Mexico.

Officials from the U.S. Fish and Wildlife Service, the National Park Service, Canada’s Wildlife Service and Parks Agency and Mexico’s Secretariat of the Environment and Natural Resources have designated 13 wildlife preserves as protected areas, the Fish and Wildlife Service said on Wednesday.

The “Trilateral Monarch Butterfly Sister Protected Area Network” will develop international projects to preserve and restore breeding, migration and winter habitat for the orange and black butterflies.

Every autumn, millions of monarchs leave eastern Canada and the United States and fly distances of 2,800 miles and more to the oyamel fir forests of Mexico’s Sierra Madre Mountains for the winter. Monarchs west of the Rocky Mountains migrate south to eucalyptus groves in southern California.

The informal agreement will include sharing information about ways to preserve the habitat and migratory pathways of the butterflies, said Donita Cotter, a spokeswoman for the U.S. Fish and Wildlife Service.

It will not require any legislation.

“I think it’s wonderful,” Monarch researcher and ecologist Dr. Lincoln Brower of Sweet Briar College in Virginia said in a telephone interview.

“I think it will make a good symbolic statement.”

But Brower said the agreement will do little to preserve the butterflies unless stronger action is also taken to stop logging in Mexico and to change farming practices in the United States that are destroying the plants the butterflies rely on.

“We are going to lose the whole thing if they don’t stop this silly illegal logging in Mexico,” Brower said.

Illegal loggers have been destroying the trees in Mexico’s Monarch Butterfly Biosphere Reserve, while development is threatening the California eucalyptus groves. Brower said there is evidence that heavy use of weedkillers is wiping out the milkweed plant, which is the only thing that Monarch caterpillars will eat.

This agreement brings attention to the threats, Brower said. “It is important that the countries keep up pressure on each other,” he said.

The Blackberries Grow Sweet Where Chiggers Grow Hungry

By Steve Vantreese

Like bacon and eggs, some things just seem to go together.

So it is with blackberries and chiggers, an interwoven duo that’s good news and bad in a package deal.

Blackberries are the familiar fruits of several species of Rubus genus plants that grow as upright and spreading canes. The canes produce leaves and spring flowers, followed by some of the sweetest natural fruits in our wild environment.

Blackberry plants are some of the first to “volunteer” in open or cleared ground, canes reaching several feet in the few months of a single growing season. A blackberry cane produces fruit in its second year, then dies, newer canes carrying on with production.

The most apparent feature of the blackberry plant is that it bristles with needle-sharp thorns that grab at the clothing of human pedestrians, bogging them down and readily piercing tender skin.

The canes are generally avoided because of their painful “sticker” characteristics — except right about now and into mid-summer as their berries ripen. They yield delicious fruit long famous as prime ingredients in cobblers and other desserts, and they are quite desirable for eating berries alone.

The berries turn glossy black when ripe. When “green,” they’re an attractive red.

Humans have no exclusive favor for blackberries. The fruits of the thorny canes are an important seasonal food for most species of Kentucky wildlife. Many varies of songbirds, wild turkey and quail eat them. So do raccoons, opossums, coyotes, foxes, squirrels, box turtles, deer, mice and voles. The deer, for one species, likes them ripe, green — red, that is — or past their prime in a dried condition.

Despite the thorns, the plants themselves are important to wildlife. Deer eat the leaves and rabbits nibble the canes. Several songbirds are attracted to the canes for nesting habitat, and numerous birds, rabbits and small rodents utilize the prickly thickets as escape cover.

In early to middle July, people often turn to wild thickets for gathering berries to eat fresh or to freeze. Just after these gathering sessions is when they often note the itchy red welts on their skin that represents the handiwork of chiggers.

Chiggers, the larva of harvest mites, are red-orange, six-legged arachnids that you’ve probably never seen. That’s because it would take roughly 120 of them marching along in a tight nose-to-rump formation to make an inch-long column. They are so small as to be invisible to the human eye.

Adult harvest mites don’t do this, but chiggers are parasites that feed, when given the opportunity, on humans and other animals. The chigger doesn’t suck blood, but it crawls on a host, finds its way to a hair follicle or pore, then jabs a cutting mouthpart into the skin. From there is injects a sort of saliva that digests and liquefies tissue, then sucks it up. The chigger itself doesn’t bury into the skin.

Chigger “bites” on people show up as red, itchy bumps that are the leftover result of the digestive juice injected into the skin. By the time people start scratching chigger welts, the tiny animal itself already may have dropped off, full and satisfied.

Human hosts of chiggers often use a folk remedy of painting welts with nail polish to “smother” the chiggers, which likely already have departed. The nail polish, indeed, may give some relief from itching by keeping air from the welts. Over-the-counter ointments with antihistamines or topical anesthetics may provide more relief from the torment.

Chiggers seem inseparable from blackberries, although they could be as prevalent on growth around blackberry canes as on the canes themselves. Weedy habitat is generally effective in giving chiggers access to human pickers.

For berry picking or any other activity in tall grasses, weeds and brush, the best recommendation for blocking off chiggers is a combination of a permethrine-based repellent sprayed thoroughly on one’s clothing, and an application of a DEET-based insect repellent on exposed skin.

Scientists Say Warm Seas Threaten Coral Reefs

CHARLOTTE AMALIE, U.S. Virgin Islands — Caribbean Sea temperatures have reached their annual high two months ahead of schedule – a sign coral reefs may suffer the same widespread damage as last year, scientists said Monday.

Sea temperatures around Puerto Rico and the Florida Keys reached 83.5 degrees Saturday – a high not normally seen until September, said Al Strong, a scientist with the U.S. National Oceanic and Atmospheric Administration’s Coral Reef Watch.

“We’ve got a good two more months of heating,” Strong told The Associated Press in a telephone interview from Washington. “If it were to go up another degree, it would be pretty serious. That’s what we had last year.”

Researchers fear another hot summer could be disastrous for coral still recovering from last year, when up to 40 percent of coral died in abnormally warm seas around the U.S. Virgin Islands.

High sea temperatures stress coral, making the already fragile undersea life even more susceptible to disease and premature death.

Scientists have not pinpointed what is behind the warm sea temperatures but some speculate global warming might be the cause.

NOAA alerted scuba-dive operators and underwater researchers to be careful around the reefs, which are easily damaged by physical contact, Strong said.

The warning is in effect until the waters cool off – which is not likely for a few months.

Land-based runoff can also damage the reefs, Strong said.

“Now is not the time to dump a lot of fertilizer on the golf course,” he said. “This is a time of high stress and a time to be more aware when you’re out there.”

A building block for undersea life, the coral reefs are a sheltered habitat for fish, lobsters and other animals to feed and breed. They also deflect storm waves that might otherwise wash away the Caribbean’s famed beaches.

A record 9 percent of elkhorn coral – vital for reef building – died last year around the U.S. Virgin Islands and much more was damaged. Elkhorn is one of the faster-growing corals at some 8 inches a year, compared with less than an inch for other varieties.

Millions of people visit the Caribbean each year to dive and snorkel over the region’s coral reefs, part of a multibillion-dollar tourism industry.

Mindless Reading Seen As Fundamental

WASHINGTON — Better pay attention, reader. This whole story may be a blur.

For the first time, researchers have demonstrated the ill effects of mindless reading – a phenomenon in which people take in sentence after sentence without really paying attention.

Ever read the same paragraph three times? Or get to the end of a page and realize you don’t know what you just read?

That’s mindless reading. It is the literary equivalent of driving for miles without remembering how you got there – something so common many people don’t even notice it.

In a new study of college students, researchers from the University of Pittsburgh and the University of British Columbia established a way to study mindless reading in a lab.

Their findings showed that daydreaming has its costs.

The readers who zoned out most tended to do the worst on tests of reading comprehension – a significant, if not surprising, result. The study also suggested that zoning out caused the poor test results, as opposed to other possible factors, such as the complexity of the text or the task.

The researchers hope their work inspires more research into why zoning out happens, and what can be done to stop it.

For now, they want the problem to be taken seriously.

“When you talk about this work at conferences, it does lend itself to a lot of jokes,” acknowledges University of Pittsburgh professor Erik Reichle, co-leader of the study.

“It’s so ubiquitous. Everybody does it,” he said. “I think that’s one of the main reasons it’s been overlooked. And there’s been a view that it is tough to study experimentally. Hopefully, now, there will be more interest in the topic.”

The federal government is showing some.

Reichle and fellow psychology professor Jonathan Schooler did the study on a $691,000 grant from the Institute of Education Sciences, an arm of the Education Department. It is one of 178 federally backed projects aimed at giving schools a scientific basis for sound policies.

Over three experiments, students used computers to read the first five chapters of Leo Tolstoy’s “War and Peace.” (Reichle wanted some boring reading – better for zoning out.)

Reichle said the dry text itself did not skew the results toward mindless wandering. After all, the students were on alert, unlike the typical reader.

Participants were told to monitor and report instances of zoning out as they read text on a computer. Half of them got computer reminders, too: “Were you zoning out?”

Despite all that, many still reported zoning out at a regular pace.

“That’s the amazing thing,” Reichle said. “It shows how often this can happen even under conditions that are designed to keep it from happening.”

The students said as their eyes scanned the words, their minds often were elsewhere.

They were hungry, or thirsty, or tired. They were thinking about plans, worries or memories. Some drifted into fantasies. Others stuck with the book, but their minds wandered into tangents about the plot.

Karen Wixson, a nationally recognized reading expert and professor of education at the University of Michigan, cautioned not to read too much into all this.

“This is a long ways away from having implications for reading instruction,” Wixson said. “It could, eventually, down the line. But to draw inferences about this as a contributing factor toward reading comprehension would be a huge, huge leap.”

To apply to younger kids – the target audience of reading classes – the findings would have to be replicated among school-age children, Wixson said.

She said participants may have zoned more often because they were reading off computer screens, and because they had no real incentive to pay attention, as they would in school.

But at the International Reading Association, Cathy Roller sees some direct payoff. She directs research and policy for the association, which represents literacy professionals.

By recognizing zoning out as problem, she said, teachers can do something.

Like asking students to put a checkmark next to paragraphs as they finish them and then summarize what they just read.

Or having students scan all the pictures and bold type before reading the text of a story, so that they have a general understanding of what’s to come.

Zoning out may simply mean that the prose isn’t interesting, Roller said. But it could also be a clear signal that students don’t understand the work.

“You don’t want to generalize narrow studies into large implications,” Roller said. “But zoning out is probably not a whole lot different than not comprehending. And telling people to start using some good comprehension strategies is not likely to do any harm.”

Roller knows. She had just been zoning out while reading a literature review.

By the way, last sentence here. If you missed anything, there’s no shame in rereading.

On The Net:

Institute of Education Sciences: http://www.ed.gov/ies/

Erik Reichle: http://www.pitt.edu/reichle/

International Reading Association: http://www.reading.org/

US to Subsidize State Purchases of Tamiflu

NEW YORK (Reuters) – The U.S. government said on Friday it will spend about $149 million under a two-year contract with Swiss drugmaker Roche Holding AG to provide federally subsidized Tamiflu tablets to all 50 states, so they can begin stockpiling the drug as a potential treatment for any pandemic influenza outbreak.

“Our ultimate goal is to stockpile sufficient quantities of antiviral drugs to treat 25 percent of the U.S. population,” U.S. Secretary of Health and Human Services Mike Leavitt said in a release.

Under the contract, 59 jurisdictions will be able to buy Tamiflu at a federally negotiated price from Roche and receive a 25 percent federal subsidy for a prescribed number of treatment courses, the release said.

Fireworks, Gun Bust in Syosset: Nassau Cops Say They Found More Than 200 Pounds of Explosives, Cache of Firearms in Home

By Michael Frazier, Newsday, Melville, N.Y.

Jun. 30–A Syosset man was arrested yesterday after police found several hundred pounds of illegal fireworks crammed into the attic of his home, authorities said.

Nassau police began investigating the home of Abraham Finkler, 24, after receiving a tip he was selling fireworks at his house at 142 Southwood Circle, police spokesman Det. Lt. Kevin Smith said.

When officers raided the home, they found more than 200 pounds of fireworks and a cache of long-barrel firearms, Smith said. Police said they also found 10 pounds of marijuana in the house but have not yet charged Finkler with drug possession.

Finkler’s 16-month-old baby slept in a room just below the fireworks and near where the guns were stored, police said.

“This child was placed in a room sandwiched by two rooms that had weapons and right below a place crammed with fireworks,” Smith said.

Finkler was arrested on charges of failing to have a proper license and certificate for storage, possession of commercial-grade explosives and improper storage of explosives and fourth-degree possession of a dangerous weapon, all felonies, police said.

He also faces misdemeanor counts of endangering the welfare of a child and dealing with fireworks.

Finkler’s wife, Corrine Martinez, 27, who wasn’t at home during the raid, was arrested on a charge of endangering the welfare of a child, but she was later released without bail, police said.

The couple’s child was with the mother.

Police said the investigation was preliminary, but they said Finkler’s house was under surveillance for some time after they received the tip.

Investigators learned Finkler picked up large quantities of fireworks in Pennsylvania and sold them from his home. He stored them in the attic, which police measured as having a temperature of 100 degrees, police said.

“The heat in the attic could have ignited the fireworks and blew the roof of the house off,” Smith said.

Fireworks – from sparklers to cherry bombs – are illegal in New York State. New York is joined by Delaware, Massachusetts, New Jersey and Rhode Island in outlawing fireworks unless used with a special permit.

In New York City and Long Island, authorities are on the lookout for fireworks violations. On Wednesday, Suffolk County police arrested a Ridge woman after discovering an estimated 350 cases of assorted fireworks on her property worth $100,000.

The New York Police Department’s vice squad, which helps keep illegal fireworks off the streets, has made 147 fireworks possession arrests between Jan. 1 and June 20.

While authorities seek to seize illegal fireworks, fire officials note that each year, dozens of injuries occur on July Fourth alone.

“Even sparklers burn at very, very high temperatures, up to 1,000 degrees, and are very dangerous for children,” said Vincent McManus, division supervisor of the Nassau County fire marshal’s office.

What makes them illegal

Under New York State law, fireworks or dangerous fireworks are defined as any blank cartridge, blank cartridge pistol or toy cannon in which explosives are used. Sparklers, roman candles, bombs and skyrockets are examples.

The law states: Any person who shall offer or expose for sale, sell or furnish, any fireworks or dangerous fireworks is guilty of a Class B misdemeanor. According to the law, anyone who sells or provides fireworks valued at $500 will be charged with a Class A misdemeanor. All misdemeanors are punishable by fines and up to 1 year in prison.

—–

Copyright (c) 2006, Newsday, Melville, N.Y.

Distributed by McClatchy-Tribune Business News.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Japan Elderly Population Ratio Now World’s Highest

TOKYO (Reuters) – Japan, struggling to deal with a falling birth rate and an aging population, said on Friday its ratio of elderly people to total population was now the world’s highest, surpassing that of Italy.

The ratio of people aged 65 or older reached 21.0 percent of the total population in 2005, beating Italy’s 20.0 percent, the government said in a report released on Friday.

The ratio of people aged 15 or younger in the total population was the world’s lowest at 13.6 percent, surpassing Bulgaria’s 13.8 percent, the report said.

“This shows a strong trend toward fewer children,” Kuniko Inoguchi, the minister in charge of dealing with the falling birth rate, told reporters after a cabinet meeting.

“We are determined to do our best to deal with the problem.”

Japan’s low birth rate and graying population have aroused concerns about future growth in the world’s second-largest economy and the sustainability of its pension system.

Japan’s population — now about 127 million — declined last year for the first time since 1945. Experts had long forecast the shift, but it came two years earlier than expected.

Japan’s fertility rate, or the average number of children a woman bears in her lifetime, fell to a record low 1.25 in 2005.

Japan’s slumping birth rate has been attributed to long working hours for both men and women, the high cost of putting children through a highly competitive school system, and barriers to women advancing in the workplace while raising children.

The government said in December that Japan’s population would shrink by half in less than a century unless something was done to reverse the falling birthrate.

Space Shuttle Cleared for Saturday Launch in Florida

By Irene Klotz

CAPE CANAVERAL, Florida (Reuters) – NASA said on Thursday it is ready to lift its ban on space shuttle flights, convinced that only another launch will vanquish lingering safety concerns with the ship’s fuel tank that were exposed by the 2003 Columbia disaster.

“It’s been a long year with a lot of hard work,” shuttle deputy program manager John Shannon said at a news briefing.

Mission managers cleared shuttle Discovery and its crew of seven for launch from the Kennedy Space Center in Florida on Saturday. Liftoff is scheduled for 3:49 p.m. EDT (1949 GMT).

NASA’s top engineer and safety officials had argued to delay the launch until additional repairs could be made to the shuttle’s fuel tank, which triggered the loss of Columbia and the deaths of seven astronauts.

Michael Griffin, the U.S. space agency chief who made the final call to proceed with launch, has acknowledged that any major technical problem likely would end the shuttle program permanently.

But with the fleet set to retire in four years, time is running out to finish building the International Space Station. Griffin decided that even if the worst-case scenario occurred and Discovery sustained Columbia-like damage from a debris impact during launch, the shuttle crew could live aboard the station while they awaited rescue.

Columbia was damaged when a piece of foam insulation fell off its fuel tank and hit the shuttle’s wing during launch. It broke apart 16 days later as it flew through the atmosphere for landing.

NASA’s first redesign of the tank was tested last year on the first post-Columbia mission, but it again shed large pieces of potentially dangerous foam. Managers decided to remove two foam wind deflectors from the tank, which were the primary sources of debris lost during Discovery’s 2005 launch.

Additional work on foam covering 37 metal brackets, however, was deferred, despite the objections of some engineers and safety officials. NASA officially designated the hazard as “probable” during the life of the shuttle program, and potentially “catastrophic.”

Shannon said he has no idea if that classification is accurate.

“We don’t have enough information to characterize it. I think we will learn a lot on this flight,” he said.

NASA’s more immediate concern is the weather. Lighting and thunderstorms at the space center forced technicians on Thursday to delay loading the shuttle’s onboard propellants, which are used to generate electricity during flight.

Forecasters predicted a 60 percent chance that poor weather will force NASA to delay Discovery’s flight.

Following Doctors’ Orders Reaps Health Benefits

LONDON (Reuters) – People who follow doctor’s orders and take their medicines regularly are more likely to live longer lives than other patients — even if the medicines are placebos.

About one in four people prescribed drugs do not take them as they should. Patients may disagree with the prescription, or don’t think it is helping them or the medicine could be producing an unpleasant side effect.

In an analysis of 21 studies involving more than 46,000 people, Canadian scientists found those who took their drugs as prescribed — even if the drugs were placebos or dummy pills given as part of a study — did better than those who didn’t.

“In the studies that we included in our study, if people followed their medications regularly they lived longer. They had a less likely chance of dying,” said Dr Scot Simpson, of the University of Alberta, in Edmonton, Canada.

The scientists, who reported the findings in the British Medical Journal, believe that people who adhere to treatment regimens are more likely to have a healthier lifestyle in general.

“If you are using a medication regularly than you are likely following other healthy lifestyle recommendations like eating a healthy diet, exercising, getting regular checkups,” Simpson said.

He suggested that taking medication regularly could be a type of surrogate marker, or indicator, that in general the patient has a healthy lifestyle.

Market District(TM) From Giant Eagle(R) Introduces a New World of Food With Concept Stores in Pittsburgh

PITTSBURGH, June 29 /PRNewswire/ — The launch of two Market District(TM) stores is being announced today as a new concept from Pittsburgh-based supermarket retailer Giant Eagle(R), Inc. The Market District store concept embodies a culinary destination for food aficionados paired with the convenience of a full service market. The first two stores open officially with a ribbon-cutting ceremony at 10:00 a.m. on June 29. The stores, located at 7000 Oxford Drive in Pittsburgh’s South Hills region and 5550 Centre Avenue in the city’s Shadyside neighborhood, are expected to draw customers from nearby Pennsylvania, Ohio and West Virginia regions.

(Photo: http://www.newscom.com/cgi-bin/prnh/20060629/NYTH052 )

The Market District concept was developed to appeal to food enthusiasts, those who enjoy taking part in and learning about the sight, smell and taste of the exciting world of food. The stores are the perfect choice for those passionate about food, and feature a wide array of freshly prepared foods made in-store every day. The Market District stores simultaneously satisfy the customer need for a full weekly shopping trip. In a single location, customers can purchase unique, fresh and specialty items alongside mainstream national brands while enjoying convenience-oriented services such as pharmacy, photo development and dry cleaning.

The two Market District stores offer numerous opportunities to discover the “oooo” in food:

   * A Brazilian-style churrasco featuring meats and vegetables fire-roasted     to lock in sumptuous flavor;    * The finest in charcuterie showcasing domestic and imported cured meats     from countries such as Italy and Spain, and unique products such as     Saucisson pork from the mountains of France;    * A 500 item Kosher section and deli created with the guidance of rabbis     and offering popular brands like Empire Kosher, Kedem, and Aaron's, as     well as Tnuva and other popular Israeli brands;    * A cheese department and cheese cave with more than 400 domestic and     imported choices from regions around the globe, such as French Morbier,     Rembrandt Aged Gouda from Holland and Royal Windsor from England;    * A traditional pizza oven, sushi bar and authentic Italian creations     including fresh mozzarella and pasta, and pasta sauces made from     scratch;    * A fresh fruit smoothie bar and coffee roasting station where green     coffee beans are roasted daily and brewed to perfection;    * Nearly 5,000 specialty food and beverage products from 19     countries/regions around the world including Africa, India, Poland,     England and Asia, and more than 4,000 natural, organic and gluten-free     items;    * An in-store bakery where bakers use traditional baking methods,     authentic ingredients and a Bongard hearth oven from France to produce     the best in pastries, pies and cakes, specialty desserts and more than     20 organic and artisan breads;    * A full-service meat and seafood department presenting hundreds of     traditional favorites in addition to hard-to-find selections such as     rabbit, venison, quail and buffalo;    * A bountiful produce department with 500 varieties and unusual selections     such as cippolini onions, cactus pears, exotic herbs and approximately     120 organic fruits and vegetables;    * A chef demonstration station where culinary experts showcase products     from across the store, along with easy instructions for home     preparation;    * An ongoing schedule of in-store events to entertain and educate     shoppers, including cooking demonstrations from resident chefs,     celebrity chef appearances, book signings, and live music and free Wi-Fi     access in the Market District Caf©;    * In comparison to the 68,000 square foot Shadyside store, the larger size     of the 117,000 square foot South Hills location allows for additional     offerings, including a baby section, toy section, office products and     housewares, bulk foods and spices and a candy rotunda featuring freshly     made fudge and chocolate bark as well as chocolates from the acclaimed     Belgian chocolatier Leonidas.   

“The Market District concept is not just another food store,” said Kevin Srigley, Senior Vice President, Market District. “The stores welcome customers to a new world of food, with unique meat, produce, cheese and grocery selections from around the globe, selected by our dedicated staff. The stores have an open-air market feeling with an amazing array of specialty items, natural and organic products, exotic spices, artisan breads, and a wealth of fresh meat, seafood, and produce selections that are anything but ordinary.”

Srigley added, “But Market District also satisfies customer needs for a full weekly shop. While customers can find unique items not available elsewhere, they also can purchase everyday items like national brand detergent and popular beverages under the same roof, priced comparably with Giant Eagle supermarkets.”

Market District is the place for food enthusiasts, but the brand’s tie to Giant Eagle is not forgotten. Market District features the attractive promotions, weekly specials and pricing, and the ability to purchase gift cards for popular retailers and earn fuelperks!(R) loyalty rewards with the Giant Eagle Advantage Card(R).

A new world of food knowledge and service from trained professionals

The unique combination of food enthusiasm and a complete shopping experience is only a part of the Market District story. Srigley said that the 300 employees at the Shadyside location and the 500 employees at the South Hills store are yet another point of difference. More than 50 chefs, bakers and food professionals are on hand throughout the store to share their knowledge. Graduates from the Culinary Institute of America, the Pennsylvania Culinary Institute, and the Bidwell Training Center are working in various roles in the Market District stores. In addition, a number of culinary students are conducting externships at the two locations. Certified Cheesemongers, trained employees who have become cheese experts, also add to the experience. On-going employee training includes how products are made, quality of ingredients, country of origin, and recipe and product usage suggestions.

“Our food training is extensive,” said Srigley. “Our people experience food from producers located all over the world, from small farmhouses to large suppliers. They then utilize this knowledge to help satisfy the culinary curiosity of our customers.

“Importantly, we also spend a significant amount of time training on superior customer service. We aim to deliver a food experience that is second to none,” he added.

Retail theater that creates a personal experience

In addition to many unique food experiences, Market District offers shoppers the opportunity to enjoy educational classes and demonstrations throughout the year. A chef demonstration cooking area in the heart of store and an open presentation area for prepared foods enables Market District chefs and food specialists to actively engage customers.

For example, seasonally-appropriate classes will teach customers how to prepare a cheese board and make holiday centerpieces, and year-round, customers will be able to watch coffee being roasted, sushi being prepared, and pasta made fresh daily in the store.

“We want customers to enjoy a fresh food shopping experience bursting with how-tos, how-longs, which-kinds, and we-did-it-for-yous,” concluded Srigley.

During the coming weeks, customers will have the opportunity to meet food celebrities like Thai food specialist Naam Pruitt, author of Lemongrass and Limes on July 1; Sara Moulton, the executive chef of Gourmet magazine and host of Sara’s Secrets on The Food Network on July 15; Rick Bayless, host of the PBS television series Cooking Mexican, a contemporary regional Mexican cooking program on July 20; PBS Television host Katie Brown who provides easy and affordable advice on food preparation/ presentation and casual entertaining on August 19; and Joan Nathan, author and PBS host of Jewish Cooking in America on September 12 and 13.

Beginning June 29, the grand opening celebrations kick off with in-store events and food sampling, local chef demonstrations, community activities, and sweepstakes throughout the month of July.

About Giant Eagle Market District

The Giant Eagle Market District destination store concept offers an enhanced food shopping experience geared toward food enthusiasts. Market District offers specialty and unique items not found elsewhere in an environment where customers’ passion for food can be cultivated by a staff of food experts. In two locations in the southwestern Pennsylvania region, the Market District stores feature teams of chefs and other culinary professionals preparing fresh foods from scratch every day. Market District also offers customers the rare opportunity to find natural, organic, specialty and other unique items paired with the convenience of favorite national brands and everyday needs all under the same roof. Further information can be found at MarketDistrict.com.

Giant Eagle, Inc., ranked 34 on Forbes magazine’s largest private corporations list is one of the nation’s largest food retailers and food distributors with approximately $5.5 billion in annual sales. Giant Eagle has 216 supermarkets in addition to more than 100 fuel and convenience stores throughout western Pennsylvania, Ohio, north central West Virginia and Maryland.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20060629/NYTH052AP Archive: http://photoarchive.ap.org/AP PhotoExpress Network: PRN3PRN Photo Desk, [email protected]

Giant Eagle, Inc.

CONTACT: Rob Borella, Corporate Communications of Giant Eagle, Inc.,+1-412-967-3637, [email protected]; or Dick Roberts of RobertsCommunications, +1-412-535-5000, [email protected]

Web site: http://www.marketdistrict.com/